



King's Research Portal

DOI:

[10.1152/physrev.00034.2015](https://doi.org/10.1152/physrev.00034.2015)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017). Pathophysiology of Migraine: A disorder of sensory processing. *Physiological Reviews*, 97(2), 553-622. <https://doi.org/10.1152/physrev.00034.2015>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Pathophysiology of Migraine – A disorder of sensory processing

Peter J Goadsby^{1,2}, Philip R Holland¹, Margarida Martins-Oliveira^{1,2†},

Jan Hoffmann³, Christoph Schankin⁴ and Simon Akerman^{2,¶}

¹Basic and Clinical Neurosciences,
Institute of Psychiatry, Psychology and Neuroscience
King's College London, UK

²Department of Neurology, University of California, San Francisco, San Francisco CA, USA

³Department of Neurology, University of Hamburg-Eppendorf, Hamburg, Germany

⁴Department of Neurology, University Hospital Bern - Inselspital, University of Bern,
Bern, Switzerland

[¶]Current address- Department of Oral and Maxillofacial Pathology, Radiology and Medicine,
New York University College of Dentistry, New York, New York, USA

[†]Department of Experimental Biology, Faculty of Medicine of University of Porto; Institute for
Molecular and Cell Biology (IBMC) and Institute of Investigation and Innovation in Health (I3S),
University of Porto, Porto, Portugal

Running title- Migraine pathophysiology

Correspondence:

Prof PJ Goadsby
NIHR-Wellcome Trust Kings Clinical Research Facility
Kings College Hospital
London SE5 9PJ
UK

Email: peter.goadsby@kcl.ac.uk

Contents

Abstract	6
I. Introduction	7
A. Historical Aspects	7
B. Where we do stand now?	9
C. Objectives of the review	10
II. Clinical Manifestations	10
A. International Classification of Headache Disorders (ICHD)	11
B. Premonitory Symptoms	12
C. Aura phase	13
D. Headache Phase	14
E. Postdrome	15
III. Imaging migraine pathophysiology	16
A. Neurophysiology of migraine as a backdrop to imaging	16
B. Inter-attack imaging studies	17
1. Structural studies	17
2. Functional studies	19
C. Premonitory phase	25
D. Aura phase	26
E. Headache phase	27
1. Head pain	28
2. Migraine attacks	28
3. Photophobia	30
4. Blood-brain barrier	32
F. Postdromal phase	33
IV. Anatomy of trigeminovascular pain pathways	33
A. Peripheral afferent projections	34
B. Central afferent projection	35
C. Ascending projections from the trigeminocervical complex (TCC)	36
D. Brainstem and thalamic projections to subcortical and cortical structures	37
E. Interpretation of human imaging in context	39
V. Modulation of trigeminovascular pain pathways	40

A. Brainstem modulation	41
1. Superior salivatory nucleus (SuS).....	41
2. Locus coeruleus (LC).....	43
3. Rostral ventromedial medulla (RVM)	44
4. Nucleus raphe magnus	45
5. Periaqueductal grey (PAG)	47
6. Neurotransmitter systems modulating the trigeminovascular system	48
B. Hypothalamic modulation	52
1. Posterior hypothalamic nucleus	53
2. Paraventricular hypothalamic nucleus	55
3. All Hypothalamic nucleus.....	56
VI. Thalamic processing of trigeminovascular pain	58
VII. Cortical processing of trigeminovascular pain.....	60
VIII. Neural Basis for Headache Pain Quality and Associated Symptoms	61
A. Premonitory symptoms	62
B. Headache characteristics	64
C. Photophobia and phonophobia	66
1. CGRP and photophobia	68
D. Nausea and vomiting.....	69
1. Hypothalamic mechanisms	69
2. Brainstem mechanisms	71
IX. Aura, CSD and the Trigemino-vascular System.....	74
A. CSD and brain injury	75
B. CSD and migraine genetics	75
C. CSD physiology	76
D. CSD and trigeminovascular activation	78
X. Genetics of Migraine.....	80
A. Familial hemiplegic migraine (FHM)	80
1. CACNA1A.....	81
2. ATP1A2	81
3. SCN1A.....	82
4. Pathophysiology of FHM.....	82
5. Triggering and FHM.....	83
B. Casein Kinase 1 δ (CK1 δ).....	83

C. TWIK-related spinal cord potassium channel (TRESK).....	85
D. Genome wide association studies (GWAS).....	86
XI. Neural basis of migraine triggers.....	88
A. Chemical triggers and inflammation.....	90
1. Triggering and vasodilation are uncoupled.....	90
2. Inflammatory mechanisms do not explain migraine therapies	91
3. Brain mechanisms and triggering	92
B. ‘Skipping meals’	95
1. Anatomy of feeding and fasting.....	97
2. Neuropeptides during feeding and fasting	98
3. Implications for migraine.....	102
B. ‘Sleep disruption’	106
1. Anatomy of sleep	106
2. Neurochemicals in sleep regulation	108
C. ‘Stress’	113
1. Neuropeptides in stress	114
2. Orexins and corticosteroids.....	114
3. Leptin and corticosteroids.....	115
4. Neuropeptide Y (NPY)	116
5. Stress and migraine	116
XI. Pharmacology of Migraine – Treatments	117
A. Serotonin (5-HT).....	118
1. Triptans- Serotonin, 5-HT _{1B/1D} receptor agonists	119
2. Ditans- Serotonin, 5-HT _{1F} receptor agonists	120
B. Calcitonin gene-related peptide (CGRP).....	121
1. Gepants- CGRP receptor antagonists.....	123
2. CGRP peptide and receptor monoclonal antibodies (-numab & -nezumabs).....	124
C. Nitric Oxide Synthase	124
D. Pituitary adenylate cyclase-activating peptide (PACAP)	126
XII. Theories of migraine	127
Conclusion	137
Acknowledgements.....	157
References.....	158

Abstract

Plaguing humans for more than two millennia, manifest on every continent studied, and with more than one billion patients having at attack in any year, migraine stands as the sixth most common cause of disability on the planet. The pathophysiology of migraine has emerged from a historical consideration of the “humors” through mid-twentieth century distraction of the now defunct Vascular Theory to a clear place as a neurologic disorder. It could be said there are three questions: why, how and when? Why: migraine is largely accepted to be an inherited tendency for the brain to lose control of its inputs. How: the now classical afferent trigeminal durovascular afferent pathway has been explored in laboratory and clinic; interrogated with immunohistochemistry to functional brain imaging to offer a roadmap of the attack. When: migraine attacks emerge due to a disorder of brain sensory processing that itself likely cycles, influenced by genetics and the environment. In the first, premonitory, phase that precedes headache; brainstem and diencephalic systems modulating afferent signals, light- photophobia or sound- phonophobia; begin to dysfunction and eventually to evolve to the pain phase and with time the resolution or postdromal phase. Understanding the biology of migraine through careful bench-based research has led to major classes of therapeutics being identified: triptans- serotonin 5-HT_{1B/1D} receptor agonists, gepants- calcitonin gene-related peptide- CGRP receptor antagonists, ditans, 5-HT_{1F} receptor agonists, CGRP mechanisms monoclonal antibodies and glurants- mGlu₅ modulators; with the promise of more to come. Investment in understanding migraine has been very successful and leaves us at a new dawn, able to transform its impact on a global scale, as well as understand fundamental aspects of human biology.

I. Introduction

Migraine is a severe and disabling brain condition (340), listed as the 6th most disabling disorder globally by the World Health Organization; and the most disabling of all neurological disorders (303). Unfortunately its ranking is increasing with time (620, 827). It has a one year prevalence of 15-18% worldwide (536, 539), if both episodic and chronic migraine are included, and has a huge financial burden on global economies; costing the US \$US19.6 (757) and the European Union €27 billion (43) annually. It is likely that the true socio-economic cost of migraine is currently significantly higher given a recent study highlighting nearly £6 billion in service use and lost employment in the UK alone (591). Migraine predominantly affects females, 3:1, and significantly affects quality of life (137), in many cases during peak years of productivity. It is characterized by attacks of unilateral, throbbing head pain, with sensitivity to movement, visual, auditory and other afferents inputs (386). Other symptoms such as tiredness, irritability, reduced concentration and yawning can precede the headache by up to 48 hours (300): the premonitory phase. Most attacks are followed by hours or a day of feeling unwell, usually with tiredness called the postdrome (299, 465). Additionally in approximately one-third of migraine patients their attacks are associated by neurological deficits associated which include cortical perturbations, collectively termed migraine aura (678).

A. Historical Aspects

Headache has been known for probably 6000 years ago, although it is not clear what type of headache (232). Migraine, indeed the more modern construct of chronic migraine, can be readily recognized in the work of Willis in the Seventeenth Century (855). The debate over the pathophysiology of migraine has largely centered on neural or vascular mechanisms that may be involved in triggering and driving attacks. The arguments have existed for several centuries and have cycled somewhat. Historically, nearly 150 years ago both seemed to be prevalent, migraine was thought of as a disorder of the brain by Edward Liveing. In his famous text *'On Megrim, Sick Headache, and some allied disorders: a contribution to the pathology of nerve-storms'*, he describes migraine as the result of 'nerve-storm, an inherited tendency for the discharge of nerve force, a 'neurosals seizure'' (544). At the same time Peter Wallwork Latham lectured (509, 510) and published *'On Nervous or Sick-Headache'* (511), describing the likely origin of migraine through vasodilation, triggered, interestingly, by aura; both theories have been reviewed in historical context (840). Latham used experimental observations in his laboratory, and migraine triggers, to demonstrate his theory, and he could be considered a trailblazer in some ways.

The studies of Wolff and colleagues in the 1940s on cranial blood vessels in conscious patients revisited the idea of migraine perhaps most likely being a vascular disorder (358, 679, 861). The concept persisted for nearly five decades until the development of sumatriptan both supported it (266), and yet led to its further questioning (435). As it emerged sumatriptan had both vascular and neural effects, so the role of the cranial vasculature was questioned. The theory of migraine pain being due to a sterile inflammation of the dural meninges caused by antidromic

activation of the trigeminal nerve evolved (566). However, the spectacular failure of as many as ten compounds that were active in the preclinical dural neurogenic inflammation model has cast considerable doubt on the concept (660). The description of purely neural effects of sumatriptan, such as those on nociceptive dural vasculature neurons in the trigeminocervical complex (419, 462) began a renaissance of thinking of migraine and its treatment as primarily a neural construct.

B. Where we do stand now?

Migraine certainly involves the brain: in some respects the controversy remains rather similar and pivots around two issues: initiation and the origin of the pain. While the initiation of a migraine attack is frequently associated with reported internal and external triggers, even this concept is being revisited by a more central interpretation that arises when considering the premonitory phase. The origin of the neuronal mechanisms that underlie the primary condition in susceptible people are still not known, and that must be a primary goal of research in this area. It is certainly widely accepted that migraine involves activation and sensitization of trigeminovascular pathways, as well as brainstem and diencephalic nuclei (21, 91). Furthermore a primary dysregulation of sensory processing is likely to result in the constellation of neurological symptoms that affect our senses. It has been suggested that migraine may be considered as a brain state of altered excitability (158, 182, 183, 206, 750). Certainly migrainous premonitory symptoms can occur many days before the headache (300, 466, 712); they are neurological symptoms that are non-nociceptive in their nature, which points to an origin in the brain. Furthermore the identification of multiple genes responsible for familial hemiplegic

migraine (FHM) (268), which increases the likelihood of severe aura symptoms, and the identification of a genetic predisposition in family studies (795), provides strong support for the view that migraineurs may be genetically susceptible or predisposed. While the term excitability is often used to characterize these responses, a state of hypersynchrony (49, 627) would explain the clinical symptoms of migraine very well.

C. Objectives of the review

The objective of this review is to describe the clinical manifestations of migraine in a context of the clinical and preclinical data that illustrate the anatomy, physiology and pharmacology relevant to these symptoms. The reviewed data will support the theory that migraine, at its core, is a disorder of the brain, caused by a dysfunction in areas of the brainstem and diencephalon that alter the perception of sensory inputs, and cause other neurological deficits. We will show how brain function is broadly affected when these systems changes take place in migraine.

II. Clinical Manifestations

Migraine is a complex and multifaceted disorder of the brain which in its entirety may last over several days. Migraine has been classically dissected into four phases: the premonitory, aura, headache and the postdrome phase. These may occur in a linear sequential order but in most cases migraine phases show a significant overlap, such that the linear ordering is both attractive and deceptive in its simplicity. While we will try to dissect the pathophysiology of the symptomatology in stages, it is important to recognize that some symptoms, such as tiredness

or concentration impairment, may well attend all phases. In reality, only head pain, by its absence or presence, marks itself out.

A. International Classification of Headache Disorders (ICHD)

The International Classification of Headache Disorders (ICHD), a valuable tool for the standardized diagnosis of primary and secondary headache disorders, which is now available in its third edition (ICHD-3, summarized in Table 1) (386). From its first (384) through second (385) editions, it led to a significant improvement in diagnostic accuracy, and to improved and focused preclinical and clinical research, in particular clinical trials, in an unprecedented way. However, given its aim to define the clinical picture for the use in a clinical setting, it focuses on the headache and aura phases as they are characterized by disabling symptoms that commonly require medical intervention. Its weakness is the over-reliance on a polythetic approach where there are a broad set of criteria without one or other being necessary or sufficient. This contrasts to a monothetic approach where some or all parts are necessary and sufficient. The conflict comes with face validity for clinicians; it remains an unresolved issue. The impact on physiology is where migraine symptoms, such as osmophobia (464, 714, 878), are not mentioned because they are not usually “needed” by a polythetic approach, which may leave them less studied. In the review, we aim to capture as much of the pathophysiology as possible, and will be inclusive where possible, symptom-wise, and use the concept of phases, as limited as they be in a disorder that often is marked by a continuum.

B. Premonitory Symptoms

The majority of migraineurs experience a range of premonitory symptoms well before the typical migraine headache initiates. Despite being described in the literature for decades (228) their pathophysiological relevance and their clinical implications have been largely neglected. Premonitory symptoms of a migraine attack, which may precede the headache phase by up to 72 hours (300), include changes in mood and activity, irritability, fatigue, food cravings, repetitive yawning, stiff neck, and phonophobia. These symptoms may endure well into the aura, headache (373) and even postdrome phases (105, 299, 465). The current ICHD-3beta precludes the existence of premonitory symptoms within two hours of headache onset (386); this clearly has no logical basis and needs attention. We adopted above the definition of the symptoms starting anytime prior to headache. The consistency of these symptoms allows some migraineurs to reliably predict their migraine attacks (300). The fact that these symptoms are to a large extent of hypothalamic origin and imaging studies using H₂O PET show an increase in hypothalamic blood flow during the presence of premonitory symptoms (559), suggests a prominent role of the hypothalamus in the early stages of the attack.

Interestingly many of the trigger factors described by migraineurs, such as for example sleep deprivation, hunger or bright light may in fact represent premonitory symptoms of an already ongoing attack. This relationship explains why observations in clinical studies that aimed at prospectively identifying and validating trigger factors of migraine commonly differ from findings obtained from questionnaire-based studies in which patients merely describe their own perception of factors triggering their migraine attacks (401).

Understanding the pathophysiological mechanisms underlying the premonitory symptoms may offer insights in the structures of the central nervous system involved in the early phases of a migraine attack and ultimately contribute to identifying a novel therapeutic approach that would exert its action before the headache begins.

C. Aura phase

About a third of migraineurs experience transient neurological deficits, the migraine aura, in the context of their migraine attacks (678). The ICHD-3 defines the migraine aura as one or more transient, fully reversible neurological deficits, of which at least one has to have a unilateral localization, that develop over five or more minutes and of which each deficit lasts between 5 and 60 minutes. Detailed prospective diary study work has shown that 26 % of patients have at least one of three auras that lasts longer than an hour (825). This draws attention to the polythetic problem, since investigation of aura lasting over an hour would be a large waste of resources. Five per cent of auras are over four hours (825); so perhaps that is a useful cut-off. While a visual aura, which may show positive (fortification spectra), negative (scotoma) or both phenomena is found in over 90 % of the cases, and the most common deficit, sensory, motor, speech, brainstem and retinal aura symptoms may also occur. Aura symptoms may precede the headache phase but may last well into the headache phase or even initiate during the headache phase. In contrast to the common belief that the aura and headache phases follow a sequential order, recent studies have demonstrated that the overlap of these phases is very common rather than being the exception (373). In migraineurs suffering from

motor aura symptoms such as in hemiplegic migraine, aura symptoms usually show a longer duration and may last up to 72 hours. In these severe cases of migraine aura, the deficits usually coexist with migraine headache. Remarkably, positive phenomena in hemiplegic aura are very unusual; one would predict jerks prior to weakness if there was invariably an initial depolarization. Since that is not the rule, the clinical phenomenology insists that one keeps an open mind about migraine aura pathophysiology going forward.

A transient wave of neuronal depolarization of the cortex, the cortical spreading depression (CSD), is believed to be the pathophysiological brain mechanism underlying the clinical phenomenon of migraine aura. While in humans the electrophysiological correlate of a CSD has not been demonstrated during a migraine aura, the correlation between the neurophysiological characteristics of a CSD, its retinotopic propagation on the visual cortex and the characteristics and dynamics of the visual deficits suggest CSD as its pathophysiological correlate (158, 513). Indirect observations derived from imaging studies further support this concept (192, 366, 640). Whether CSD is causally linked to the initiation of headache is still extensively debated and discussed in greater detail in below, nevertheless, based on the current understanding of migraine, it is unlikely that CSD is involved in the initiation of the complete syndrome of migraine (307).

D. Headache Phase

In the latest edition of the ICHD-3, migraine is defined as headache attacks lasting 4-72 hours that are accompanied by nausea, photophobia and phonophobia, or both. The headache is

characterized as unilateral, pulsating, of moderate or severe intensity and aggravated by physical activity; two of these characteristics suffice to fulfill the diagnostic criteria. In comparison to previous editions, ICHD-3 distinguishes chronic migraine, which occurs on 15 or more days per month, from episodic migraine in a more practical fashion, building on the appendix definition (637). Whether the distinction has utility as it stands, ie whether the fifteen day cut-off is appropriate, remains unclear. As yet the distinction has not offered ground-breaking physiological insights.

E. Postdrome

The postdrome phase has been largely neglected and is not even defined in the glossary of terms in ICHD-3beta (386). The findings from the few studies that have focused on this last phase of a migraine attack indicate that its characteristic symptoms reflect those observed during the premonitory phase (105, 299, 465). A prospective, systematic electronic diary study, typical postdrome symptoms include tiredness, difficulties in concentrating and neck stiffness. It remains unclear whether these symptoms initiate in the premonitory phase and persist throughout the headache phase into the postdrome phase, if they may also initiate during the headache phase, or even appear after the headache phase has ended. Migraineurs commonly relate symptoms of the postdrome phase to the medication that successfully abolished their headache indicating that these symptoms appear or re-appear after the headache phase has ended while they seem to play a negligible role during the headache phase. However, a meta-analysis of a clinical trial program revealed that postdrome symptoms are seen in the placebo arm most prominently when pain is relieved (318).

III. Imaging migraine pathophysiology

The phases of migraine, including the inter-attack phase, which are described above clinically present a useful way to consider brain imaging results. Given the basic concept that migraine is inherited- a trait, which is well illustrated in electrophysiological studies (206, 709), we shall cover those studies in brief as a backdrop before discussing imaging findings. All these methods suffer to some extent from the principle issue of trait and state. This is true of functional inter-ictal studies as there is no external validation that nothing has started or that the attack has ended. It can be argued that triggered studies have the advantage of homogeneity relative to when the migraine attack process commenced. Another overall issue that applies to all physiological studies in migraine; indeed all studies where controls are used is how one factors in false negative history in controls. The cumulative lifetime incidence of episodic migraine in North American females is 43% (759). If one considers probable migraine and chronic migraine, and the vigorous debate around overlap with tension-type headache, being sure a control does not harbor migraine biology is very challenging. The authors find in any study they have done finding “vanilla” controls is the most difficult part of the work. These caveats apply across all these modalities.

A. Neurophysiology of migraine as a backdrop to imaging

The application of neurophysiological methods in migraine patients has offered important insights into the condition. These approaches offer temporal over spatial discrimination and

prior to MRI, and still to some extent, better opportunities for repetition. What has emerged very clearly from studies in visual, somatosensory, auditory and nociceptive domains is activation that differs from controls reliably. A prevailing synthesis of the data is to consider thalamocortical dysrhythmia (185, 819) to be key to migraine pathophysiology (206). It has been observed for some time that migraine patients fail to habituate normally between attacks, for example the intensity dependence auditory evoked potentials is augmented between attacks in migraine patients (37, 834). Remarkably this normalizes in the days before an attack (452). Interestingly this measure has a serotonin dependence that can be altered by triptans, serotonin 5-HT_{1B/1D} receptor agonists (See Section IX) (671). Potentiation of the passive “oddball” auditory event-related potential similarly suggests migraineur’s brains do not habituate in non-migraineurs do (833), as does an intercal habituation deficit as measured by the nociceptive blink reflex in migraineurs (213). This has led to the concept that the migraine brain over-responds, as distinct from being hyperexcitable (38, 181, 182, 709)

B. Inter-attack imaging studies

1. Structural studies

Several studies have identified differences between migraineurs and control subjects in respect of brain structure. Structural studies are typically cross-sectional, and have to be interpreted in view of functional interactions of pain processing areas with the trigeminal system. Voxel-based morphometry has demonstrated reduced gray matter in pain processing areas, such as the anterior cingulate cortex, amygdala, insula, operculum, and the frontal, temporal and precentral gyri. Interestingly, gray matter reduction in the anterior cingulate cortex was

correlated with the frequency of migraine attacks (812). In contrast, gray matter volume was increased in the caudate nuclei bilaterally in migraineurs with high frequency attacks if compared to patients with low frequency (555). The somatosensory cortex, and especially the somatotopical representation of head and face further depicted increased thickness in comparison to controls (199). The same group used diffusion tensor imaging to evaluate white matter integrity. They demonstrated reduced fractional anisotropy in migraineurs along the thalamocortical tract, in migraineurs with aura also in the ventral trigeminothalamic tract, and in migraineurs without aura in the ventrolateral periaqueductal gray (PAG) (199). In another study, diffusion tensor imaging was applied to 16 patients and 15 controls to measure the extent of tissue damage in the brain. Only minor diffusivity changes were identified in the gray matter whereas the normal-appearing white matter and changes in brain volume were equally distributed in both groups (689). In a larger study with 22 patients and 20 controls, T1 relaxation time was shorter in the thalamus of migraine with aura patients compared with migraine without aura and healthy controls. (359). In an international collaboration 3T scans from 131 migraineurs were obtained and pooled and showed volume loss in patients compared to controls in the central nuclear complex, anterior nucleus and lateral dorsal nucleus, as well as reduced striatal volume (553). Overall, the studies demonstrate that the ability of developing migraine attacks is reflected by structural alterations in pain processing areas such as the anterior cingulate cortex and the trigeminal somatosensory system. From the nature of the method, it remains unclear if these changes are the consequence of repetitive migraine attacks or if they are involved in migraine pathophysiology. Using diffusion tensor MRI it was shown that fractional anisotropy was higher and mean diffusivity lower in migraine without aura

patients compared to controls in their thalami between attacks. This change normalized in migraineurs during attacks (184). Importantly, there was correlation between changes in the right thalamus and the days from the last attack (184). Building on these observations using voxel-based morphometry with T1-weighted 3T MRI it was shown that migraine without aura patients have lower gray matter density in the right inferior parietal lobule, right temporal inferior gyrus, right superior temporal gyrus, and left temporal pole interictally, with no reductions ictally (180). Taken together the data suggest plastic changes attendant the migraine attack that may underlie disorder progression.

2. Functional studies

Functional studies complement structural brain imaging. They are typically divided into those looking at the function of the migrainous brain at rest, i.e. the true inter-ictal state, and in those investigating its *response* to external stimuli.

i. Metabolism and Receptor Pharmacology

The classic way of analyzing functional differences between two groups at rest is to assess regional brain metabolism with ^{18}F -FDG PET. This identifies functional differences in migraineurs *independently* from specific external stimuli, as with BOLD-fMRI, or from pre-defined brain areas, as with seed-based 'resting state' analysis. Therefore, studies using ^{18}F -FDG PET can be regarded as very close to the biology of the disease, although exposure to radiation and poor spatio-temporal resolution are clearly limiting factors. Kim and colleagues (467)

compared twenty interictal episodic migraineurs with control subjects. Migraine was associated with hypometabolism of central pain processing areas including bilateral insula, bilateral anterior and posterior cingulate cortex, left premotor and prefrontal cortex, and left primary somatosensory cortex. This suggests a dysfunction of central pain processing in the interictal state possibly reflecting the readiness of the brain to develop migraine attacks. Interestingly, there was no area of hypermetabolism.

ii. Stimulated blood flow changes

Photophobia is one of the key non-head pain symptoms defining migraine (386). Patients typically describe light being too bright (abnormal sensitivity to light) or even painful by causing or worsening head or eye pain (phototic allodynia). Even interictally migraineurs tolerate less luminence than healthy controls (817). Similarly, migraineurs but not controls activate the visual cortex (cuneus and lingual gyrus) when exposed to different luminous intensities as shown in seven interictal migraineurs with $H_2^{15}O$ -PET (116). Interestingly, the application of trigeminal pain also led to an activation in the same areas in control subjects. This indicates that activation of the trigeminal system, as might happen during migraine attacks, could result in a facilitation of the retino-geniculate-cortical pathway of visual processing and/or a dysfunction of visual association areas causing photophobia.

Using fMRI, Moulton and colleagues (614) measured the brainstem response to heat stimuli and identified a reduced response in the nucleus cuneiformis, which is known to be a

component of brainstem pain modulating circuits. During migraine attacks, this dysfunction might lead to hyperexcitability of trigeminovascular neurons and thus to the perception of headache. The same group further found the anterior temporal pole of migraineurs being more active after painful heat stimulation when compared to control subjects (613). The temporal pole further depicted increased functional connectivity to various brain regions that might be involved in migrainous symptoms, such as the anterior cingulate cortex, the somatosensory cortex, amygdala, and others. Similarly, it can be shown by investigating the response to painful heat stimulation to the dorsum of the hand that migraineurs with high frequency attacks had reduced BOLD-response in the basal ganglia, putamen, caudate and pallidum, compared to controls (555).

Demarquay and colleagues (207) evaluated olfactory processing in migraineurs with habitual olfactory hypersensitivity. They assessed regional cerebral blood flow (rCBF) in 11 migraineurs and 12 controls. During odor-stimulation migraineurs had increased rCBF in the left temporal pole and lower values in the frontal and temporo-parietal regions, posterior cingulate gyrus and right locus coeruleus. Subjects with olfactory hypersensitivity differed from those without in the left piriform cortex and antero-superior temporal gyrus. Some specific symptoms in migraineurs, such as olfactory hypersensitivity, are therefore associated with a unique cortical response even outside of attacks. Taken together, these data suggest that various cortical and subcortical areas in the brain of migraineurs respond differently to external stimuli when compared to healthy controls. This might imply that a migraineur's brain is 'dys-excitable' (750)

with pre-conditioned functional abnormalities that concertedly exacerbate during migraine attacks.

iii. Resting-State Studies

While structural brain imaging identifies differences between grey or white matter and stimulus-driven fMRI locates individual dysfunctional areas, the 'resting state' approach assesses the cross-talk between different areas (functional connections) by measuring the correlation of low-frequency spontaneous fluctuations between remote brain areas (280, 281).

Mainero and colleagues demonstrated that migraineurs have stronger connectivity between the PAG and several brain areas that are relevant for nociceptive and somatosensory processing. They further showed an association between this connectivity and frequency of migraine suggesting some pathophysiological relevance of this correlation for pain modulation in migraine (554). Cutaneous allodynia is thought to be the manifestation of central sensitization during migraine attacks. Comparing the 'resting state' connectivity of migraineurs with and without cutaneous allodynia, differences in the connectivity of the PAG/nucleus cuneiformis to various discriminative pain processing centers (brainstem, thalamus, insula, cerebellum) and higher order pain modulating areas (frontal and temporal regions) were identified (719). This implies that individual symptoms during migraine attacks are reflected by interictal abnormal communication between pain-modulating areas. Further, although both groups were migraineurs (386) with normal routine investigations, the presence of ictal

allodynia seems to determine different sub-syndromes of migraine indicating that migraine itself might also be pathophysiologically diverse. Linking studies in the headache phase, seed-based resting state fMRI has demonstrated increased connectivity between primary visual and auditory cortices and the right dorsal anterior insula, and between the dorsal pons and the bilateral anterior insulae; neither correlated with migraine frequency (801), suggesting the changes were a trait of migraine pathophysiology. Another intriguing possibility is fMRI for classification. Using a seed-based approach, resting functional connectivity of the right middle temporal, posterior insula, middle cingulate, left ventromedial prefrontal and bilateral amygdala regions best discriminates migraine and control brains (166). While having a circularity because the gold-standard remains clinical, it can be seen such approaches may yield both insights into biology and *NextGen* approaches to treatment trial outcomes as a biomarker of change, for example in preventive studies.

In contrast to the seed-based resting-state networks, i.e. those identified by looking for the connectivity of one or other 'seed' area (e.g. PAG or nucleus cuneiformis), task-free resting state studies using independent component analysis without *a priori* hypothesis have been conducted. Tessitore and colleagues (788) compared this default mode network of 20 patients with migraine without aura to 20 age- and gender matched controls. Migraineurs had decreased connectivity in prefrontal and temporal regions of the default mode network. The authors speculate that such dysfunction of the default mode network might be related to maladaptive reactions to stress or environment putatively being characteristic for migraine.

In summary, being a migraineur means having subtle differences in brain structure and function even outside of attacks. Importantly, most areas are part of the unspecific pain processing areas or of the trigeminal system. A major challenge is to understand how these differences predispose to migraine attacks, or in other words, which structures drive the 'migraine cycle' from interictal via premonitory phase to the headache phase and, finally, the postdrome period that then runs over back to the interictal phase.

iv. Mitochondrial Energy Metabolism

The recognition of migraine as a component of mitochondrial cytopathies (221) offers an avenue to explore how that biology may produce migraine. An initial study of mitochondrial DNA did not find any of the typical MELAS or MERRF mutations (470). The successful completion of a randomized controlled trial of riboflavin (vitamin B2) as a preventive treatment of migraine (710), further lends an argument to pursue metabolic dysfunction as a possible susceptibility in some patients. Using ^{31}P -NMR spectroscopy Welch and colleagues (843) showed a change in phosphate metabolism in patients with migraine with aura during an attack. Again with ^{31}P -NMR spectroscopy a later study in patients with migraine without aura showed changes in phosphate metabolism (607). Similar results were seen in children (545). Using a 3T MRI and ^{31}P -NMR spectroscopy it has been shown in the occipital cortex of patients with migraine without aura that there are changes in energy metabolism (683). There is, as could be expected some distribution of the energy changes across the patients studied, so it seems likely that these findings could explain some, and not all, of the biology of migraine expression.

C. Premonitory phase

From a clinical perspective, the premonitory phase that connects the asymptomatic interictal phase with the headache attack has to be crucial for understanding the mechanism of migraine ignition. One of the most important fMRI studies in this respect assessed the (de-)activation pattern elicited by trigemino-nociceptive stimulation of the nasal mucosa as the headache day approached (749). When compared to control subjects, interictal migraineurs have reduced activation of the spinal trigeminal nuclei. This deactivation had a cyclic behavior over the course of a migraine interval: there was normalization prior to the next attack and a significant reduction of deactivation during the attack (Figure 1). This cyclic behavior might thus reflect the increased susceptibility of the brain to generate the next attack, and the identification of its pacemaker would be crucial for our understanding of the start of a migraine attack.

The earliest clinical signs of a migraine attack are so-called premonitory symptoms, which occur prior to head pain but already tell the patient that a headache is on its way. Based on their manifestation, they are likely related to the hypothalamus (56, 482) and include concentration problems, tiredness, irritability or depression. When compared to the headache phase, they typically resemble some of the non-headache symptoms of a migraine attack and thus might persist during the headache phase. Recently Maniyar and colleagues (559) triggered migraine attacks in eight patients with migraine without aura in patient who could predict the occurrence of headache by a pronounced premonitory phase. During the premonitory phase, i.e. still in the absence of head pain, $H_2^{15}O$ -PET demonstrated activation of the hypothalamus,

the midbrain ventral tegmental area, and the PAG (Figure 2). This functional correlate of premonitory symptoms suggests a possible role of the hypothalamus in generating migraine attacks. Of great interest in this regard are data from a single patient whose responses to trigeminal nociceptive stimuli were tracked with BOLD-fMRI over a 30 day period. Hypothalamic responses were increased as the attack neared, and there was coupling of the effects with the dorsolateral pons (715). In addition, the hypothalamus might be important for the non-headache symptoms during the pain phase since when studied in seven spontaneous migraine attacks with H_2^{15}O - PET activation of the hypothalamus was seen (209) – although the location of both activations were distinct. It is noteworthy that activations seen in the trigeminal-autonomic cephalalgias (575, 576, 581, 582, 748) are more posterior than reported in migraine.

D. Aura phase

The typical visual aura usually begins prior to the headache phase, but can also occur at the same time or even independently from any headaches (373, 825). It often starts with a blind or scintillating spot in the center of the visual field (15). Lashley (506) reported some observations of his own visual aura: in his case, the scotoma increased in size over about one hour drifting in a C-shape toward the temporal field of one side. The velocity of the corresponding spread over the visual cortex was calculated to about 3 mm/min. A hypothetical underlying mechanism was established only a few years later by Leão (517-519), who stimulated rabbit cortex electrically and found an EEG depression spreading at a similar rate of 3 mm/min centrifugally from the site of stimulation, and suggested it might be the basis for migraine aura (520). Over decades it was suggested that typical visual aura could be attributed to such a ‘cortical spreading depression’

(CSD, see below) (513). The occurrence of CSD in humans remained hypothetical until Olesen and colleagues (640) injected ^{133}Xe into the carotid artery during human migraine aura and demonstrated a spreading alteration of rCBF. Two decades later, patients who could trigger their visual aura or who were able to get access to the study center in the early phase of a visual aura were scanned with fMRI using checkerboard stimulation (366). The change of blood oxygenation level-dependent (BOLD) signal in the visual cortex in response to this checkerboard stimulation during the course of a visual aura behaved in various aspects similarly to the CSD from the animal model (518, 519). This included a signal spread with a velocity of about 3.5 mm/min, which corresponded to the clinical prediction (506) and the CSD elicited in rabbit cortex (518, 519). This suggests that visual aura in migraine might indeed be a consequence of a CSD-like event. Hadjikhani and colleagues (366) further identified the origin of this peculiar response to checkerboard stimulation being in the visual association cortex V3A.

E. Headache phase

As described earlier perhaps the most striking symptom of a migraine attack for most patients is headache, although additional symptoms have to be present to make the diagnosis, such as nausea, photophobia, phonophobia and movement sensitivity (386). Accordingly, the imaging pattern obtained during migraine attacks always represents a combination of these symptoms with some possibly reflecting individual symptoms, such as head pain, photophobia or allodynia, and others giving evidence of the underlying mechanisms.

1. Head pain

The phenotype of primary headache disorders is far more complex than head pain alone that is for instance elicited by noxious stimulation of the skin. However, the experience of pain is present in noxious head pain and spontaneous migraine attacks, and the signature identified in functional brain imaging of experimental head pain should also be found in migraine headache. In other words, the demonstration of *additional* areas in primary headache disorders might be regarded more specific for migraine and thus might reflect symptoms other than head pain or even mechanisms driving migraine attacks. Functional brain imaging of noxious pain in the head will be discussed at this place since it greatly simplifies our understanding of functional brain imaging of migraine. Using H_2^{15}O -PET in seven healthy subjects, May and colleagues (585) measured rCBF after the injection of a small amount of capsaicin into the forehead. They found an increase of rCBF in the pain state in several brain areas including the bilateral insula, the anterior cingulate cortex, the cavernous sinus and the cerebellum. Importantly, there was no activation of the brainstem.

2. Migraine attacks

One of the most influential migraine studies of the last two decades measured rCBF using PET with ^{15}C -labeled O_2 integral inhalation in nine migraineurs during spontaneous right-sided migraine attacks. When compared to the pain-free interval, there was an increase of rCBF during migraine in the cingulate cortex, the auditory association cortex, and the parieto-occipital junction near the visual association cortex. In addition, the migraine state showed

increased rCBF in the midbrain, the dorsal rostral pons close to the PAG and raphe nuclei (842). In comparison to the non-specific pain-signature of the capsaicin experiment above (585), this study located various migraine symptoms to different areas of the brain with the experience of head pain to the cingulate cortex, photophobia to the visual association cortex, and phonophobia to the auditory association cortex. These signals disappeared after successful termination of the attack. However, the increased rCBF in the brainstem persisted in the early pain-free phase. This structure might thus not just reflect a migraine symptom but it indicates a dysfunction of importance for the generation or in sustaining of the migraine attack itself (Figure 3). The relevance of the brainstem for the pathophysiology of migraine is further supported by clinical studies and basic research. For instance, the new onset of migraine in previously non-migraineurs who have been treated with deep brain stimulation of the PAG for other pain conditions (677, 822) and the accumulation of iron in the PAG over the duration of illness (844) point to the PAG being crucial for the development of migraine. As described here in several sections, several animal studies support this view by demonstrating that brainstem nuclei, such as PAG and raphe nuclei have great influence on trigeminovascular processing in experimental migraine models (21).

More refined techniques with higher spatial and temporal resolution have led to functional brain imaging studies supporting the importance of the brainstem for migraine pathophysiology. Bahra and colleagues (66) compared migraine to another primary headache (cluster headache) and demonstrated that the brainstem activation is specific for migraine. Afridi and colleagues (13) assessed the laterality of this activation in unilateral migraine attacks.

They found it being ipsilateral to the headache side and concluded that unilateral pain might be a consequence of unilateral brainstem dysfunction. Importantly, as described above, Maniyan and colleagues (559) also found the dorsal rostral pons and the PAG, but also the hypothalamus being activated in the early premonitory phase supporting the view of a 'migraine mediator' in these areas. When combining the clinical picture of migraine being a dysmodulation of sensory: nociceptive, light, sound, and olfactory, input and the findings from functional brain imaging, brainstem or hypothalamic structures, or both, seem to be crucial for the pathophysiology of migraine and might reflect the anatomical location of brain dysfunction leading to the complex pattern of migraine attacks.

3. Photophobia

Denuelle and colleagues (208) studied eight migraineurs during headache attacks, after relief by sumatriptan and in the migraine-free interval. By applying continuous light stimulation, they found that *low luminance* stimulation resulted in an increase of rCBF as measured by $H_2^{15}O$ -PET: there was hyperperfusion of the visual cortex during the headache attack (cuneus), after headache relief (cuneus and lingual gyrus), but not in the inter-ictal state. This might reflect hyperexcitability of the visual cortex during migraine attacks. By definition, the persistence after headache relief was *independent* of the presence of head pain. This might point to the structural correlate of photophobia being located in the primary and supplementary visual cortex. Interestingly, the areas activated *during* migraine attacks by *low* luminance were the same as the areas activated *interictally* by *increasing* luminous intensities supporting the view

that migraine and even its associated symptoms are continuously subject to a cycling mechanism.

Although conducted in the premonitory phase studies of non-headache symptoms without pain have been valuable in showing the independence of these phenomena from pain yet their important biology in migraine. It has been shown comparing patients with triggered premonitory attacks that those with photophobia, photic hypersensitivity given the lack of pain, had activation of extrastriate visual cortex (Brodmann area 18) (559). In addition, interictal connectivity in the visual system is seen using resting state methods in the lingual gyrus (785). Similarly to the premonitory visual findings, when comparing patients with or without nausea in the same experimental design, those with nausea had activation in the rostral dorsal medulla in an area that included the nucleus tractus solitarius, dorsal motor nucleus of the vagus nerve and the nucleus ambiguus, as well as activation in the periaqueductal gray (PAG) (560). These studies build a picture of the brain regions involved in migraine and clearly show mechanisms that are not simply pain-dependent.

Different visual migrainous phenomena are associated with a dysfunction of different areas of the visual association cortex. For instance, the cuneus and lingual gyrus are involved in photophobia (208), whereas V3A might be the origin of typical visual aura (366). When further comparing the imaging results during migraine premonitory phase, i.e. hypothalamic and brainstem activation with those of cortical activation during typical migraine aura, it seems likely that aura and migraine are different phenomena.

4. Blood-brain barrier

The integrity of the blood-brain barrier (BBB) in migraine is a crucial question particularly for therapeutics (see section X). It has been speculated for some time that the BBB may be disrupted in migraine (378). Schankin and colleagues (708) used a bespoke PET ligand ^{11}C -dihydroergotamine, measuring the influx rate constant K_i , average dynamic image and time activity curve using arterial blood sampling. At rest, there was binding of ^{11}C -dihydroergotamine in the choroid plexus, pituitary gland, and venous sinuses as expected from the pharmacology of dihydroergotamine (367). This was not altered in controls or migraine patients with a nitroglycerin-triggered attacks; and is broadly consistent with the known data suggesting the BBB is intact in migraine (243, 328). However, whether medicines access the brain is an entirely different question. Sumatriptan, classically considered peripherally acting, has a concentration of 10-20% the venous levels in the CSF of dog (433). After oral administration of sumatriptan 100mg in volunteers not having migraine, it could be measured in the CSF (626) in amounts sufficient for pharmacological actions. Similar discussions are had concerning gepants, calcitonin gene-related peptide receptor (CGRP) antagonists. Using ^{11}C -MK-4232, a CGRP receptor antagonist and PET ligand, it has been shown that telcagepant, a clinically proven CGRP receptor antagonist (Table 4) has low receptor occupancy (425). Lastly, it is often said, in a careless manner that monoclonal antibodies do not cross the BBB. It is clear from very careful, older studies that about 0.1% of the intravenous concentration can be found in the CSF (262). These data have recently been corroborated with ^{125}I -LY2951742 ligand study, again a clinically proven IgG4 CGRP peptide monoclonal antibody (Table 4) found again at about 0.1%

concentration in CSF versus plasma (447). There are two themes from these data: first, from a macro perspective the BBB is normal in migraine; secondly, BBB and CSF access is not an all-or-nothing principle. The real question is how much of any treatment is needed for a clinical effect in the brain. This is certainly an unresolved but important question.

F. Postdromal phase

The postdromal phase follows the end of head pain for hours or days when the patient is pain-free but still does not feel back to normal. In contrast to the headache phase and the premonitory phase, the postdrome has not been studied specifically with brain imaging. This remains a substantial opportunity and a real challenge.

IV. Anatomy of trigeminovascular pain pathways

The previous section has described what we have learned from imaging the brain in migraineurs. Distinct areas of the brain are activated suggesting a role for them in migraine pathophysiology; whether this is triggering the attack, generating the pain, or an involvement in some of the associated neurological symptoms that occur in the duration of an attack. Much has been learned from preclinical anatomical and physiological studies about the association of these different brain regions to each other, defining the involvement of specific brainstem and diencephalic nuclei and cortical areas in this network. These studies have also been able to determine how nociceptive information from craniovascular structures is processed resulting in

the perception of headache during migraine, as well as associated neurological sensory symptoms.

A. Peripheral afferent projections

The pain associated with the head in a migraine attack, including the frontal, temporal, parietal, occipital and high cervical region, is thought to be the consequence of activation of the trigeminovascular system (Figure 4). The anatomy of the trigeminovascular system has been well described over the last 70 years and this has helped to understand the pathophysiology of migraine and the distribution of its pain. The brain is known to be largely insensate, but a rich plexus of nociceptive nerve fibers that originate in the trigeminal ganglion innervate the pia, arachnoid and dural blood vessels, including the superior sagittal sinus and middle meningeal artery, as well as large cerebral arteries (594, 658, 679). Activation of these structures, particularly the dura mater, with mechanical, chemical or electrical stimulation results in headache pain very similar to the pain in migraine, as well as other symptoms associated with migraine, including nausea and photophobia (594, 658, 679). Interestingly, stimulation of sites away from these blood vessels is much less nociceptive, with correspondingly lower symptoms of headache. The nociceptive innervation of the intracranial vasculature and meninges includes non-myelinated (C-fibers) and thinly myelinated (A δ -fibers) axonal projections, mainly through the ophthalmic (V1) division of the trigeminal nerve, but also to a lesser extent, through the maxillary (V2) and mandibular divisions (V3). There is also a neuronal innervation of the dura mater from the cervical dorsal root ganglia (563). The axon terminals of nociceptive nerve fibers that innervate the dura mater contain vasoactive neuropeptides including calcitonin gene-

related peptide (CGRP), substance P, neurokinin A and pituitary adenylate cyclase-activating peptide (PACAP) (237, 804-806) (Table 1), which are thought to be released upon stimulation causing vasodilation of dural and pial vessels (234, 662, 852).

B. Central afferent projection

There is also a central afferent projection from the trigeminal ganglion that enters the caudal medulla of the brainstem, via the trigeminal tract, which terminates in the spinal trigeminal nucleus caudalis (Sp5C; TNC), as well as the upper cervical spinal cord (C1-C2). Nociceptive A δ - and C-fibers predominantly terminate in the superficial laminae, I and IIo, as well as deeper laminae V-VI (22, 135, 408, 541, 542, 601) of the TNC and cervical extension. Stimulation of the dural vasculature in animal models, including the superior sagittal and transverse sinuses, and middle meningeal artery, results in activation of neurons in the TNC, C₁ and C₂ regions of the cervical spinal cord – together known as the *trigemino-cervical complex* (TCC) (135, 329, 334, 461). Furthermore stimulation of the greater occipital nerve also causes neuronal activation in the same regions and enhances convergent inputs from the dural vasculature (75, 76). These data suggest that the trigeminal nucleus extends beyond its caudalis boundary to the dorsal horn of the higher cervical region in a functional continuum that includes the cervical extension. This convergence of neuronal inputs into the TCC (330, 422, 463) and the convergence of inputs from intracranial and extracranial structures probably accounts for the distribution of pain perception in migraine over the frontal and temporal regions, plus the involvement of parietal, occipital, and higher cervical regions (74). Therefore the severe and throbbing nature of pain in migraine is thought to result from activation, or the perception of activation, of these

nociceptive inputs from intracranial and extracranial structures, that converge and are relayed through the TCC. Activation of these neural pathways in animal models of migraine has become a reliable way to further understand migraine pathophysiology, as well as being used to screen for potential therapeutic targets.

C. Ascending projections from the trigeminocervical complex (TCC)

All nociceptive information from craniovascular structures is relayed through the TCC, and via ascending connections to other areas of the brainstem and diencephalon, involved in the processing of pain and other sensory information. Functional physiological and tracing studies have allowed mapping of these ascending connections. Activation of these structures is thought to contribute to the perception of pain during migraine, and also to autonomic, endocrine, cognitive and affective symptoms that last throughout the entire migrainous episode.

There is a reflex connection from the trigeminal nucleus to the parasympathetic outflow to the cranial vasculature via the superior salivatory nucleus (SuS) (584). The SuS is activated by dural electrical stimulation (473), or directly from the brainstem (336), and this traverses back to the TCC via the parasympathetic outflow to the craniovasculature (25, 312). There are also direct ascending connections with other medullary pontine nuclei including the rostral ventromedial medulla (RVM), nucleus raphe magnus (NRM), parabrachial nucleus and locus coeruleus (543, 688), and midbrain nuclei, the ventrolateral periaqueductal gray (vlPAG) and cuneiform nucleus (543), with demonstrated functional nociceptive inputs from the dura mater (133, 135, 236, 330, 418, 422). Somatosensory and visceral nociceptive information from the head and

orofacial structures, via the TCC, is also conveyed directly to hypothalamic nuclei, along the trigeminohypothalamic tract, including the anterior, lateral, posterior, ventromedial, perifornical and supra-optic hypothalamic nuclei (126, 129, 556-558), and activated by dural nociceptive stimulation (85, 556). Likewise, functional dural inputs are relayed through the caudal medullary TCC, via the quintothalamic (trigeminothalamic) tract, to the thalamus (543, 579, 731, 820, 851). Specifically dural nociceptive inputs are processed in the ventroposteromedial (VPM) thalamus and its ventral periphery, the medial nucleus of the posterior complex, including posterior thalamic nucleus and the intralaminar thalamus (132, 135, 346, 347).

D. Brainstem and thalamic projections to subcortical and cortical structures

The processing of pain is complex and mediated by a network of neuronal structures which include the cingulate cortex, insulae and thalamus (211, 799). The thalamus is believed to be at the heart of the central processing and integration of nociceptive information, and is regarded as a relay center for handling the incoming sensory information, and even modulating it. A so called '*Pain Matrix*', which includes the thalamus, as well as primary (S1) and secondary (S2) somatosensory areas, anterior cingulate cortex (ACC) and prefrontal cortex, is believed to be involved in integrating all sensory, affective and cognitive responses to pain, and becomes active during nociceptive processing (211, 799). The extent to which parts of this matrix is attentional as much as a pain-related is debated (615). Other subcortical structures, which have anatomical connections to brainstem and thalamic nuclei, are known to be involved in this fluid network depending on the context of the pain, and likely contribute to the complexity of

neurological symptoms experienced by migraineurs, additional to their headache. The amygdala and hippocampus are structures likely to be crucial in processing affective and cognitive responses to pain, respectively. Retrograde tracing from the amygdala reveals projections from the parabrachial nucleus and specifically lamina I and II of the TNC (445), which may contribute to an altered emotional state during migraine, and its comorbidity with anxiety disorders and depression (130). Furthermore, indirect projections from the trigeminal nucleus, through the amygdala to the hippocampus (484), confirmed in rodents, may contribute to altered cognition. It is likely that in time, continued research will reveal the importance of these and other subcortical structures to the pathophysiology of associated neurological symptoms in migraine.

Craniovascular projections, via trigeminovascular neurons, to VPM thalamic nuclei (876, 877), have been identified and are believed to be the principal thalamic relay conveying nociceptive information to higher cortical pain processing regions (659). Other thalamic nuclei, which may also be involved in processing nociceptive craniovascular inputs includes the posterior (Po) and lateral posterior/dorsal (LP/LD) thalamic nuclei (132, 202, 632). Two recent studies have been able to trace the connections of these nuclei to the regions of the cortex that ultimately process this information (illustrated in figure 4). In rat (631) and cat (501), dural nociceptive VPM neurons projected to mainly primary (S1) and secondary (S2) somatosensory cortices, as well as the insula. These data suggest that the processing of craniovascular sensory and discriminatory information, particularly in the ophthalmic (V1) trigeminal division, is somatotopically organized to cortical regions, which may account for the ability of migraineurs to localize their intracranial

pain to specific head regions, as well as the intensity and quality of their pain. On the other hand, dural nociceptive PO, LP and LD thalamic neurons project to many functionally distinct and anatomically remote cortical regions, including S1 and S2, but also to motor, parietal association, retrosplenial, auditory, visual and olfactory cortices (631). These data suggest that the processing of craniovascular nociceptive information in PO, LP and LD thalamic neurons relay directly to cortical areas, suggesting a role in cognitive and motor deficits during migraine, as well as allodynia, photophobia, phonophobia and osmophobia.

E. Interpretation of human imaging in context

In the section on imaging studies the specific regions of the brain activated during spontaneous and experimentally-induced migraine, and their contribution to other symptoms is explored. The anatomical and physiological preclinical studies described in this section plot the pathway of nociceptive craniovascular inputs through the trigeminovascular system that project and are processed in higher pain processing centers, and parallel the findings from the imaging studies in migraineurs. Thus, there is clear translation between preclinical studies and clinical findings, with evidence of dorsal pontine and midbrain activation occurring during a migraine attack (9, 842), even during premonitory symptoms, triggered by an experimental mediator (559). Also PET imaging studies demonstrate evidence of activation of hypothalamic nuclei (209), and activation in the ACC, frontal cortex, visual and auditory cortices, as well as the thalamic nuclei contralateral to the side in which the pain is experienced (9, 66, 842). Therefore, similar processing centers to those utilized after nociceptive activation are involved, with recent work using functional connectivity approaches that describes statistical dependencies between

spatially segregated neurons (748, 755, 801). The anatomy and physiology of the pain pathways involved in migraine are well described and help us to understand their role in the pathophysiology of the generation of pain in migraine and the associated neurological symptoms.

V. Modulation of trigeminovascular pain pathways

Ascending connections from the TCC to many areas of the brain are involved in processing nociceptive somatosensory information from the head and face, and determine how it is perceived. However there are also many endogenous mechanisms that modulate trigeminovascular nociceptive traffic, which can further determine the perception of this information. As indicated in section III there is clear evidence of activation in areas of the brainstem and diencephalic nuclei before, during and after the cessation of migraine with treatment (9, 13, 66, 209, 842) that cannot be explained as solely a consequence of the pain response. Certainly descending modulation of somatosensory processing is not unique to migraine and has previously been described with respect to spinal responses. Brainstem modulation can have both a facilitatory effect, contributing to chronic pain (270) and an inhibitory influence, through supraspinal and spinal stimulation, on spinal nociceptive processing (271, 666, 703). There is still much debate surrounding the role of brainstem and diencephalic activation during migraine. Does this activation signal an area of the brain where migraine may be triggered, or is it a consequence of activation of the trigeminovascular system, which drives other symptoms in migraine?

Human imaging studies have helped us learn a great deal about the central mechanisms likely responsible for symptoms in migraine, and those involved in its pathophysiology but a limitation of human imaging studies is that they cannot dissect specific nuclei, only general regions. This often poses more questions than providing answers. However preclinical studies have been able to dissect specific nuclei that provide endogenous modulation of trigeminovascular nociceptive traffic, which may or may not also be involved in the more general modulation of pain (descending projections are summarized in figure 5). These studies may provide us with more of the answers that are necessary to determine the role of these brain areas in migraine.

A. Brainstem modulation

1. Superior salivatory nucleus (SuS)

The SuS, located in the pons, is part of the trigeminal autonomic reflex, receiving a reflex connection from the trigeminal nucleus (584). It contains the cell bodies of neurons that are part of the cranial parasympathetic autonomic vasodilator pathway (745). These neurons project predominantly through the greater petrosal branch of the facial (VIIth) nerve, via the sphenopalatine (pterygopalatine) ganglion (360) to the cranial vasculature, including the dura mater and lacrimal gland. Activation of the SuS and its parasympathetic projection to the cranial vasculature is thought to contribute to the autonomic symptoms sometimes found in migraine (26, 494), but particularly in trigeminal autonomic cephalalgias, such as cluster

headache and paroxysmal hemicranias (309). The SuS also has bidirectional connections with areas of the hypothalamus, including lateral (423, 745) and paraventricular hypothalamic nuclei (424, 688, 745) as well as the A5 and the parabrachial nucleus, and limbic and cortical areas (745). These are regions involved in feeding, sleep and stress, which may contribute to triggering mechanisms in migraine, as well as to associated neurological symptoms (131).

Studies in rodents have demonstrated that direct stimulation of the SuS activates two populations of neurons in the TCC (25, 26). First, via retrograde activation of the trigeminal autonomic reflex, within the brainstem, there are responses that are not blocked by inhaled oxygen. The second population of neurons causes activation of the parasympathetic outflow to the cranial vasculature, which indirectly activates trigeminal afferents from the dura mater to the TCC, also resulting in autonomic symptoms. Autonomic symptoms are demonstrated by increased flow in the lacrimal duct/gland. Both neuronal and autonomic responses are attenuated by inhaled oxygen and blockade of the autonomic pterygopalatine ganglion (26) (Figure 6). Furthermore, chemical manipulation of the SuS with either lidocaine or an excitant differentially modulates light-responsive TCC activity (635). Activation of the parasympathetic outflow to the cranial vasculature, through stimulation of the sphenopalatine ganglion (311, 338) and the facial nerve (304, 305) also causes increases in cerebral blood flow at the cortical level. Neurons that project from the SuS to the extracranial vasculature are believed to release vasoactive intestinal peptide (VIP) as their primary transmitter (341, 344), which is known to be released during cluster headache (320) and paroxysmal hemicrania (321), and during migraine

attacks that present with cranial autonomic symptoms (325). VIP may, in part, be the mediator of autonomic symptoms associated with these primary headaches.

There is also evidence of 5-HT_{1D} receptors and CGRP in the sphenopalatine ganglion on neurons that innervate the lacrimal gland and trigeminal ganglion (438). Therefore they are in a position to modulate trigeminovascular nociceptive activation and autonomic symptoms, which may explain why triptans can relieve symptoms in migraine, and why naratriptan is able to attenuate neuronal responses in the TCC and increases in lacrimal flow after SuS stimulation (26). These data imply that the SuS can activate neurons of the trigeminovascular system, but also modulate the responses of nociceptive inputs, as well as make changes at the level of the cortex, implying an ascending effect. Activation of these neurons is likely to contribute many of the symptoms experienced by migraineurs, including pain, cranial autonomic symptoms, and symptoms related to hypothalamic activation that are characteristic of migraine.

2. Locus coeruleus (LC)

The LC is also located in the pons and is the principle site of noradrenaline synthesis in the brain (36) and receives projections from the paraventricular hypothalamic nucleus (688). Imaging studies have indicated that dorsal pontine regions may be activated before and during migraine, which might include the LC (559). Its stimulation causes a frequency-dependent reduction in intracranial blood flow, indicating vasoconstriction, measured as an increase in internal carotid resistance (335, 336). This response is predominantly mediated by a α_2 -adrenoceptor mechanism (337). Furthermore, the maximal level of reduced cerebral blood flow

after LC stimulation was in the occipital cortex (319), an area where blood flow changes occurring during migraine aura are thought to begin (192, 640). Accompanying this intracranial vasoconstriction is a frequency-dependent increase in extracranial blood flow, indicative of vasodilation, measured by a drop in the vascular resistance in the external carotid (335). These responses demonstrate that brainstem nuclei can generate vascular changes in the intra and extracerebral vasculature that have been demonstrated during migraine (502), and particularly cause cortical blood flow changes similar to those found in migraine aura, which therefore may be triggered by brainstem activation.

3. Rostral ventromedial medulla (RVM)

The RVM is a cluster of neurons in the medulla. It is predominantly identified as receiving bidirectional projections from the ventrolateral PAG (vlPAG), as well as the spinal dorsal horn (80, 273, 412). This pathway is thought to provide descending control of pain processing to the spinal dorsal horn because of the high concentration of endogenous opioid signaling and has been described as the ‘endogenous pain modulatory pathway’ (272, 275, 573). ‘ON’, ‘OFF’ and ‘Neutral’ cells in the RVM, all of which are non-serotonergic (291, 292, 572), have been hypothesized to provide descending control of spinal nociceptive neurons (272, 274). ‘ON’ cells facilitate firing of neurons that receive nociceptive inputs, and are inhibited by opioids, whereas ‘OFF’ cells are tonically active and their firing inhibits nociceptive inputs, and they are activated by opioids (273). The role of ‘Neutral’ cells is not clear; they do not respond to noxious heat to the tail in rodents, hence their description. However they have been shown to respond to other forms of noxious stimulation to other regions of the body, including the face, in either an ‘ON’

or 'OFF' fashion, which might indicate they are subtypes of these cells (253). The role of the RVM in the descending control of nociceptive spinal neurons may also be applied to the trigeminovascular system as well, controlling dural nociceptive inputs to the TCC. Studies have shown that RVM neurons identified as either 'ON', 'OFF' or 'Neutral' cells, by their response to paw withdrawal, in a lightly anesthetized state, also responded to an inflammatory soup applied to the dura mater (236). 'ON' cells were potently activated by the inflammatory soup with firing maintained for 105 minutes. 'OFF' cells were transiently inhibited during initial application of inflammatory soup with recovery after 10 minutes, and 'Neutral' cells were unaffected. Furthermore, in conscious animals, the dural inflammatory soup also causes hypersensitivity to cutaneous facial and hind-paw innocuous stimulation (236), caused by central sensitization of trigeminovascular neurons (132, 135) (see section VI). These responses are inhibited by application of bupivacaine directly into the RVM, locally anesthetizing descending projections to the TCC (236). These data demonstrate that dural nociceptive trigeminovascular activation activates specific neurons in the RVM, involved in the modulation of pain processing, and local changes within this region can modulate the perception of sensory stimulation and neuronal activation in response to dural or cutaneous facial nociceptive activation.

4. Nucleus raphe magnus

The nucleus raphe magnus (NRM) is at the level of the RVM and makes up part of the endogenous pain modulatory pathway described above (271), sending specifically serotonergic projections to the TCC and spinal cord in rats and cats (546, 547). It is a region that is activated

by dural nociceptive stimulation (473) and 'ON' and 'OFF' cells respond to meningeal, corneal and facial cutaneous stimulation, alongside other extracephalic inputs including tail, hind- and fore-paw (254). In the same study, intravenous treatment with naratriptan increased the spontaneous activity of 'OFF' cells after 10 and 30 minutes, while mean 'ON' cell firing activity is significantly decreased. Therefore facial cutaneous and dural meningeal stimulation, which activates 'ON' or 'OFF' cells in the NRM, as well as being activated by stimulation in other regions, may be modulated by anti-migraine treatment. Furthermore, conditioning electrical stimuli applied to the NRM inhibits dural and periorbital-evoked nociceptive neuronal responses in the TCC (498). Interestingly, cortical spreading depression (CSD), believed to be the experimental correlate of migraine aura (see Section VII), causes a significant reduction in the discharge firing in the NRM, which subsequently antagonizes the inhibitory effects of NRM stimulation on dural-evoked neuronal firing in the TCC (498). It is widely established that the NRM represents the predominant serotonergic projection to the trigeminal nucleus in the brain, which indicates that this is the pharmacology of these responses, but manipulation of GABAergic and orexinergic receptor systems in this region also differentially modulates dural-nociceptive trigeminovascular inputs. Micro-injection of lidocaine and GABA causes facilitation of dural-nociceptive trigeminovascular neuronal responses, which is mediated by GABA_A-receptor activation (773), as a GABA_A-receptor agonist causes similar facilitation, and a GABA_A-receptor antagonist causes inhibition of dural nociceptive responses (773). Likewise, micro-injection of orexin A and orexin B into the NRM, which is mainly an inhibitory structure, facilitates neuronal activity in the TCC, an effect that was predominantly driven by OX₂ receptors (772). It is clear from these data that manipulation of the NRM is specifically involved

in the tonic descending modulation of neuronal firing in the TCC in response to peripheral intra- and extracranial nociceptive inputs.

5. *Periaqueductal grey (PAG)*

The ventrolateral periaqueductal grey (vlPAG) has become identified with migraine pathophysiology since Weiller's (842) imaging study demonstrated dorsal midbrain activation during a migraine attack, in a region that could include the PAG. Subsequent imaging studies conducted in spontaneous or experimentally-triggered migraine have repeatedly demonstrated midbrain activation before, during and after the cessation of pain with sumatriptan treatment, in migraine (9, 13, 66, 209, 559). These studies indicate that the PAG may be involved in the pathophysiology of migraine, particularly in the modulation of trigeminovascular nociceptive responses, although the exact role of the PAG in migraine pathophysiology is hotly debated and discussed later in this section.

The PAG is a midbrain structure, within the brainstem, which makes direct projections to the medullary and spinal dorsal horn, but predominantly indirectly via the RVM, where it is believed to contribute to the descending endogenous pain processing pathway. It also makes connections with hypothalamic, thalamic and cortical neurons, which associate it with higher pain processing and potentially other associated neurological symptoms in migraine. The dorsal raphe nucleus that sits within the PAG can influence brain mechanisms in terms of blood flow (342, 343) and sleep (278). The clearest indication of the PAG's role in pain mechanisms is from studies that showed that electrical stimulation of the PAG produces analgesia in conscious

rats (685), a response which has been replicated to some extent in humans (588, 872).

Therefore there is clear evidence of the PAG's role in endogenous pain modulation to spinal nociceptive processing, predominantly via the RVM. There is also clear evidence that the PAG is involved in modulating trigeminovascular nociceptive processing, particularly with dural inputs. Electrical stimulation of the vlPAG in cats causes a transient inhibition of dural nociceptive trigeminovascular neurons (474). Similarly in rats, when bicuculline, a GABA_A receptor antagonist, is micro-injected local into the vlPAG, dural-evoked trigeminovascular nociceptive neurons are inhibited, as well as basal trigeminal tone (471, 472). These descending inhibitory mechanisms appear to be mediated to some extent by the P/Q-type voltage-gated calcium channel. Trigemino-vascular nociceptive responses are facilitated by local micro-injection of agatoxin, a P/Q-type voltage-gated calcium channel blocker, although this response seems to be modulated by non-GABAergic neurons, as the facilitation does not block the GABA_A-mediated response (471, 472). As described in the 'Migraine Genetics' section, P/Q-type voltage-gated calcium channels are implicated in familial hemiplegic migraine (FHM), where a missense mutation in the *CACNA1A* gene that encodes the $\alpha 1$ subunit of the neuronal Ca_v2.1 P/Q-type voltage-gated calcium channel is present in the majority of patients (645). This mutation leads to multiple gain-of-function effects, including enhanced neurotransmission and reduced susceptibility to CSD (813). These data combined provide a suggestion of a specific genetic mutation that may cause dysfunction in the descending brainstem modulation of trigeminovascular nociceptive traffic involved in migraine.

6. Neurotransmitter systems modulating the trigeminovascular system

Descending brainstem modulation of spinal and trigeminovascular nociceptive traffic may also be modulated by different neurotransmitter systems implicated in migraine. Triptans, specific 5-HT_{1B/1D} receptor agonists (310), were the first dedicated anti-migraine therapeutics, believed to act either at the cranial vasculature, or more likely, in the authors' view, at the level of the TCC (433, 435). It is worth noting that glutamatergic transmission is well established in the trigeminocervical complex with NMDA (171, 317, 516, 764) and GluK1 involvement (46), as is opioidergic transmission (761), although neither have provided clinically useful to date (Table 4, 345).

i. Endocannabinoids

Endocannabinoid (22, 24, 27, 28, 361) mechanisms have been implicated in migraine pathophysiology and may represent a potential novel therapeutic approach. When either naratriptan or CB₁-mediated endocannabinoids (Figure 7A and B) are locally micro-injected into the vIPAG they cause transient inhibition of dural nociceptive neurons in the TCC, as well as inhibiting basal trigeminal tone (24, 77). There is no effect on noxious or innocuous cutaneous facial inputs in the ophthalmic dermatome of the trigeminal nerve. Interestingly, the CB₁-mediated effects are inhibited by co-application with a 5-HT_{1B/1D} receptor antagonist. These data may imply that the endocannabinoid responses are mediated by neurons, or at least within the same synapse, that may also contain 5-HT_{1B/1D} receptors, and that part of the therapeutic effects of triptans, may also be mediated in the vIPAG.

Endocannabinoids are described as 'synaptic circuit-breakers' (459) acting as retrograde neurotransmitters in the PAG and RVM. They are released from post-synaptic sites acting on pre-synaptic CB₁ receptors to prevent the release of GABA and glutamate. The mechanism through which these neurotransmitter systems in the brainstem provide descending modulatory control of trigeminovascular nociceptive processing is not clear and we propose a mechanism through activation of 'ON' and 'OFF' cells (Figure 7C and D). In the PAG local injection or endogenous release of serotonin (or triptan) and endocannabinoids inhibit the release of GABA from presynaptic terminals, causing the disinhibition of output neurons (703), which activate monosynaptic glutamatergic projections to 'OFF' cells in the RVM to modulate nociception (609). It is also known that activation of post-synaptic orexin 1 receptors in the PAG stimulate the synthesis and release of endocannabinoids, resulting in retrograde inhibition of GABA release (398), which may be involved in this mechanism. At the same time we hypothesize that this descending glutamatergic projection also synapses with an inhibitory interneuron in the RVM, which inhibits activity of 'ON' cells, thus switching off activity at the level of the TCC second order neuron. Within the RVM endocannabinoids inhibit GABAergic projections to 'OFF' cells, increasing 'OFF' cell activity by disinhibition (597, 598). Also endocannabinoids inhibit glutamate release from glutamatergic projections to 'ON' cells, thus reducing 'ON' cell activity at the level of the TCC. There is also thought to be state-dependent and bidirectional control of pain modulation through serotonergic projections from the RVM to the TCC that is distinct to 'ON' and 'OFF' cells (269).

ii. Functional consequences of brainstem modulatory dysfunction

It is often argued that if a dysfunction of brainstem nuclei, that includes the descending pain modulatory system, is involved in the pathophysiology of migraine, which alters the perception of nociceptive activation of the trigeminovascular system, it would also affect the way that pain is processed at the spinal level. However, it has been shown repeatedly that the descending modulation of trigeminovascular nociceptive traffic seems to be different from that of spinal nociceptive processing. In the vIPAG descending modulatory effects tend to only alter dural-evoked A δ -fiber trigeminovascular nociceptive responses, as well as basal trigeminal tone, but it does not alter either noxious or innocuous cutaneous facial responses, particularly C-fiber responses (24, 77, 410, 471, 472). However; previous studies clearly indicate that the PAG-RVM pathway provides descending control of only noxious cutaneous pinch-evoked C-fiber responses at the spinal level (836, 837), with innocuous inputs and spinal tone unaffected. In preclinical studies stimulation of cranial structures predominantly causes activation of neurons with A δ -fiber latencies in both the TCC and VPM thalamic neurons (501, 631, 729), which project to the somatosensory cortex, and even when C-fiber intensity stimulation is used, only A δ -fiber latency responses are identified. It is not clear why there are so few C-fiber latency responses in this trigeminovascular pain pathway that project to the cortex. It may indicate that the nociceptive trigeminovascular projections that are thought to be activated primarily during migraine are mediated predominantly by A δ -fibers, and hence the descending modulation from the brainstem is mediated by a separate population of neurons to those that project to the spinal cord and modulate spinal nociceptive processing.

Spinal nociceptive responses appear to differ from trigeminovascular nociceptive responses, which may explain why spinal pain perception is not altered during migraine and treatment. Triptans are the classic example, they are extremely effective in the acute treatment of migraine, but carry little (823) or no analgesic properties with respect to other pain types, such as facial pain (379). In preclinical studies noxious, mechanical trigeminal neuronal responses are inhibited by naratriptan, whereas similar noxious mechanical spinal responses are unaffected (187). Furthermore 'ON' and 'OFF' cells in the NRM, that respond to noxious stimulation throughout the body, including cephalic and extracephalic regions, respond to naratriptan treatment, but as described above, we know they only relieve migraine related head-pain. It is often thought that this difference is related to the location of 5-HT_{1B/1D} receptors on cranial blood vessels and at the level of the TCC. However, it is clear triptans have effects in the VIPAG (77), and indeed on trigeminothalamic neurons (730), and clearly alter neuronal responses in the NRM, which would imply they would affect pain processing in general, but they do not. It is possible that the population of neurons that project to the trigeminovascular system behave differently and respond differentially to noxious inputs, and hence the clear definition of migraine as a separate and unique pain disorder.

B. Hypothalamic modulation

Imaging studies in migraine have predominantly located activation in the midbrain, with increased activation in the hypothalamus before (559) and during (209) also demonstrated. Activation in the hypothalamus more posteriorly in trigeminal autonomic cephalalgias (339) is well described (575, 576, 580, 581). The hypothalamus is involved in a number of crucial

physiological functions including controlling the sleep-wake cycle, feeding, thirst, arousal and urination, as well as autonomic and endocrine regulation (650, 727). These mechanisms implicate it in the early origins and premonitory symptoms of migraine, where sleep disturbance (348), changes in arousal (197) and mood, food craving, thirst and urination (300) are known to occur and can increase the likelihood of an attack, as well as early symptoms.

The hypothalamus is also thought to be involved in pain processing. It has reciprocal connections with the TCC, including the trigeminal nucleus caudalis (556, 558, 688), as well as many structures involved in the processing of nociceptive inputs, including the nucleus tractus solitarius, RVM, PAG and NRM (727). Nociceptive stimulation of the dura mater activates neurons in the anterior, posterior, ventromedial, and supra-optic hypothalamic nuclei, and potentially paraventricular hypothalamic nuclei (85, 557). Hypothalamic nuclei also have descending projections to the SuS (423, 424, 688, 745), where they are thought to be involved in autonomic regulation, and its activation may contribute to autonomic symptoms in migraine (494), and especially trigeminal autonomic cephalalgias (315), as well as contributing to further activation of trigeminal afferents from the cranial vasculature (25, 26, 635).

Hypothalamic descending projections are known to be involved in the descending modulation of nociceptive inputs at the spinal level (277), and several of these descending projections have been shown to modulate trigeminovascular nociceptive processing.

1. Posterior hypothalamic nucleus

The posterior hypothalamic region is activated as a consequence of dural electrical stimulation in cat (85), and is implicated in imaging studies from both migraine and trigeminal autonomic cephalalgias. Orexins A and B are hypothalamic neuropeptides that are made solely in hypothalamic nuclei, including the posterior hypothalamic region (356) and are involved in the hypothalamic regulation of sleep, feeding and arousal and the autonomic system (405, 700, 802). Intravenous orexin A is able to inhibit dural-evoked trigeminovascular transmission, but locally injected into the posterior hypothalamus, orexin A and B differentially modulate dural and cutaneous evoked nociceptive trigeminovascular responses (78). Orexin A inhibits dural electrical and thermal facial cutaneous evoked neuronal responses in the TCC, while orexin B facilitates these same responses. Given the role that both the hypothalamus and orexinergic system play in pain modulation, feeding, arousal and sleep regulation, these data provide a causal link between the possible origin for the triggering of migraine and premonitory symptoms (hypothalamus), a neurotransmitter system (orexinergic) known to be involved in the homeostasis of these triggers and symptoms, and a role of both in the descending control of trigeminovascular nociception, thought to contribute to the pain in migraine.

Another hypothalamic neuropeptide that has similarly been implicated in hypothalamic mechanisms in migraine is somatostatin that has five recognized receptor subtypes (429). It is involved in the regulation of food intake (754) and glucose metabolism by acting as a tonic inhibitor of glucagon release during low glucose concentrations (162). Injection of a non-specific somatostatin antagonist, cyclosomatostatin, into the posterior hypothalamus, inhibits dural and facial cutaneous nociceptive neuronal inputs in the TCC (79), demonstrating a

potential role in the descending modulation of trigeminovascular nociceptive traffic.

Interestingly, systemic octreotide, a somatostatin analogue agonist, was effective in the treatment of cluster headache, but not migraine (527, 577), indicating that these hypothalamic neurotransmitters may not be universally involved in all primary headaches, but certain types, demonstrating the importance of these specific descending mechanisms to their pathophysiology.

2. Paraventricular hypothalamic nucleus

The paraventricular hypothalamic nucleus (PVN) is a region that shows increased neuronal activation after both electrical dural stimulation in cats (85) and dural inflammatory soup in rats (557), but in both cases the data are increased without showing significance, or not increased in all animals. However clear descending projections to the TNC, particularly nociceptive laminae I and IIo, and the SuS have recently been demonstrated (688). In the same study a host of local chemical manipulations in the PVN were shown to alter dural nociceptive and basal neuronal activity in the TNC (688). Micro-injection of muscimol, the GABA_A receptor agonist, into the PVN, inhibited basal and dural-evoked trigeminovascular neuronal activity. The level of inhibition was attenuated when rats had been previously exposed to a 'stress' protocol. Gabazine, a GABA_A receptor antagonist, was able to facilitate dural-evoked responses. Similarly, microinjection of the autonomic and sensory neuropeptide, PACAP-38 facilitates basal trigeminal neuronal activity and after-discharges (responses greater than C-fiber latency), and the PACAP antagonist, PACAP6-38 inhibited basal and all nociceptive dural-evoked trigeminovascular neuronal responses. Finally micro-injection of naratriptan, a 5-HT_{1B/1D}

receptor agonist, used in the acute treatment of migraine attenuated both basal and dural-evoked trigeminovascular responses. These findings demonstrate the powerful modulatory role the PVN has on trigeminovascular nociceptive traffic, and with descending projections to the SuS, it clearly has a role in modulating, or even triggering, nociceptive, autonomic and stress-related processes in migraine, and likely, trigeminal autonomic cephalalgias.

3. A11 Hypothalamic nucleus

The A11 hypothalamic nucleus is located along the rostrocaudal axis of the periventricular grey of the caudal hypothalamus (193), providing direct dopaminergic inhibitory projections to the spinal cord dorsal horn (193, 740), believed to be the sole source of dopamine in the spinal cord (413). Dopamine activation is known to alter dural trigeminovascular nociceptive responses, at the level of the peripheral dural vasculature, through dopamine D₁ receptor mechanisms (18, 156) and centrally at the level of the TCC through dopamine D₂ receptor mechanisms (89, 156). Electrical stimulation of the dopaminergic A11 projection causes a significant inhibition of noxious dural and cutaneous facial-evoked inputs in the TCC, mediated through D₂ dopamine receptors (156). However, lesioning the A11 nucleus facilitates both noxious and innocuous dural and cutaneous facial-evoked inputs (155, 156). The facilitation in neuronal firing to noxious stimuli is reversed by both 5-HT_{1B/1D} and dopamine D₂ receptor agonists, but only the D₂ receptor agonist was able to reverse the facilitatory effects in neuronal firing of innocuous stimulation to the cutaneous facial region (155). In normal conditions, it is likely that the A11 nucleus provides descending tonic inhibitory control of incoming trigeminovascular nociceptive traffic through the release of dopamine, acting on dopamine D₂ receptors. During migraine it is

possible that a dysfunction of the A11's inhibitory projection to the TCC removes the tonic inhibition through dopamine release, causing a facilitation of neuronal responses and hyperalgesia and allodynia to somatosensory inputs in the trigeminal distribution. The use of dopamine antagonists is often cited as not consistent with A11 involvement, although clinically employed medicines with randomized controlled trial evidence (294), have more complex pharmacology than simple dopamine receptor interactions. Interestingly restless leg syndrome, which is believed to be caused by a dysfunction in the A11 nucleus (172), is treated with D₂ receptor agonists (644), and there is certainly a suggestion that migraine is co-morbid with restless leg syndrome (72, 686).

The data regarding the hypothalamic modulation of trigeminovascular pathways clearly demonstrate that several regions are involved in modulating basal and incoming nociceptive inputs to trigeminovascular neurons. It is possible that a dysfunction in any one of these regions may result in altered processing of nociceptive inputs that is processed and generates migrainous pain, or indeed this dysfunction could actually result in triggering activation of previously quiescent trigeminovascular neurons that is perceived as noxious activation, if these neurons receive projections from dural afferents, and is processed as migraine. Furthermore, nuclei in the hypothalamus are uniquely placed and involved in the regulation of many other homeostatic processes, such as feeding, sleep/wake, arousal, stress, that potential triggers of migraine may alter the way nociceptive information is processed, but also the triggering of migraine through the hypothalamus also results in many of the associated neurological symptoms (411). Future studies into the role of the hypothalamus in migraine are likely to

dissect further significant revelations that help us to elucidate its pathophysiological mechanisms.

VI. Thalamic processing of trigeminovascular pain

The thalamus is the major center for processing sensory nociceptive information in the brain, and relaying this information for processing in cortical structures where it is perceived by individuals. Ventroposteromedial (VPM), posterior, lateral posterior/dorsal thalamic nuclei have all been demonstrated to receive functional nociceptive inputs from the dura mater (132, 202, 632, 876, 877), and this can modulate how this painful experience is perceived. Several of the most effective acute and preventive treatment strategies are able to modulate dural nociceptive trigeminothalamic inputs, when locally applied to the VPM. Acute treatments such as ‘triptans’ (5-HT_{1B/1D} receptor agonists) (730) and CGRP receptor antagonists (769) are able to inhibit acute dural nociceptive inputs. Likewise, the migraine preventives propranolol (729), sodium valproate (47) and topiramate (44) are also able to inhibit dural nociceptive trigeminothalamic inputs in the VPM. Targeting specifically the thalamus alters the perception of the nociceptive input coming from the periphery without the peripheral effects of drugs, which results in a reduced pain response. Additionally targeting the thalamus allows one to dissect novel effective therapeutic targets without peripheral effects, which are suitable for those patients with cardiovascular and cerebrovascular disorders. Indeed, in the topiramate study it was possible to dissect out that the major pharmacological mechanism in the VPM was via glutamatergic kainate (iGluR5) receptors, an effect that was also found at the TCC (44).

iGluR5 receptor targets have been proven to be effective in the acute treatment of migraine (448, 704), demonstrating a purely centrally mediated approach can treat migraine, with effects mediated by the VPM. Targeting the processing of trigeminovascular nociceptive information in the thalamus may represent a step forward in the development of therapeutics.

Evidence of thalamic activation during migraine is clear (9, 66), but the role it plays is thought to go beyond that of merely a relay in processing sensory nociceptive information to the somatosensory cortices. It has also been demonstrated that activation in thalamic nuclei can also contribute to the modulation of trigeminovascular and other spinal nociceptive inputs. Below we describe in detail how cutaneous allodynia; the perception of pain in response to normally innocuous stimuli, in the cephalic and extracephalic regions, is likely the consequence of sensitization of central trigeminal and thalamic neurons (132, 135). The particular contribution of the thalamus is the spread of cutaneous allodynia beyond the site of pain to contralateral cephalic and extracephalic regions via sensitization of thalamic neurons, particularly in the posterior, VPM and lateral regions. Hence the perception of somatosensory trigeminovascular and spinal inputs are altered as a result of sensitization of thalamic neurons. The authors of these studies propose that the mechanism of sensitization may be the result of a sequential sensitization of first, second and third-order trigeminovascular neurons through incoming signals coming from the peripheral dural trigeminal innervations (132, 135, 766). Although activation and sensitization of thalamic neurons via mechanisms directly through medullary, midbrain and hypothalamic nuclei, as described above, could potentially also drive this response (Section– Theories of Migraine).

VII. Cortical processing of trigeminovascular pain

In recent years evidence has been growing that migraineurs suffer an alteration in cortical excitability that may act as a susceptibility factor for migraine attacks (60, 61, 182, 505, 749). While the mechanism of how this might contribute to migraine is not known, it is certainly undeniable that there is endogenous corticofugal modulation of trigeminovascular nociceptive inputs via medullary and midbrain structures. In a recent study in rats descending projections from the cerebral cortex, specifically from contralateral insular and primary somatosensory (S1) cortices, to laminae I-II and III-IV, respectively, of the TNC were demonstrated (630), although ipsilateral functional connections have also been demonstrated (771). These descending connections have been previously shown in humans (490). Functionally it has been demonstrated that CSD, the experimental paradigm believed to represent the neural mechanism of migraine aura (Section VII), is able to inhibit neuronal activity in the NRM. Further, repetitive CSDs were able to reverse the descending inhibitory effects that the NRM has on dural nociceptive trigeminovascular responses (498), demonstrating a cortico-NRM modulation of trigeminovascular nociceptive inputs.

Cortical spreading depression is known to cause neuronal activation in the TNC, an effect that has been hypothesized to be mediated by activation of peripheral dural nociceptive trigeminovascular mechanisms (879, 880). However, CSD evoked increases in basal trigeminovascular discharge firing has been shown to be at least partly independent of a peripheral trigeminovascular action, indicating a mechanism driven within the central nervous

system (500). Further studies show that different regions of the cortex differentially effect peripheral trigeminovascular nociceptive inputs. CSD initiated in the contralateral insular cortex induced facilitation of dural-evoked neuronal responses in the TNC, whereas CSD initiated in the contralateral S1 somatosensory cortex inhibited the same responses (630). CSD initiated in the primary visual cortex enhances or inhibits dural-evoked responses, but does not affect noxious facial cutaneous-evoked responses (630). Of note, CSD initiated in the ipsilateral parietal region, an area which conveys the somatosensory and visual cortices, also causes a significant inhibition of dural-evoked nociceptive neuronal firing in the TCC in 9/30 neurons; a response that is mediated by the 5-HT_{1B/1D} 'triptan' receptor (771). The remaining 21 neurons were unaltered by parietal CSD. These cortico-brainstem-trigeminal networks are positioned to influence dural and cutaneous nociception, and altered cortical excitability, believed to affect susceptibility in migraineurs, would clearly change how intra and extra-cranial somatosensory information is processed, and ultimately perceived by the migraineur.

VIII. Neural Basis for Headache Pain Quality and Associated Symptoms

As indicated by the ICHD-III β (386) and outlined in section 2 specific criteria are laid out for the headache quality in migraine, and migrainous symptoms are not just restricted to headache pain but it is also accompanied by many other symptoms of the sensory system and homeostatic function that occur throughout the duration of the migraine attack. These can include hypersensitivity to sensory inputs such as light (photophobia), sound (phonophobia) and touch (cutaneous allodynia), but also symptoms caused by disruption to normal homeostatic functions such as altered sleep, feeding and even mobility. Most patients

consistently experience a subset rather than all symptoms, but each seems to be driven by similar pathophysiological mechanisms. Below we outline the likely neural basis for the headache quality, and some of the most well-known associated symptoms that accompany migraine.

A. Premonitory symptoms

Premonitory symptoms are part of the non-headache symptoms of migraine attacks. Per definition, they occur prior to the onset of headache and are different from migraine aura. In a prospective electronic diary study, Giffin and colleagues (300) assessed whether migraineurs were able to identify non-headache symptoms that could predict migraine attacks. From the symptoms entered by the patients, seventy-two percent were indeed able to do so. The most common premonitory symptoms were feeling tired and weary (72%), concentration problems (51%), and neck stiffness (50%). Less common, but importantly associated with a higher predictability of migraine attacks were yawning, blurred vision, noise sensitivity, difficulties of higher cortical function (such as reading, writing, speech, thinking), and feeling emotional and irritable. In addition, homeostatic regulation seems to be disturbed during the premonitory phase manifesting with thirst, nausea, hunger, frequent urination, or constipation (300). This complex pattern of symptoms has led to the hypothesis that the symptoms might be hypothalamic in nature and/or diffuse cerebral (106). Due to the difficulties of predicting migraine attacks, only a few basic science studies have addressed the pathomechanism of these symptoms despite the enormous implications for our understanding of migraine.

As mentioned in detail in section III, Stankewitz and colleagues (749) used fMRI after trigeminal nociceptive stimulation and found interictal reduced activation of the spinal trigeminal nuclei. This normalized prior to the next attack with even increased activation during the attack (Figure 1), although strictly not a study of the premonitory phase since the clinical phenomenology were not documented to make that distinction. Maniyar and colleagues (559) triggered acute migraine attacks with nitroglycerin and assessed rCBF in eight migraineurs using $H_2^{15}O$ -PET. Similar to the clinical description (106, 300), they found a complex pattern of rCBF increase during the premonitory phase including subcortical (posterior hypothalamus, ventral tegmental area, PAG, dorsal pons, putamen, caudate nucleus, and the pulvinar nucleus of the thalamus) as well as cortical areas (occipital cortex, frontal, prefrontal, temporal, parietal cortex, anterior cingulate, and posterior cingulate) (Figure 2). The premonitory symptoms of the study participants were tiredness, neck stiffness, thirst, frequent urination, photophobia, nausea, yawning, and mood changes. By combining the clinical picture with the functional imaging results we can map various premonitory symptoms to specific brain areas with putative novel treatment options of migraine. A key structure seems to be the hypothalamus, which could account for yawning, frequent urination, thirst, mood changes, through connections with the limbic system; food intake, craving and changes in sleep-wake cycle. Possible neurotransmitter systems involved in these processes are the dopaminergic system (56), vasopressin (482) and the orexins, which have in part been implicated in migraine therapy (78, 284, 829, 830). Interestingly, the late premonitory phase does not show the hypothalamic activation whereas, particularly, the cortical activity does persists, and even into the headache phase (559). One speculative interpretation is that the hypothalamic involvement might ignite the migrainous

process that finally results in the dis-inhibition of the top-down modulation of the trigeminal activity resulting in head pain and thus the migraine attack (21).

B. Headache characteristics

According to the ICHD the headache in migraine has to have at least two properties that include *unilateral, pulsating quality, moderate or severe intensity and aggravation by or causing avoidance of routine physical activity* (Table 1). As discussed in section I activation of trigeminovascular pain pathways that innervate the dural vasculature is thought to be responsible for this headache quality. Studies in the 1940s on conscious patients undergoing cranial surgery confirm this (658, 679). They found that manipulation of the dura mater with mechanical distension or electrical stimulation produced pain referred to the head that was localized to different regions depending on the sites of stimulation. While this stimulation did not trigger migraine in these patients, it did cause pain referred to specific regions of the head as well as some of its common associated symptoms (658, 679). Stimulation of the superior sagittal sinus produced pain in the peri-orbital region; stimulation of the middle meningeal artery produced pain in the parietal or temporal region; and stimulation at the floor of the posterior fossa, sigmoid, transverse and occipital sinuses produced pain in the occipital region. Interestingly stimulation away from the dural vessels was much less pain-producing.

Clearly activation of axons that innervate the dural vasculature and originate in the trigeminal ganglion is painful, and produces head pain. It seems likely that activation, or the perception of activation under normal conditions, of these nociceptive nerve fibers, sometimes termed

meningeal nociceptors, which innervate the dural blood vessels is likely responsible for the severe and throbbing nature of pain in migraine. It remains unclear where that percept is processed. In preclinical studies, stimulation of the nociceptive specific dura mater (347, 497) causes much greater increases in cerebral blood flow and release of CGRP and VIP, neuropeptides known to be released in severe migraine, than after stimulation of the trigeminal ganglion (324). While no animal model can claim to be inducing migraine, preclinical animal models that use mechanical or electrical stimulation of these dural blood vessels are likely activating the nociceptive pathways involved in generating the severe and pulsatile nature of the pain in migraine, as well as neurotransmitter release coincident in migraine.

In preclinical studies mechanical or electrical stimulation of the dura mater only produces a short burst of neuronal activity in the TCC, whereas migraine pain and trigeminovascular activation is sustained for many hours. These short bursts of neuronal firing are likely to represent the severe and throbbing/pulsatile quality of head pain experienced during migraine, although experimentally for only a short time. However, it is believed that peripheral and central sensitization of trigeminovascular neurons may contribute to migraine duration. In preclinical studies an inflammatory soup placed upon the dura mater is able to activate and sensitize peripheral and central trigeminovascular neurons for several hours (135, 766). This sensitization causes hypersensitivity to mechanical stimulation of the dural vasculature, including the sagittal and transverse sinuses, as well as expansion of the intracranial dural receptive field. More recent studies have shown that chemical migraine triggers, such as the nitric oxide donor, nitroglycerin, also causes sensitization of central trigeminovascular neurons,

which produces hypersensitive responses to dural electrical stimulation (20). These studies demonstrate that peripheral and central sensitization of the trigeminovascular projection to the dural vasculature can exacerbate neuronal responses to innocuous mechanical and noxious intracranial dural inputs. This neural mechanism may provide an explanation for why normally innocuous physical activities such as exercise, or even unavoidable actions such as coughing, bending and taking the stairs, can exacerbate the headache in migraine, and are frequently avoided where possible. It may also add to the throbbing nature of pain in migraine as well as explaining why migraineurs tend to try to stay still as much as they can, and more often stay in bed during an attack.

C. Photophobia and phonophobia

How migraineurs commonly deal with their migraine is a clear indication of their hypersensitivity to sensory stimulation. Many patients will certainly report that during an attack they will go to bed, turn off the lights, and avoid any type of sensory stimulation from light, sound, touch or smells. As if they are shutting themselves away from all possible sensory inputs. Indeed included in the classification of migraine by the ICHD is that accompanying their migraine must be at least one of photophobia, phonophobia, nausea and vomiting (386). Photophobia in migraine may take the form of migraine pain being worsened by light, photic allodynia; where the light is itself unpleasant without pain, photic hypersensitivity. In recent years studies have begun to disseminate the likely neural mechanisms involved in their pathophysiology, specifically related to migraine (631). Findings determined that exacerbation of migraine headache requires an intact optic nerve, irrespective of visual ability. Damage to

the optic nerve prevents the exacerbation of migraine headache to light, yet blind migraineurs with an intact optic nerve can experience worsening pain as a consequence of light (632). Studies in rats were also able to demonstrate that light is able to activate specifically dural-nociceptive posterior thalamic neurons, and this activation increases with increasing light intensity (632). A subgroup of these posterior thalamic neurons receives inputs from retinal ganglion cells, and these posterior thalamic neurons project to the somatosensory, visual and associative cortices (Figure 8A). Similar findings have been made with respect to the TCC, where light can also activate nociceptive trigeminal neurons (635). The neural substrate for the exacerbation of migraine headache by light would seem to be a consequence of convergence of photic signals from the retina, via an intact optic nerve, onto dural nociceptive trigeminothalamic neurons, which subsequently project onto cortical areas (S1 and S2) involved in nociceptive processing.

As described in section III migraineurs also report a hypersensitivity or abnormal sensitivity to light, something which is likely to be the consequence of cortical hyper-responsiveness. Interictally in migraineurs luminous stimulation ($600\text{--}1800\text{ Cd/m}^2$) activates the visual cortex bilaterally, but there is no such activation in controls. Furthermore, when visual luminescent stimulation was combined with trigeminal pain stimulation; using heat applied to the ophthalmic region of the face, cortical activation was determined in the visual cortex in controls and it potentiated activation in migraineurs (116) (Figure 8B). During spontaneous migraine low luminescence (median 240 Cd/m^2) that does not provoke visual cortical activation outside of migraine, does cause activation during migraine, and also after pain relief with sumatriptan

treatment (208) (Figure 8C), although this activation was statistically lower than during migraine. These studies demonstrate that interictally and ictally there is cortical hyperexcitability to light in migraineurs, and convergence of trigeminovascular nociceptive inputs with photic signals, potentially in the posterior thalamic region described above (632), from where axons project to the visual cortex, may explain the neural mechanism for hypersensitivity to light in migraineurs. Given that there is cortical hyperexcitability even after pain relief, it implies that cortical hyperexcitability, and heightened sensitivity to light is not dependent on nociceptive trigeminovascular activation. Therefore modulation of cortical excitability may also be under the control of other regions of the brain relevant to migraine pathophysiology, potentially brainstem nuclei.

1. CGRP and photophobia

Biochemically it seems that CGRP may also have a role in photophobia. Genetically engineered mice with elevated expression in nervous tissue of the human receptor activity-modifying protein 1 (RAMP1), which is an important and required subunit of the CGRP receptor (694), spend less time in light environments than control littermates. In addition intracerebroventricular administration of CGRP causes a significant increase in light aversion, compared to those that received vehicle; a response that is prevented with simultaneous treatment with the human CGRP receptor antagonist, olcegepant (696). CGRP injection in control mice also caused the development of an aversion to strong light, a response that is attenuated by a triptan, 5-HT_{1B/1D} receptor agonist (453), indicating that activation of endogenous CGRP receptor can drive this hypersensitive response. One possible mechanism

would be promotion of a trigeminal nociceptive pathway (635). These studies combined demonstrate the likely neural pathways involved in the development of symptoms of photophobia, and that CGRP, which is released in migraine (289, 325), contribute to these symptoms, although it is not clear at which loci the effect is driven. The neural mechanism for phonophobia has not been directly dissected. However one could readily speculate that cortical hyperexcitability in areas of the auditory cortex that are involved in the processing of sound may be involved, which receive projections from nociceptive neurons that relay via the trigeminovascular system and thalamic nuclei.

D. Nausea and vomiting

Nausea and vomiting are common features of migraine, and disturbance of food intake is frequently reported, whether this is reduced food intake from nausea, or food craving, which is often reported in the premonitory phase.

1. Hypothalamic mechanisms

The hypothalamus is regarded as the regulator of homeostatic function, and regions such as the paraventricular and ventromedial hypothalamic nuclei are known to have altered neuronal activation as a consequence of hunger or satiety as described below (See- Migraine Triggers). Furthermore, dopamine is known to have a role in nausea and vomiting, with dopamine D₂ receptor antagonists known as the classic anti-emetics, while agonists, apomorphine and piribedil both provoke increased emesis in migraineurs (92). Migraineurs also present with

increased yawning, nausea, vomiting and dizziness as a result of apomorphine treatment (109, 149). These data suggest a hypersensitivity to dopamine and its effects, and a response that is centrally mediated, as peripheral dopamine antagonists cannot reverse yawning symptoms in rats (725, 726). These studies do not suggest a locus of action, but hypothalamic regions are known to be affected by dopamine. Levels of dopamine in the ventromedial hypothalamus are known to go down as a result of feeding, and eating does not begin again until dopamine levels are re-established (596).

Alteration to homeostatic functions, which includes feeding and sleep, are also common in migraine. In a rodent model of migraine, dural inflammatory soup causes neuronal activation in the parabrachial nucleus and ventromedial hypothalamus, believed to be via sensitization of central trigeminovascular neurons (557). In half of the rats there was also activation in the paraventricular and dorsomedial hypothalamus. These animals exhibited reduced feeding 0-4 hours after the inflammatory soup placement, followed by increased feeding for the following 8 hours, as a likely compensation mechanism. Furthermore there were also increased levels of mRNA for the anorectic peptide cholecystinin (CCK) in activated parabrachial neurons and higher mRNA for CCKB receptor in activated ventromedial hypothalamic neurons. These data suggest that central sensitization of trigeminovascular neurons activate ascending food suppressing neuronal projections, which alter feeding in these animals. It is crucial to note rodents cannot vomit, and therefore it is not a symptom that can be measured in these animals. These studies suggest that only headache mechanisms driven by peripheral inputs lead to nausea and loss of appetite, but premonitory symptoms in migraineurs, which include

nausea, suggest that these hypothalamic mechanisms may be activated without trigeminovascular activation that may lead to headache. More likely is that a single pathophysiology leads to both nausea and trigeminovascular activation.

2. Brainstem mechanisms

Brainstem mechanisms involving the PAG-RVM pathway and the role these structures have in controlling homeostatic function may also contribute to associated symptoms in migraine, such as disruption to feeding, and even sleep. These mechanisms may offer a single explanation for the contribution to symptoms of the trigeminovascular system and homeostatic function. We describe below in Section IX how continued wakefulness and skipping meals will activate ‘ON’ cells (65, 278, 279), which may alter the descending control of nociceptive responses to central trigeminovascular neurons, as well as connections to the hypothalamus. Through these same mechanisms associated symptoms may be generated. Certainly excessive urination, hunger, eating and food craving (or altered feeding in general), the need for sleep, and avoidance of moving around are all associated with ‘OFF’ cell discharge, and perhaps during migraine these responses are prolonged or exacerbated. Without doubt symptoms of altered feeding, nausea and vomiting, as well as other homeostatic processes, through the duration of migraine likely involve the hypothalamus, as well as altered dopamine levels, and are exacerbated by trigeminovascular activation and sensitization. It is also likely that connections to the brainstem PAG-RVM pathway contribute. The nature of their exact mechanisms in migraine and their contribution to symptoms is not clear but it certainly seems likely that a single pathophysiology through the brainstem PAG-RVM pathway can result in altered perception of noxious

somatosensory stimuli, as well as changes to homeostatic processes that contribute to symptoms of altered feeding and sleep through the hypothalamus.

2. Allodynia

Another aspect of pain, similar to the hypersensitivity to light and sound that patient's experience is hypersensitivity to touch, described as (cutaneous) allodynia and hyperalgesia.

Allodynia: the perception of pain in response to a normally innocuous stimulus to the skin or scalp, and hyperalgesia; hypersensitivity to noxious stimuli, occurs in up to two-thirds of migraine patients (535, 723). It has been recognized at least since the 19th century (357). In migraineurs it is predominantly evident in the cephalic/facial region and pain can be provoked by simply brushing or drying one's hair, shaving or showering. It can also extend to extracephalic regions, and become an all-over body allodynia, such as during dressing (127, 128). Interestingly, the frequency and severity of cutaneous allodynia is more marked in more frequent and severe migraine, and may be considered a marker for the chronification to more severe and chronic forms of migraine (95, 100). Whether it marks a process that is starting or simply reflects what has happened is unclear. Preclinical studies have helped describe the neural basis for allodynia in migraine (135, 136). Studies which used dural inflammatory soup have demonstrated that sensitization of central trigeminovascular neurons causes expansion of the cutaneous facial receptive field, as well as hypersensitive responses to brush, pressure and pinch of this receptive field (135). These responses are indicative of cutaneous facial allodynia and hyperalgesia. The development of similar hypersensitivity to innocuous and noxious inputs to the facial cutaneous peri-orbital region has been demonstrated using the experimental

migraine trigger nitroglycerin, in rodents (20). Indeed allodynia can be seen in patients triggered with nitroglycerin to have a migraine, when they report it as part of their normal spontaneous attack (Karsan, Bose & Goadsby, unpublished observations). It seems that sensitization of central trigeminovascular neurons is likely to cause referred extracranial pain as well as the hypersensitive response to cutaneous facial stimulation, and as a consequence symptoms of cephalic facial cutaneous allodynia and hyperalgesia.

i. Thalamic involvement

While peripheral and central sensitization of trigeminovascular neurons is thought to account for the facial cutaneous hypersensitivity in the referred pain region experienced by many migraineurs it cannot explain the extracephalic hypersensitivity; cutaneous allodynia and hyperalgesia which extends beyond the head and face to other regions of the body during migraine (128, 136). Central sensitization of trigeminothalamic neurons may likely to contribute to this mechanism. Preclinical studies using the dural inflammatory soup demonstrate that 50 % of thalamic neurons located in the posterior, VPM and lateral regions become hyper-responsive to noxious and innocuous inputs from contralateral cephalic and extracephalic regions (132). In patients that suffer extracephalic allodynia during migraine, BOLD imaging signals in the thalamus that are induced by brushing or innocuous heat to the hand were significantly larger when the patients were suffering with a migraine attack than before or after (132). The spread of cutaneous allodynia and hyperalgesia beyond the site of pain to contralateral cephalic and extracephalic regions is likely the result of sensitization of thalamic neurons. While the

pathophysiology of chronic migraine is not well understood (217) the frequency and severity of cutaneous allodynia may indicate that central sensitization of trigeminal and thalamic neurons becomes more common, and is perhaps less transient with little recovery between attacks. This is likely to be an avenue of research in both clinical and preclinical settings in the coming years.

IX. Aura, CSD and the Trigeminovascular System

As highlighted previously 25-30% of migraine patients suffer focal neurological symptoms (678) that commonly present as visual scintillations/scotoma, paresthesia and loss of sensation that often precede the headache by 30-60 minutes (386). Given that approximately 75% of all migraine patients do not suffer from aura, the level of attention it has received on the face of it seems disproportionate to its relative importance to migraine pathophysiology. Airy (15) drew beautifully his aura, while Lashley (506) described a slowly propagating wave of scotoma with scintillating border that drifted across his visual field at a rate of approximately 3 mm/min. Refining this further one patient recorded meticulously more than 1000 attacks that map well onto visual cortex (369). This major focus on aura, probably because of its neurological correlate, and its now believed experimental correlate, cortical spreading depression (CSD), driven by two alternative theories. (1) Aura is the initial event which triggers migraine (110) and (2) Aura is simply a parallel factor of migraine which occurs in a minority of cases (308). While the headache field continues to debate the importance of aura for migraine and its symptomology, experimental studies have been extremely important in unraveling the possible role of CSD.

A. CSD and brain injury

For some time CSD like events had not been clearly demonstrated in migraine with aura patients, despite the evidence available from cases of brain injury (259, 589, 768). In a number of patients who had undergone craniotomies for subarachnoid hemorrhage, stroke and traumatic brain injury direct cortical electrocorticography recording demonstrated repetitive CSDs, which were negatively associated with outcome. It is clear from the available clinical data that the occurrence of CSDs may have a severe detrimental outcome and this has recently been supported using experimental stroke models in familial hemiplegic migraine (FHM) mice (249). FHM mice exposed to transient occlusion of the middle cerebral artery experienced increased numbers of CSD, greater brain damage and poorer outcome than controls. Originally the association between CSD and aura was postulated based on a number of similar features including rate of propagation. More recently advances in brain imaging have enabled characteristic blood flow changes to be observed in humans, where an initial brief hyperemia (or hyperperfusion) is followed by a more prolonged oligemia (or hypoperfusion) spreading across the cortex, starting at the occipital lobe (192, 366, 636, 702). The hypoperfusion correlates with the scotoma experienced by some patients during aura (369); and it is thought the hyperperfusion correlates with the negative symptoms.

B. CSD and migraine genetics

The genetics of migraine are clearly complex and are addressed in the Section X. It is however clear from a number of studies that alterations in CSD properties are a common phenotype.

Initial studies characterizing the transgenic FHM mice which represent rare monogenic forms of migraine with aura highlighted an increased susceptibility to CSD, likely via increased cortical excitability. This increased propensity for cortical spreading depression was initially highlighted in FHM 1 (*CACNA1A*) mice (813) and later in FHM 2 (*ATP1A2*) mice (524). Despite early suggestions(586, 787), the lack of a clear link with more common forms of migraine (795), the above models of genetic susceptibility for migraine with aura have advanced our understanding of possible links between the two related conditions (795). Recently a mutation in the casein kinase 1 δ (CK1 δ) enzyme was found to be associated with increased prevalence of migraine with aura; interestingly a common phenotype of the newly developed transgenic mouse is also an increased susceptibility to CSD (119).

The question of the role CSD has in migraine remains, that is, does CSD predispose individuals to migraine without aura or is it simply an additive phenotype which transforms migraine without aura, to that with aura? Regardless of the ongoing debate which will only be answered by detailed translational research the impact of CSD on the trigeminovascular system is giving up its secrets.

C. CSD physiology

Cortical spreading depression (CSD) was originally described in 1944 by Leao (518, 519) as a spreading suppression of spontaneous EEG activity evoked by electrical stimulation of the rabbit cortex, and he later demonstrated that an initial depolarizing wave preceded the prolonged depression. It is now clear through a number of excellent studies that CSD results

from the depolarization, followed by a sustained hyperpolarization (or quiescence (512, 513)) of neurons and glial cells with almost a complete reversal of membrane potential resulting in breakdown of normal ionic gradients (743). Although the exact role of glial cells is unclear as blockade of astrocytic calcium waves (661) fails to block the spread of CSD indicating two parallel phenomenon. As a result of CSD the cortical microenvironment is dramatically altered with large increases in extracellular potassium and hydrogen ions along with the release of arachidonic acid, glutamate, serotonin and nitric oxide and concurrent decreases in intracellular sodium (743). Changes in perfusion that accompany the metabolic/electrocortical changes during CSD result in cortical blood flow changes: hyperemia (increased blood flow) followed by sustained oligemia (reduced blood flow) (120, 519). These changes are thought to be a consequence of neurovascular coupling where perfusion increases to meet the demand of depolarization, and decreases following the hyperpolarization or quiescence (732). However, recent data has indicated that this neurovascular coupling is impaired during the oligemic phase (665) or there may even be an uncoupling of the vasomotor and neuronal changes (120, 153), especially under conditions of brain injury (259, 589, 768). Interestingly from a clinical perspective brainstem changes may be seen with CSD in rat (616), although many antimigraine drugs do not alter it when used acutely (460). Moreover, the phenomenon is more easily triggered in female mice (121), implicating sex steroids. In addition it has been shown female mice with mutations known to produce familial hemiplegic migraine (see Section X), S218L and R192Q, are more susceptible than CSD than males (248),

It has been demonstrated, using experimental animal models, that CSD induced by mechanical stimulation; pin-prick to the cortical surface, causes blood flow changes (23, 407) that travel across the cortex, vasodilation of the middle meningeal artery and increased neuronal activity of the TCC (110). This arterial vasodilation occurs coincident with the spread of blood flow changes, but also independently, after the initial increase in blood flow. More recently electrophysiological studies have demonstrated that CSD induced with chemical, mechanical or electrical stimulation can produce prolonged activation in approximately 50% of meningeal nociceptors (879, 880), which could last for nearly two hours in some cases. If one looks at this data set as whole it would appear that CSD, approximately half the time, is able to activate neurons of the trigeminovascular system, specifically at the C1-C2 level of the spinal cord, and activation of meningeal nociceptors may contribute to the delayed dural vasculature changes that appear to be independent of CSD wave. However, this activation of trigeminovascular structures is not always observed (235, 499, 500), which may be explained by experimental and species differences, and has been observed independent of a peripheral input (500).

D. CSD and trigeminovascular activation

The exact mechanism leading to increased CSD evoked trigeminovascular throughput is like so many other aspects, still debated (62, 134, 157, 313). Interestingly, medicines used in migraine prevention can block CSD (19, 63), as does vagal nerve stimulation (163). Recent evidence suggests that localized release of molecules activates meningeal nociceptors that can drive peripheral inputs to the TCC. In one study CSD was shown to activate neuronal Panx1 megachannels, which can result in local sensitization of trigeminovascular afferents (457).

However, CSD can also evoke brainstem and trigeminovascular mechanisms without activation of meningeal nociceptors, indeed painless aura is a well-recognized concept (825). It is known to disrupt normal pain modulatory centers including the NRM (498), altering the processing of nociceptive inputs to the TCC. Direct corticotrigeminal projections have been demonstrated using a combination of electrophysiology and tract tracing. Two distinct functional networks exist (630), the first of which arises in the insula, projects to lamina I and II neurons in the TCC and facilitates trigeminovascular nociceptive tone. The second originates in the primary sensory cortex, and project to deeper TCC lamina (III and IV) and is inhibitory. The exact impact of CSD on two distinct populations of cells each with opposing effects is difficult to ascertain in the rat due to spatial localization and rapid spread of CSD. However, in gyrencephalic brains where spatial distribution is greater and CSD is thought to be more localized it is possible that individual CSDs could result in both a clear suppression and facilitation of trigeminal pain, based upon their anatomical localization.

Thus it is likely that a combination of CSD peripheral trigeminovascular activation and central pain modulatory dysregulation underlie the association of CSD/aura and migraine. Perhaps the field of migraine research has been too focused on if CSD/aura is a trigger for migraine (discussed in the theories of migraine section) with or without aura, as many triggers are known to exist and should look at the disease as a whole. As presented above, migraine occurs in three stages with a premonitory phase starting 24-48 hours before the attack long before CSD is known to occur. It is thus conceivable that a central disruption predisposes individuals to

specific triggers, of which CSD/aura is one of many which may potentiate an already perturbed system.

X. Genetics of Migraine

The existence of a strong genetic component in migraine seems obvious from clinical practice (504) and is supported by population-based family studies (695, 758). These studies show immediate family members of migraineurs have a substantially increased risk of suffering from migraine compared to relatives of matched controls (758). Interestingly, the relative risk differed depending on the presence of aura and the degree of disability. First-degree relatives of patients suffering from migraine with aura had a 4-fold increase of relative risk of migraine while relatives of patients with migraine without aura showed only a 1.9-fold risk increase (695). Further hints are provided by twin-studies that reveal a significantly higher pairwise concordance rate of migraine in monozygotic compared to dizygotic twins (295-297, 810, 811). While specific genetic changes in common forms of migraine are yet to be reported, some specific biology has been identified that does inform our understanding of migraine aura.

A. Familial hemiplegic migraine (FHM)

FHM represents a monogenic subtype of migraine with aura that involves at least one limb weakness. It does not, in spite of the name, usually involve plegia, rather weakness; the term

hemiplegic is retained for historical consistency rather than neurological accuracy. The three responsible genes currently recognized were identified by classical linkage analysis in which genetic markers are compared to a specific disease trait. All three known FHM mutations encode mechanisms that impact ion transporters, the *CACNA1A* (FHM1) (645), *ATP1A2* (FHM2) (203) and *SCN1A* (FHM3) (215) genes; their dysfunction ultimately leads to an increase in neuronal excitability (63).

1. *CACNA1A*

The *CACNA1A* gene was the first gene to be identified as causal for FHM1 (645). It is located on chromosome 19p13 and encodes the $\alpha 1$ subunit of neuronal Cav2.1 (P/Q-type) voltage-gated calcium channels (845). All known FHM1 mutations induce gain-of-function effects as they enhance channel open probability thereby increasing neurotransmission (368, 664, 798). Two mouse models; R192Q (813) and S218L (797) transgenic mice, have been developed to gain insight into the functional consequences of these mutations through a large amount of preclinical *in vivo* studies. Findings from these animal studies have substantially enhanced the understanding of migraine aura.

2. *ATP1A2*

The second FHM gene, *ATP1A2*, is located on chromosome 1q23 and encodes the $\alpha 2$ subunit of sodium-potassium pumps (203, 784). Until now over 30 mutations within the *ATP1A2* gene have been associated with FHM2. All of them induce a loss-of function on sodium-potassium ATPases increasing the potassium ion levels within the synaptic cleft.

3. *SCN1A*

Mutations within the *SCN1A* gene located on chromosome 2q24 represent the underlying cause for FHM3 (215). The gene encodes the $\alpha 1$ subunit of neuronal Nav1.1 voltage-gated sodium channels. Genetic mutations within the *SCN1A* gene that have been associated with FHM mostly exert a loss-of-function effect that mainly affects inhibitory neurons although gain-of-function effects have been described.

Finally, in many patients suffering from hemiplegic migraine none of the three known FHM mutations can be identified, especially in cases without familial clustering (268). These cases of so-called sporadic hemiplegic migraine (SHM) (791) indicate that other genetic abnormalities may exist in the pathogenesis of SHM (786). If these involve other unknown FHM genes or a specific combination of other multiple low-risk genetic variations is not known (657).

4. *Pathophysiology of FHM*

All known FHM mutations encode proteins involved in ion transport and lead to higher concentrations of glutamate and potassium in the synaptic cleft increasing neuronal excitability which may increase the susceptibility for the induction of CSD and thereby migraine aura, which is believed to be the underlying cause of the transient motor deficit occurring in hemiplegic migraine (63). However, it is still likely that other factors such as increased incoming neuronal signals from the periphery or hormonal changes, that may affect neuronal activity, may play a role or even be required for inducing CSD even if an increased susceptibility resulting from the FHM mutations exists. Whether functional consequences go beyond the increased propensity of CSD, for instance if in affected migraineurs CSD induces activation of nociceptive pathways

involved in the pathogenesis of migraine, has not been entirely clarified. Certainly FHM1 mice have reduced calcitonin gene-related peptide expression in the trigeminal ganglion (578). Consistent these data, Fos protein expression in FHM1 mice, when subject to dural stimulation, is not increased or altered by a triptan, as it is in wild-type mice. In contrast, FHM1 mice display enhanced transmission in thalamus (654). Moreover, it can be shown in rat that transcranial magnetic stimulation, which is effective for acute migraine with aura (537) and probably as a preventive when used regularly (94), can block CSD effects on trigeminothalamic neurons after a single pulse (45). These data suggest the burden of FHM1 pathobiology may be thalamic.

5. Triggering and FHM

One important, and as yet unexplained feature of FHM, is its lack of sensitivity to otherwise typical migraine triggers, such as nitric oxide donors (374, 376) or CGRP (375). This is not simply a matter of the aura phenotype, since both nitric oxide donors (441) and CGRP (372) trigger migraine without aura attacks, predominantly, in patients with simple migraine with aura. Rarely, aura can be seen triggered by NO-donors (12); this is the exception. It has also been shown that evoked potential habituation in FHM differs from other forms of migraine (370), although interestingly FHM patients identify similar trigger factors for their attacks as migraine with aura patients (371).

B. Casein Kinase 1 δ (CK1 δ)

In clinical practice migraineurs commonly report that abnormal sleep may trigger migraine attacks and that migraine leads to an abnormal sleep pattern (859, 860). Attacks frequently

start in the early morning (399), a time in which affected individuals usually are in their REM sleep phase or shortly after waking up. In addition, changes in wakefulness may be part of the premonitory symptoms of a migraine attack. These observations and the fact that migraineurs show a higher incidence of narcolepsy (194, 195) suggest that migraine may be linked to circadian mechanisms.

A missense mutation in the gene encoding casein kinase 1 δ (CK1 δ) has been linked to migraine (119, 863). The *CK1 δ* gene is a ubiquitous serine-threonine kinase involved in the regulation of sleep patterns. A missense mutation in the DNA-sequence of the *CK1 δ* gene results in a threonine-to-alanine alteration at amino acid 44 (T44A) of the protein leading to reduced enzyme activity. This genetic alteration and its functional consequences lead in humans, and transgenic mice with the human mutation inserted, to the clinical phenotype of the Familial Advanced Sleep Phase Syndrome (FASPS), which is characterized by an abnormal sleep pattern consisting of early sleep times and early-morning awakening (794, 864). In six individuals of one family the genetic alteration has not only been associated to familial advanced sleep phase syndrome (FASPS) but also to migraine with and without aura (119). This observation suggests that beyond being a central element in the regulation of sleep, CK1 δ may be functionally relevant in migraine pathophysiology. A second missense mutation with a histidine-to-arginine change at amino acid 46 of the *CK1 δ* gene has been identified to cause reduced enzyme activity and co-segregate with FASPS and migraine highlighting its potential functional relevance in both disorders (119).

To assess their functional relevance in migraine, a series of *in vivo* studies have been conducted on transgenic *in vivo* models with mice carrying the T44A mutation (119). These studies revealed that compared to their wild-type littermates, mice carrying the T44A mutation show increased hyperalgesia after intraperitoneal injection of nitroglycerin, a substance known to induce neuronal activation in the dorsal horn in mice and migraine attacks in migraineurs. Mice carrying the *CK1δ-T44A* gene also show a reduced threshold for the induction of CSD as well as an enhanced vasodilation of meningeal and cortical arteries following CSD. The latter is interesting in the context of CK1δ playing a role in glutamatergic transmission (164). Moreover, mice with the T44A mutation display a similar reduced trigeminocervical complex activation profile (400), as that cited above for FHM1 mice (654), linking in some respects the migraine-related biology of these two very different mutations. These observations suggest a pathophysiological influence on migraine aura and its functional consequences. Taken together, these preclinical and clinical findings suggest that mutations in the *CK1δ* gene may contribute to the pathogenesis of migraine and migraine aura.

C. TWIK-related spinal cord potassium channel (TRESK)

A candidate gene approach led to the identification of the frameshift mutation F139WfsX24, encoded within the *KCNK18* gene, which prematurely truncates the TRESK protein to 162 residues inducing a complete loss-of-function, in a large multigenerational family affected by migraine with aura (493). The influence of TRESK on neuronal resting membrane potential, its wide distribution throughout the CNS, its functional implication in pain pathways and the segregation with migraine with aura led to the conclusion that the *KCNK18* gene may be

functionally involved in the pathogenesis of migraine, and the TRESK channel even represents a potential therapeutic target. This hypothesis has been supported by the fact that two-pore domain (K2P) potassium channels, such as the TRESK channel, are targeted by several volatile anesthetics leading to its activation. Investigation of mutant TRESK function points towards altered hyperexcitability in trigeminal ganglion neurons (540) and further that TRESK channel openers can reverse this hyperexcitability and may hold potential as therapeutic targets (365). However, further studies have revealed that other genetic mutations that also cause a complete loss-of-function of the TRESK channel do not specifically segregate with migraine (48) have raised doubt on the functional consequence of mutations within the *KCNK18* gene that lead to a dysfunctional TRESK channel, in regard to the pathogenesis of migraine. Nevertheless, the influence of K2P-channels on neuronal excitability and on pain pathways may warrant further studies to investigate their potential as a therapeutic target.

D. Genome wide association studies (GWAS)

In recent years GWAS have identified a series of single nucleotide polymorphisms (SNP) that may be relevant for the pathogenesis of migraine (53, 54, 159, 160, 283). GWAS are based on the hypothesis-free analysis of a large amount of SNPs in relation to specific disease traits. The advantage of this technique lies in the fact that compared to other genetic approaches a large number of genes can be analyzed with respect to a specific disease. However, due to the large amount of tests, GWAS are associated with several caveats inherent to the technique. Results have to be cautiously corrected for multiple testing and only associations with p -values below 5×10^{-8} can be considered significant (250). Furthermore, the identified genetic variants are

characterized by a very low relative risk questioning their clinical significance. In contrast, if high-risk genetic variants exist which show only marginal allele frequency, a GWAS approach will likely miss this genetic association. Finally, GWAS do not capture interactions between allele variants that may be functionally relevant. As a result of these difficulties, conclusions regarding the relevance of GWAS findings for the pathophysiological mechanisms of migraine and their clinical significance, especially conclusions on an individual genetic risk, have to be interpreted with caution. Therefore an identified association should always be confirmed in independent case-control studies before any conclusions are drawn.

Regardless of these technical considerations, three GWAS have been published with respect to migraine (53, 54, 159, 160, 283). These studies identified a series of potentially migraine-relevant susceptibility genes that are involved in glutamatergic neurotransmission (*MTDH*, *LRP1* and *MEF2D*) and are functionally involved in pain-sensing pathways (*TRPM8*), neuronal development (*MEF2D*, *ASTN2*, *PRDM16*, *PHACTR1* and *TGFBR2*) and brain vasculature function (*PHACTR1* and *TGFBR2*). Among these genetic variants the most consistent results have been observed for *LRP1* and *TRPM8*. While *LRP1* encodes a lipoprotein involved in nociceptive glutamatergic signaling (147), *TRPM8* encodes a cold-sensitive calcium channel that may induce burning pain (84, 592, 656). The *TRPM8*-channel is expressed on unmyelinated C-fibers and myelinated A δ -fibers (477) and may co-express with *TRPV1*-channels and CGRP (212). Beyond peripheral sensory neurons (477), the *TRPM8*-channel has been identified on the trigeminal (2) and dorsal root ganglia (431) indicating a functional relevance in migraine. However, despite

these anatomical observations further *in vivo* studies are required to elucidate the functional consequences of mutations within the *TRPM8* gene.

A challenging and exciting observation for the future is an initial finding of the SNP, rs2651899 in *PRDM16* has an odds ratio of 2.6 in predicting triptan efficacy in acute migraine treatment (168). Such a result suggests the eventual possibility of personalized medicine for the treatment of migraine.

Taken together, recent data suggests that in contrast to FHM, which appears to be a monogenic disease, common forms of migraine are likely to be the result of several genetic factors which interact with each other and with environmental influences which finally lead to an increase in the susceptibility of migraine.

XI. Neural basis of migraine triggers

Migraine attacks are generally considered spontaneous in nature and sometimes thought of as occurring without any tangible trigger or precipitating factors, yet many patients will frequently report known exogenous or endogenous factors they believe to reliably trigger their migraine attacks, or at least increase their likelihood of occurring (504). Perhaps this confusion and the distinct lack of clarity about if and what factors can be involved in precipitating migraine attacks is a consequence of two major observations. First, it is likely that the entire phenotype and duration of the migraine syndrome is misunderstood by patients, but sometimes also by clinicians. The migraine attack does not begin at the perception of head pain, or in the case of

aura, during the first neurological aura deficits, but most likely 24-48 hours prior to these symptoms, during the premonitory phase (300). As described in the earlier sections, many patients will report having a feeling that a migraine is coming even though they are not in pain several days before the headache, and this is often characterized by specific symptoms, such as tiredness, lack of attention, and food craving (300). Indeed, imaging studies have demonstrated that there are significant changes in brain activation while these symptoms are perceived (559, 749). It is possible that a blurring of the lines between premonitory symptoms and migraine triggers has led patients and clinicians alike to believe that certain environmental factors believed to precipitate their migraine attack actually represent a symptom of their syndrome, such as craving certain foods, including chocolate and cheese, as well as tiredness. The other factor which complicates this issue is that there are very few controlled studies that have actually dissected internal or external events triggering attacks. One recent interesting study, which controlled both bright light and/or strenuous exercise as a triggering mechanism for migraine with aura, only produced modest predictability, in patients who self-reported these factors as triggering their attacks (427). This is not to say that certain factors do not trigger migraine attacks, or at least increase the likelihood of an attack occurring, and the volume of patients that describe, for example, skipping meals, sleep disturbance and stress as precipitating factors cannot be ignored. Perhaps the truth is closer to what we cannot see, or easily measure on a day to day basis, and down to the natural fluctuations in neuronal excitability in the brain that have been observed (750). The brain may be naturally protected at times of lower excitability, but much more susceptible to triggers at the peak of excitability fluctuations. Despite this lack of clarity there are still certain environmental and endogenous

factors known to increase the likelihood of precipitating an attack that warrant discussion of their neural basis.

A. Chemical triggers and inflammation

Environmental or experimental chemical triggers of migraine have proven, over the last 25 years, to be the most reliable approach for experimentally triggering migraine in the clinical setting (441). A number of molecules are accepted to trigger migraine (386). These are largely vasoactive and many are present at the nerve endings of perivascular nerve fibers innervating the cranial vasculature from the sensory, parasympathetic and sympathetic nervous systems (Table 2), and be released as a consequence of activation, although not all appear to be released during migraine.

1. Triggering and vasodilation are uncoupled

Nitric oxide (NO) donors, such as nitroglycerin (NTG), are highly volatile vasodilator agents (606), and have been recognized to trigger migraine for some years (515, 673). NTG-triggered migraine has been well described for many years as a model system (441) and has been the most studied preclinically. It produces an immediate headache in almost all subjects, but also a delayed migraine, after two-six hours, in migraineurs. Similar responses have been demonstrated with CGRP, PACAP and prostaglandin E2 (PGE2) and I2 (PGI2) (52, 58, 508, 720, 849). The mechanism for triggering these migraine attacks is still speculated upon. A common denominator is that they all cause immediate vasodilation of extracerebral blood vessels (52,

58, 639, 641, 642, 720, 849), and the reversal of vasodilation with sumatriptan aborts migraine (59, 440). Similar findings have been demonstrated preclinically in rats, with NO donors, CGRP, PACAP, PGE2 and PGI2 (29, 111, 622, 623, 767, 852) all causing meningeal vasodilation.

However, evidence of vasodilation as a cause of pain in migraine has now been effectively excluded. Human studies show no meaningful change in external carotid branches (40, 58, 713), and never demonstrated a temporal relationship between headache resolution and vascular changes with sumatriptan (531). Furthermore, both vasoactive intestinal polypeptide (VIP, 674) and prostaglandin D (848) are clear examples of vasoactive mediators causing immediate vasodilation and mild headache in healthy controls and migraineurs, but no occurrence of delayed migraine. In contrast pituitary adenylate-cyclase activating peptide (PACAP), which shares VIP receptor targets (83), is equi-efficacious in terms of vascular effects (39), and does trigger migraine (720) in patients. These data conclusively demonstrate that vasodilation is not an obligate component of migraine pathophysiology, and that the mechanism by which these substances trigger is not vascular.

2. Inflammatory mechanisms do not explain migraine therapies

There is some evidence that migraine triggers may stimulate inflammatory processes, which are responsible for activating a cascade of events involving sensitization of meningeal nociceptors, resulting in migraine headache. NTG administration causes delayed release of inflammatory mediators from the meninges (682) in rats, which are involved in activating and sensitizing meningeal nociceptors, which has been hypothesized to promote pain in a migraine attack (91).

PGE₂ is used in the inflammatory soup that is placed on the dura mater, which induces peripheral and central sensitization (135, 766) and dural PGI₂ produces peripheral sensitization of meningeal nociceptors (881). These data potentially point to a mechanism of dural inflammation and activation of meningeal nociceptors to trigger the migraine attack. NTG also produces an up-regulation of dural mRNA for inducible nitric oxide synthase (iNOS) followed by protein expression 4-10 hours after NTG, as well as plasma protein leakage that are suppressed by iNOS inhibition (682).

In contrast, iNOS inhibitors are ineffective in clinic either as an acute or preventive treatment strategies (403, 649), and likewise plasma extravasation inhibitors have also failed in the acute treatment of migraine (233, 691). Other evidence further indicates that dural inflammatory mechanisms are unlikely to be the triggers for the migraine attack. CGRP and PGE₂ are well-known inflammatory mediators, but at supramaximal doses known to cause vasodilation, neither was able to induce dural plasma protein extravasation in rats (566). Furthermore, an iNOS inhibitor was unable to inhibit either neurogenic or CGRP-induced vasodilation of meningeal vessels (31), a model that has proven predictive of therapeutic efficacy (88). Finally, PACAP is known to be released upon inflammation to protect neurons and is thought of as anti-inflammatory (835). These data imply that dural inflammatory mechanisms are unlikely to be involved in triggering migraine with these vasodilator agents, although as yet only neural mechanisms have been identified in the laboratory in terms of trigeminocervical inhibition (17).

3. Brain mechanisms and triggering

If neither dural vasodilation nor inflammatory mechanisms are responsible for triggering the migraine attack after administration of vasoactive agents, other neural structures along the trigeminovascular pathway must play role. Perhaps inside the brain is where the answers lie. Premonitory symptoms, accompanied by activation of dorsolateral pons, midbrain and hypothalamic regions, have been demonstrated in NTG-triggered migraine (13, 559), prior to any description of headache, suggesting that brainstem and diencephalic nuclei may be involved in the migraine triggering process. One would anticipate that if peripheral vascular or neurovascular mechanisms through inflammation and activation of meningeal nociceptors, are involved in triggering migraine with chemical triggers, pain should be the first symptom reported as a consequence of central trigeminovascular activation, rather than occurring after other neurological deficits. This gap in trigeminovascular activation is also demonstrated in rodents, where NTG causes activation in the mid brain vIPAG, locus coeruleus and parabrachial nucleus, as well hypothalamic nuclei, before any activation in the TNC is detected (782, 783). Furthermore changes to levels of PGE₂ and cyclo-oxygenase-2 in the rat brain after NTG occur in the hypothalamus prior to changes in the lower brainstem (821).

So are these migraine triggers activating nuclei in the brain involved in triggering an attack? Locally applied NO donors, including NTG, excite central trigeminovascular neurons (495, 496), demonstrating a direct effect of these molecules in the TCC and VPM thalamus. These data point towards a more neuronal basis to the triggering mechanism of these vasoactive mediators. Perhaps electrophysiological studies provide the clearest example of the systemic effects of migraine triggers on central trigeminovascular neurons. Messlinger and colleagues

have demonstrated that the NO donor, sodium nitroprusside produces a biphasic response on meningeal nociceptive central trigeminovascular neurons, with an initial increase in basal firing that accompanies sodium nitroprusside administration, but a delayed and prolonged facilitation for up to two hours (480). These effects are reversed by systemic administration of the CGRP receptor antagonist, olcegepant (481). This effect is most likely to be on second order central trigeminovascular neurons, as local cranial dural inhibition of CGRP receptors does not inhibit spinal trigeminal neurons (276), particularly as there is no evidence of CGRP receptors on peripheral axons, although they are present on central projecting axons (523). More recently we have also demonstrated with NTG that the delayed facilitation of basal trigeminal tone is prolonged beyond three hours, and there is also sensitization of noxious and innocuous responses to dural and cutaneous facial stimulation (20).

Locally applied CGRP also causes excitation of both central trigeminovascular (760) and VPM thalamic nociceptive neurons (769), and olcegepant inhibits glutamate-evoked firing in these areas. Furthermore, locally applied CGRP or olcegepant in the vIPAG, activates or inhibits, respectively, dural nociceptive trigeminovascular responses (668). However, given systemically CGRP does not activate or sensitize peripheral meningeal nociceptors, for up to one hour (526), which implies a peripheral neural mechanism of action is unlikely, although observations have not been made beyond this time frame. However, central trigeminovascular responses do seem to be transiently sensitized to facial vibrissal innocuous inputs after CGRP, although these responses were largely low threshold mechanoreceptors outside of the ophthalmic dermatome (188). However, the longer term effects of CGRP, beyond one hour, on central

trigeminovascular neurons, which would mirror its delayed effects in migraineurs is not known. In general it seems that vascular, and also likely, peripheral neurovascular mechanisms do not play a role in triggering migraine as a result of vasoactive agents. Indeed the vascular effects may be better described as a 'red herring', which distracts attention from their likely mechanism of action inside the brain. These data point to a neuronal mechanism of activation involved in triggering a migraine attack. One last and important factor that needs to be considered is that, other than NTG, which is highly volatile and readily diffuses into tissue, including the brain, CGRP, in particular, is a large peptide unlikely to cross the blood-brain barrier and therefore it is thought they cannot get into the brain to have an effect. PACAP on the other hand has a specific pump mechanism to facilitate its transport (69). It is interesting that triggers of all sorts are only effective in migraineurs, whose brain biology certainly appears to be different to healthy controls; whether this alters their ability to enter the brain can only be speculated upon.

B. 'Skipping meals'

It is generally accepted that metabolic disturbances, such as fluctuations in water balance, food intake, mood and sleep contribute to migraine in some patients (228, 300). According to some studies, lifetime migraineurs experience headache attacks preceded by triggering factors such as food deprivation and/or fasting (skipping meals) (196). Although it is debated whether fasting is actually a headache trigger or rather that food craving is a symptom in the premonitory phase of migraine. Blau and Cumings (108) attempted to identify a correlation between blood glucose and migraine, rather than fasting itself, and reported that fasting

caused headache in 50% of migraineurs. The authors proposed “some patients have some of their attacks of migraine fired off by missing a meal, and that this is related to a low blood sugar, which must persist in that individual for a certain length of time to cause headache”. Although there are many observations of food cravings during the premonitory phase of migraine, with researchers reporting that some patients would crave for sweet foods (228), and one study, using individual electronic diaries, reported that 18% of the patients reported hunger or food craving as triggers of their headache (300). These studies clearly demonstrate a blurring of the lines between altered feeding as either a cause or a symptom in migraine.

Some authors have tried to reconcile these two migrainous attributes, with Martin and Seneviratne (568) offering an explanation for their finding that food deprivation caused headache in 58% of patients with frequent migraine or tension-type headache. The authors write that “hunger arising from low blood sugar levels, for example, may lead to cravings for particular foods such as chocolate, on the one hand, and lead to headaches, on the other hand, but the headaches may be erroneously attributed to the food consumption rather than the low blood sugar levels”. Perhaps what these studies demonstrate most is the importance of alteration of the feeding schedule, either skipping or delaying meals, in migraineurs, as it clearly has an impact on the phenotype of patient suffering.

What is understood about the neural mechanisms that regulate feeding is that they are controlled within the hypothalamus (742, 869), a brain structure that we know to be active and involved in migraine pathophysiology (21, 559), and this structure is likely to impact our

understanding of the role of altered feeding in migraine. The hypothalamus is a major center of convergence and integration of several nutrient-related signals and, thus, hypothalamic neurons are thought to promote the homeostasis of physiological systems involved in synchronization of circadian rhythms, salt balance, appetite and energy expenditure, thirst and water balance, among other functions (690). A summary of the hypothalamic pathways and neuropeptides involved can be found in figure 9 and the subject is extensively reviewed elsewhere (220, 742, 869)

1. Anatomy of feeding and fasting

i. Hypothalamic-based mechanisms

Two populations of neurons located in the hypothalamic arcuate nucleus, one expressing the orexigenic neuropeptide Y (NPY) and agouti-related peptide (AGRP), which promote feeding, and the other expressing the anorexigenic peptides proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART), which cause a loss in appetite, are the primary integrators of nutritional information, being sensitive to signals of energy availability (reviewed in 55, 220, 742, 869). Leptin is also one of the most important regulators of energy balance since arcuate POMC and AgRP/NPY neurons are targets of leptin with opposing signaling effects: AgRP/NPY neurons are inhibited by leptin (81, 717), in contrast to POMC neurons which are excited (718). Likewise, orexins A and B are also involved in feeding regulation in the arcuate nucleus, where orexin A activates NPY-containing neurons to promote feeding (866). As well as the interaction between NPY/AgRP and POMC/CART neurons, arcuate neurons also

project to other key hypothalamic nuclei, such as the paraventricular nucleus (PVN), dorsomedial nucleus (DMH), lateral (LH) and ventromedial (VMH) hypothalamic nuclei, orchestrating adaptive responses to energy homeostasis imbalance (reviewed in 73). These are all regions known to be relevant to migraine pathophysiology. A summary of orexigenic and anorexigenic neuropeptides and their roles in homeostatic function can be found in Table 3.

ii. Brainstem mechanisms

Outside the hypothalamus, the nucleus tractus solitarius (NTS) and the VTA are also known to be involved in feeding control and pain modulation. Leptin receptor ObRb mRNA is present in the NTS (599) and leptin causes neuronal activation (251). NTS neurons project to the VTA, PAG and LC (293), and the NTS, along with the arcuate nucleus, is the only source of anorexigenic POMC neurons (442). Injection of anorexigenic neuropeptides into the NTS reduces food intake, and antagonists increase food intake (362, 850), with 75% of NTS neurons firing in response to blood glucose fluctuations (870). The VTA is implicated in modulating food craving behaviors (600), as well as the drive to access highly palatable foods (3, 4) and increased leptin signaling in the VTA decreases food intake and firing rates of DA neurons (287, 414).

2. Neuropeptides during feeding and fasting

i. Orexins

Orexins are made solely in the hypothalamus (356), but particularly in the lateral, posterior and

paraventricular nuclei of the hypothalamus (356, 700). Intracerebroventricular (ICV) or direct micro-injection into the arcuate nucleus stimulates food intake (383, 619, 701) and this response appears to be predominantly mediated by OX_1 receptors (741). During fasting and hypoglycaemia there is increased orexin release in the hypothalamus (141, 142, 458, 701), accompanied by an increase in OX_1R receptor mRNA expression in the VMH and increase in OX_2R mRNA expression in the arcuate nucleus (551). Orexins have a close relationship with glucose metabolism, with orexin cells stimulated by low glucose levels and elevation in glucose levels suppresses both spontaneous and evoked firing in orexin neurons (125). ICV (871) or systemic injection (633) of OxA causes an increase in plasma glucose levels, and peripherally administered OxA increases insulin secretion (633).

In the context of migraine, OxA and B levels are lower in the periphery during episodic migraine, whereas OxA levels are increased in chronic migraine (706). Therefore there is evidence of a potential perturbation of the orexinergic system in different migraine states. Preclinical studies demonstrate that systemic OxA inhibits dural-evoked trigeminovascular nociceptive neurons, predominantly via $Ox1$ receptors, whereas OxB has no effect (408, 409). A dual orexin receptor antagonist (DORA-12), which has equal affinity to both $Ox1$ and $Ox2$ receptors is also able to inhibit dural-evoked trigeminovascular nociceptive responses (402). However, a DORA was ineffective as a migraine preventive when dosed daily, although sedation was more commonly seen as a side effect in the active than the placebo arm (150).

ii. Neuropeptide Y (NPY)

The other main orexigenic neuropeptide is NPY, which is known to be involved in regulation of the cardiovascular system, pain modulation, appetite control and circadian rhythm synchronization, and is abundantly expressed in the basal ganglia, limbic system and hypothalamus (7). It is synthesized in the arcuate nucleus (67) and released into the PVN and LH (123, 753), where it exerts its appetite stimulating properties. ICV injection or direct micro-injection into the PVN causes stimulation of food intake (751). This response is regulated by OxA activating (866) and leptin inhibiting (756, 832) NPY-containing arcuate neurons. These NPY neurons also project to many pain modulating nuclei in the brainstem, including the PAG, DRN, NRM, LC and NTS (737), and NPY Y₁ knock-out mice show increased nociception (485) and intra-arcuate administration of NPY exerts an antinociceptive effect in intact rats and in rats with inflammation through NPY Y₁ receptor activation (530). During fasting or food restriction there is increased NPY release in the hypothalamus (846), including the PVN (455), where NPY Y₁ expression is also increased (862).

In the context of migraine, evidence of altered NPY levels is conflicting. One study shows lowered peripheral levels in episodic migraineurs (146), whereas a study that measured plasma from the extracerebral circulation found no changes during the headache phase (325). However, it is a common theme in migraine that interictally brain activation is lower, yet ictally activation appears to be normalized, and it is perhaps this relative change between states that is important rather than direct comparisons to healthy subjects. NPY Y₁ and Y₂ receptors are

present in human trigeminal ganglia (807) and NPY Y₁, Y₂, Y₄ and Y₅ are present in the rodent TCC (655). In preclinical studies intravenous NPY inhibits dural-evoked neuronal firing in rats, a response that is mediated by the NPY Y₁ receptor (570). These data indicate that NPY can alter trigeminovascular nociceptive transmission.

iii. Leptin

The main anorexigenic peptide is *leptin*, which is secreted by the adipose tissue and transported to the brain where it crosses the blood-brain barrier (285, 841). In the brain it acts on ObRb, the long form of the leptin receptor (175, 252, 621, 721, 781). Circulating leptin is thought to be an indicator to the CNS of total body energy stores (282). When injected either iv, or icv, leptin activates neurons in the PVN, ARC, VMH and DMH (252, 255, 256, 815), and suppresses feeding (733). During fasting, serum levels of leptin decrease, normalizing after refeeding (478, 608). Leptin activates the food suppressing POMC pathway, and actively inhibits the orexigenic AgRP/NPY pathway, and during fasting this effect is reversed.

There is also evidence of perturbations in leptin levels in migraineurs, with increased leptin and insulin levels in one study (90), but lower serum levels interictally in another (364). There is evidence of leptin receptor (ObRb) mRNA in neuronal cell bodies of trigeminal motor nuclei as well as the LC, dorsal vagal complex and parabrachial nucleus (363). Preclinically, leptin causes a moderate but significant reduction in firing of dural-evoked trigeminovascular nociceptive neurons (569).

3. Implications for migraine

i. Brain mechanisms, migraine and feeding

The relevance of these structures to migraine pathophysiology, and specifically the ascending projections to the trigeminovascular system and descending control of trigeminovascular nociceptive transmission has been described in detail (Section V). Briefly, it has been shown that nuclei in the region of the hypothalamus are active before (559) and during migraine headache (210). There is activation of VMH, DMH, PVN (557), posterior (PH) and supra-optic hypothalamic nuclei (85) in response to trigeminovascular stimulation, and descending projections exist from the PVN, PH, perifornical, A11 and retrochiasmatic area (1, 688), to the TCC. Projections from the PH (78) and PVN (688) are known to modulate basal and nociceptive meningeal-evoked activity of trigeminal neurons. These connections are thought to contribute to migraine symptoms such as loss of appetite and pain modulation. The VMH also sends topographically organized projections to areas involved in nociceptive modulation such as the PAG, LC, parabrachial nucleus and NTS (145) and the PVN sends descending projections to the superior salivatory nucleus (688). It is clear that various hypothalamic nuclei are ideally positioned to mediate the integration of the trigeminovascular system with dietary fluctuations including disrupted feeding patterns.

The NTS is known to be involved in pain modulation, and is activated in response to dural nociceptive trigeminovascular activation, a response inhibited by triptans (421). A region seen activated on human brain imaging in the premonitory phase of migraine would be consistent

with NTS activation (560). Given that descending mechanisms from midbrain structures have been hypothesized to contribute to the triggering of migraine, altered feeding, such as fasting or hypoglycemia, which affects neuronal firing in the NTS could alter the descending modulation of trigeminovascular neurons, as well as alter appetite during migraine. Furthermore, the NTS is intrinsically involved in the 'emetic reflex arc' (602). Consistent with that involvement, medial-caudal NTS neurons are activated in cat (463) and monkey (330, 422) when dural afferents are stimulated. Remarkably, vomiting is a common symptom of migraine that can often ameliorate, or even stop an attack (152). It is possible to speculate that NTS activation might be part of the adaptive processes that take place in the brain before and during an attack, as a consequence of the migraine.

The VTA is also involved in nociceptive processing (34, 64, 230, 698), food reward, drug addiction (479, 600), and mood disorders (697). Food cravings and alterations of mood are considered by some patients to be present in the premonitory phase of the migraine attack (228, 300) and, importantly, the VTA was shown to be active during the premonitory phase (559).

In order to control body fuels during and after periods of fasting, several adaptive mechanisms take place, including reduction of resting metabolic rate and blood glucose, the priority of gluconeogenesis over glycogenolysis, and the production of ketones. These adaptations are caused or followed by several hormonal changes, including the decline in insulin and leptin serum levels and the rise in glucagon, catecholamines and cortisol (140, 214, 263, 478, 707).

Anatomically, there is increased activation of the perifornical region, DMH, VMH and arcuate hypothalamic neurons, which include activation of orexin-containing neurons (214), and elevation of mRNA levels of orexin and melanin-concentrating hormone (MCH) (672, 701). Furthermore NPY levels in the arcuate nucleus and PVN increase in response to food deprivation or food restriction and normalize after refeeding (118, 144, 647, 699), and NPY release in the PVN increases before a programmed meal and decreases during the course of the meal (455). Also, hypoglycemia induced by insulin causes significant activation in the PVN, as well as the LC, dorsal motor nucleus of the vagus and NTS (873).

ii. Feeding peptides and migraine

Considered altogether the data are consistent with a view that blood glucose fluctuations, as a consequence of changes to orexigenic and anorexigenic neuropeptides in specific hypothalamic nuclei, may increase the predisposition to triggering migraine through altered feeding, or reflect a change in that predisposition. Two studies demonstrate consistently higher insulin levels in migraineurs compared to controls (148, 676) suggesting that insulin resistance may be present in migraineurs. A significant prevalence of insulin resistance was also observed in chronic migraine patients (261). A significant association between a polymorphism of five single nucleotides of the gene encoding for insulin receptors in migraineurs has been found (590), which may affect insulin resistance during fasting in migraineurs. Thus, migraine might be more likely in susceptible persons when there is low insulin receptor activation (590), through fasting. It is interesting that mild hyperinsulaemia is reported in NPY Y₁ receptor deficient mice (489),

which might imply that low NPY Y_1 receptor activation impairs glucose and insulin metabolism that is reported in migraineurs. Furthermore, while obesity is not considered a risk factor for migraine, it is associated with an increase in frequency and intensity of attacks (99, 102, 858). Plasma OxA levels correlate negatively and plasma leptin levels correlate positively with body mass index (BMI) (5), therefore, obese individuals should present lower plasma OxA levels and higher plasma leptin levels when compared to normal individuals. This is in accordance with the lower peripheral OxA levels seen in episodic migraineurs (146) and, also, with higher blood leptin levels shown in non-obese female migraineurs (90), compared to healthy controls. In some respects disentangling cause and effect remains the major challenge in terms of meal skipping.

Looking at the wider impact of hunger, it is a strong and basic physiological drive. It involves activation of several pathways, including the hypothalamic orexinergic system, and is the product of multiple perceptions (taste, smell, sight, thoughts, visceral) and motivations. While migraine clearly includes pain, it has also been described as an altered activation (or perception of activation) of the senses, senses that are affected by hunger, including the trigeminovascular system. We can look at this in two ways in susceptible migraineurs; first, hunger triggers changes in activation in feeding centers in the brain, aimed at promoting feeding, which affect our sensory system, altering our perception of sensory inputs, which includes noxious craniovascular somatosensory inputs, but also those of sound, vision and smell, amongst others. Secondly, it could be argued that alterations in the individual perception of hunger, might in itself also cause disturbances of somatosensory processing, especially nociceptive

processing that result in migraine head pain. Thirdly, and perhaps more likely, there is a global alteration in the perception of our motivations and senses, including hunger and nociception, which become symptoms of the same cause and trigger, and thus all these symptoms of migraine are essentially a consequence of a brain state, rather than a single trigger.

B. 'Sleep disruption'

The relationship between migraine and sleep has been debated for a number of years (625): sleep is considered an effective means of alleviating pain associated with migraine; migraine can emerge during nocturnal sleep or following a brief period of daytime sleep; attacks can be preceded by a lack of sleep. Furthermore, sleepiness might also emerge during various phases of a migraine attack (71). Sleep deprivation, or consistent interrupted or reduced sleep is also described by many patients as a possible trigger of migraine (107). The regulation of sleep, particularly within the hypothalamus, is strongly linked to the regulation of feeding processes, and the interaction of both of these homeostatic mechanisms is likely involved in the triggering of migraine.

1. Anatomy of sleep

Both sleep and feeding rhythms are synchronized to the environmental 24-h cycle mainly by light–dark information perceived by the eyes, and regulated within the hypothalamus.

Generation of these rhythms occurs in the master circadian clock, the suprachiasmatic nucleus (SCN) of the anterior hypothalamus (201, 867). The SCN output is crucial for synchronization of

many metabolic and endocrine factors, such as glucose (143, 491, 693) and leptin (456). Zurak (883) reviewed the role of SCN in migraine and suggested that dysfunction of the SCN could be related to the prodromal phase of a migraine attack, suggesting SCN as the initial site of migraine attacks.

Feeding behavior and metabolite availability can in turn regulate the circadian clock. The DMH, a suggested food entrainable oscillator (354), receives neural input from feeding control areas (790) and is a major target of the SCN (838). DMH also projects to brain regions critical for the regulation of sleep and wakefulness (167). Specifically, DMH sends GABAergic projections to the sleep-promoting ventrolateral preoptic nucleus (VLPO) (548), and glutamate-thyrotropin-releasing hormone projections to the wake-promoting LH area (167). Therefore, increased neuronal activity in the DMH might promote wakefulness by simultaneously inhibiting sleep-promoting neurons in the VLPO and activating wake-promoting neurons in the lateral hypothalamus. The DMH also sends a dense projection to the PVN (255, 789). The activation of these pathways might explain why lack of sleep or wakefulness might trigger a migraine headache attack as Fos protein expression has been demonstrated in the DMH and PVN in an experimental model of migraine in animals (557); and PVN neurons directly control both spontaneous and evoked activities of spinal TCC neurons (688).

Midbrain nuclei, already described with respect to mechanisms that control pain, may also be involved in the triggering of migraine, as well as contributing to the associated symptoms via projections to hypothalamic and other brainstem and diencephalic nuclei. As well as controlling

pain modulation, 'ON' and 'OFF' cells in the RVM and NRM are also involved in controlling responses to external innocuous stimuli, motor activity and homeostatic processes (571, 573). 'ON' cells are state-dependently active during waking hours, but not during feeding and micturition, or during sleeping (65, 278, 279, 525). Whereas 'OFF' cells are active during sleep, and active during waking only prior to micturition as well as during feeding. Therefore 'OFF' cell firing in these midbrain structures, during important homeostatic functions such as sleep, feeding and urination prevents responding to innocuous and even acute noxious stimuli, whereas during waking 'ON' cell firing facilitates alertness to sensory stimuli. Furthermore, the vlPAG participates in mechanisms of arousal, through the activation of dopaminergic neurons during wakefulness and inactivation of these neurons during sleep (549); and vlPAG is also involved in the switch between non-REM and REM sleep (286, 550). These important mechanisms probably represent important evolutionary developments to control sensory, autonomic and motor processes during different levels of alertness to provide the greatest protection to the animal from nociceptive inputs. Certainly in the context of potential migraine triggers, sleep deprivation is a homeostatic process that results in specific neuronal responses in the PAG-RVM pathway, particularly 'ON' cell activation and inhibition of 'OFF' cell firing. In migraineurs, it is possible that altered responses of 'ON' and 'OFF' cells to nociceptive and homeostatic changes, such as sleep disruption, and the neuronal projections of the PAG-RVM systems to hypothalamic nuclei and spinal and trigeminal nociceptive neurons, described above, contributes to triggering the sensory and physiological symptoms of migraine.

2. Neurochemicals in sleep regulation

Interestingly, sleep is affected by feeding, specifically endogenous energy reserves, which may impact its influence as a migraine trigger. Indeed sleep is thought to be dependent on the availability of utilizable metabolites at the cellular level (198). Sleep debt has been shown to have a harmful impact on carbohydrate metabolism and endocrine function (747). Indeed, sleep deprivation, induces an increase in glucose and insulin plasmatic levels (684) and lower glucose tolerance (747) in humans. Furthermore, melanin-concentrating hormone (MCH) is known to promote sleep (6, 824) and integrates energy homeostasis responses (722). Increased extracellular glucose levels are known to enhance the electrical excitability of these neurons (125), and thus, the excitatory actions of glucose on MCH neurons may promote rest and, conversely, a fall in glucose levels would decrease the excitability of MCH neurons, hence suppressing sleepiness (125). Collectively, these data might support the view of an impairment of glucose metabolism that has already been proposed in migraine patients (148, 676).

i. Hypoglycemia and arousal

Recent evidence indicates that hypoglycemia produces arousal from sleep in normal adult humans (68, 288). Several neuropeptides involved in food regulation are known to also influence sleep regulation and consciousness. Hypothalamic orexin levels are highest during wakefulness and lowest during sleep (258, 469), with almost total cessation during REM periods, *in vivo* (521). It is known hypoglycemia in rats strongly activates wake-promoting orexin neurons (141, 611, 651). Furthermore, insulin-induced hypoglycemia activates orexinergic and cholinergic neurons, increasing arousal in adult male rats, similar to the effect

of nocturnal hypoglycemia in adult humans (793). Thus, orexins appear to stimulate feeding and increase metabolism (774) during active, awake periods. It has been reported that deficiency in orexin neurotransmission results in the sleep disorder narcolepsy in mice, dogs, and humans (161, 532, 628, 778) and one aspect of orexin activity is the direct excitation of noradrenergic neurons in the LC to promote wakefulness (117, 416). These observations are important as clinical studies demonstrate that patients with narcolepsy show a higher prevalence of migraine (195) and that migraine attacks initiate mostly in the early morning hours (33, 399).

ii. Orexins, feeding and sleep

Another feature that connects orexins with feeding and sleep is the hunger-induced wakefulness, a well-established phenomenon in animals (112, 443), wherein food deprivation induces expression of Fos protein in orexin neurons and increases mRNA orexin levels (214), but food deprivation does not induce wakefulness in orexin-deficient mice (865). This is consistent with electrophysiological findings showing that food deprivation induces synaptic changes in orexin neurons, where the number of asymmetric (putative excitatory), but not symmetric (putative inhibitory), synapses on orexin-containing cell bodies are elevated significantly in mice after just one episode of food deprivation, compared with fed controls (415). From an adaptive evolutionary perspective, synaptic plasticity in orexin neurons may be a critical mechanism contributing to the determination of behavioral status by energy status in animals.

iii. Sleep and NPY

Arcuate *POMC* neurons and *NPY/AgRP* neurons are also involved in sleep regulation (432, 476, 522). Bilateral destruction of NPY receptor-expressing neurons in the arcuate nucleus (847) are required for integration of sleep-wake rhythms. In humans, NPY enhances sleep by prolonging the sleep period and reducing sleep latency and wakefulness (51, 390). However, studies in rats show that NPY has opposing effects on sleep patterns depending on the site of administration (752, 776, 796).

iv. Sleep, leptin and body mass

While sleep can be affected by changes in energy homeostasis, changes in sleep patterns can likewise disturb endocrine regulation of energy homeostasis (475). Leptin plasma levels show a diurnal variation, with levels increasing during nocturnal sleep in humans (738, 841). Leptin also influences sleep stages, as systemic leptin significantly decreased the duration of REM sleep and increased the duration of slow wave sleep in rats (739). Furthermore, studies in humans show lower leptin levels during short habitual sleep time (154, 618, 746, 777), suggesting that sleep restriction causes increases of appetite and higher BMI. Recent epidemiological studies have pointed to a distinct relationship between sleep duration and body weight, suggesting a U-shaped association in that both shortened and extended sleep durations coincide with increases in body weight (290, 380, 777, 826). These effects might be important in the context

of migraine, as metabolic syndrome has been suggested to explain obesity as a risk factor for migraine frequency and severity, as well as to progression from episodic to chronic migraine (99, 101).

v. Sleep disturbance- trigger or consequence

While it is still not clear whether disruption to homeostatic regulation is actually a trigger of migraine, a symptom, or contributes to both, changes of appetite (loss of appetite or hunger), sleepiness and irritability reported during migraine may be mediated by reciprocal projections between nociceptive trigeminovascular neurons and the lateral hypothalamus. In this area neurons expressing MCH or orexin regulate food and water intake, sleep and arousal, through widespread projections to the cerebral cortex, brainstem and spinal cord (104, 701, 814). It could be argued that there is a hyperactivity of the brain mechanisms responsible for the hunger behavior in the premonitory phase of migraine, leading to arousal and lack of sleep. Hence, in some cases it would not be the voluntary bedtime sleep deprivation that would trigger the headache attack but, instead, an endogenous wakefulness mechanism that would be active, or a perception of wakefulness state, that could trigger the activation of the trigeminovascular system. Sleep deprivation is also known to activate hypothalamic feeding mechanisms and, thus, not only trigeminovascular neuronal pathways would be activated through reciprocal projections between the TCC and the hypothalamus, but also changes of appetite would be likely to happen. Therefore, in some respects, it may be difficult to dissect a difference between the mechanisms triggered by food or sleep deprivation, but it is clear each

can affect the other, and may increase the likelihood of a migraine attack.

C. 'Stress'

Stress and negative emotions are commonly listed as triggers by migraineurs (227, 300).

Although stress-sensitive patients may perceive more stress in the days before an impending migraine attack, there is very little experimental evidence showing a biological stress response in migraineurs. Migraine patients were reported to have large variations in plasma cortisol levels, a stress response indicator, when compared to the control group, and a subgroup of migraine patients exhibited abnormal circadian levels of cortisol (882). A study also showed statistically significant associations between the cortisol response and both headache severity and duration (355). While stress as a trigger may also be related to other potential triggers that are a response to disrupted homeostasis, such as sleep and food deprivation reviewed above, we will describe the mechanisms through which 'stress' may contribute to these processes.

The hypothalamo-pituitary-adrenocortical (HPA) axis is recruited by the organism in response to real or perceived threats to homeostasis or 'stress'. Corticotropin-releasing hormone (CRH) and vasopressin (AVP) are produced in the parvocellular neurons of the hypothalamic PVN. These neurons secrete peptides into the portal vessel system to activate the synthesis of pro-opiomelanocortin (POMC) in the anterior pituitary, which is processed to corticotropin (ACTH), opioid and melanocortin peptides, among others. Then, ACTH stimulates the adrenal cortex to secrete cortisol (humans) and corticosterone (humans, rats and mice) as a stress response (reviewed in 205). Signals of homeostatic imbalance in the brainstem also lead to activation of

the HPA axis: ascending brainstem and spinal pathways project to the parvocellular divisions of the PVN. For instance, noradrenergic and adrenergic projections to the hypophysiotrophic zone of the PVN originate in the NTS and C1-C3 (189, 190) and participate in the HPA axis.

Furthermore, in a preclinical animal model of migraine using nociceptive activation of trigeminovascular neurons, a stress protocol in these animal reduced the ability of PVN neurons to provide descending control of trigeminovascular nociceptive neurons (688).

1. Neuropeptides in stress

Similar to feeding and sleep, stress is also influenced by the orexinergic system; orexin mRNA is increased in the LH due to stress (436). In patients with chronic headache and medication overuse headache (MOH), increased cerebrospinal fluid levels of corticotrophin-releasing factor and OxA have been demonstrated (706). These results are in agreement with a suggested hypothalamic–pituitary axis alteration in these patients (675).

2. Orexins and corticosteroids

In preclinical studies, ICV administration of orexins in the rat produces activation of parvocellular PVN neurons that are putative CRH-containing neurons (200, 244, 488). Central injection of orexins also caused significant secretion of ACTH (488) and elevation of plasma concentration of corticosterone (244, 436, 446, 488), and this response is completely eliminated by pre-administration of the CRH antagonist, α -helical CRH9-41 (446). The CRH-producing neurons in the parvocellular PVN also show abundant expression of the OX₂R gene,

as well as receiving axonal projections from orexin-producing neurons (200). Recent experimental data in this regard indicate that the CRH peptidergic system directly innervates and can depolarize orexin-expressing neurons, an effect which is blocked by a CRF-R1 antagonist. In addition, activation of orexinergic neurons induced by high arousal states, including stress, is impaired in CRF-R1 knockout mice (257, 856, 857). These data suggest that the CRF-R1 receptor mediates stress-induced activation of the orexinergic system (706). There are also experimental findings suggesting that orexins in the CNS may be involved in the activation of central CRH neurons induced by stress (436). Furthermore, it is suggested that CRH activates the orexin system, relaying orexin-A to brainstem nuclei such as the LC as well as the nucleus accumbens, VTA and amygdala (856), which are critical structures involved in determining the rewarding or aversive value of an environmental stimulus such as stress (reviewed in 697).

3. Leptin and corticosteroids

It is possible that orexins together with leptin may take part in counter-regulatory mechanisms, which, through the modulation of glucocorticoid secretion, are involved in the maintenance of physiological blood glucose levels and energy homeostasis. Indeed, as opposed to orexin-induced glucocorticoid secretion, leptin has been shown to inhibit the stress-induced activation of the HPA axis (388) and to inhibit glucocorticoid secretion (113, 301, 302, 669). Individuals who have perceived psychological stress (self-reported) had higher leptin levels, compared to those patients who reported little stress in their daily life (646). Since the central orexin system is related to physiological stress responses and activation of both orexin receptors modulates

acute dural and facial nociceptive inputs, it is likely that there is a causal link between a stress response, the potential origin of the premonitory symptoms of migraine and the descending modulation of trigeminovascular nociceptive traffic.

4. Neuropeptide Y (NPY)

NPY is an established moderator of stress responses (reviewed in 387, 744, 792), by mediating activation of the HPA axis. It has been shown that NPY-containing neurons form a prominent afferent pathway between the arcuate nucleus and the PVN (529, 534). In addition, half of the glucocorticoid receptor (GR)-positive neurons in the arcuate nucleus are also immunoreactive for NPY (392). Inadequate nutritional intake, such as food deprivation/fasting also activates the HPA axis, demonstrated by increased cortisol release in humans (87, 818) and increased activity of NPY neurons in animals (229, 377). Intra-PVN administration of NPY stimulates food intake and this effect is suppressed by CRH (389). Furthermore, NPY release in the PVN modulates activity of parvocellular neurons and increases ACTH and corticosterone release (32, 437). This activation seems to be explained by the presence of NPY Y₁ receptors on CRH neurons in the PVN (222), and NPY Y₅ receptors may also be involved in regulating HPA axis function in rats (454). Functional NPY gene variation has been proven to influence the behavioral adaptation to stress (533) and as described above, NPY is able to modulate acute dural nociceptive inputs in the TCC by inhibiting neuronal firing through the activation of the NPY Y₁ receptor (570). Thus it is possible that impaired central NPY signaling might be involved in stress-induced migraine.

5. Stress and migraine

It is assumed that, in general, acute stress should not result in detrimental effects. Instead, through physiological adaptation, the organism should become capable of functioning in the midst of this altered environment. However, we have detailed above how migraineurs seem to be particularly susceptible to environmental changes. They might therefore have enhanced neuroendocrine responses, as a manifestation of enhanced sensitivity of brainstem and diencephalic pathways, leading to inappropriate processing or interpretation of stressful information. The parvocellular division of the PVN seems most likely to play a central role in the homeostatic stress response and these neurons are known to project to the brainstem and spinal cord (775) and more specifically to regions of the TCC (688). In addition, afferent pathways such as limbic pathways that are activated by psychological stressors (444), and ascending brainstem pathways that convey visceral and sensory stimuli may also activate CRH neurons in the PVN (687). Therefore, activation of parvocellular neurons in the PVN might be key to the cascade of events leading to the activation of the trigeminovascular system and, ultimately, could explain the low stress resilience in susceptible individuals or the stress-induced migraine.

XI. Pharmacology of Migraine – Treatments

Activation of the trigeminovascular system results in the release of a number of neuropeptides based upon the sympathetic, parasympathetic and sensory innervations of the cranial vasculature, summarized in Table 2. The sympathetic innervation is characterized by NPY and noradrenaline (239-241), both of which are vasoconstrictors while the parasympathetic fibers

are characterized by VIP and PACAP, which are amongst the most potent vasodilators (240).

The sensory innervations are characterized by substance P, CGRP and PACAP (247).

Experimental activation of the trigeminal ganglia in animals and humans (324) results in the release of SP and CGRP which can be inhibited by different triptans. Given the release of SP and at the time, an emerging theory of a role for neurogenic inflammation in the pathophysiology of migraine, an unsuccessful program targeting the neurokinin 1 receptor ensued (583). The failure of substance P directed interventions was highlighted in follow up studies exploring neuropeptide changes in migraine and targeted cerebrovascular stimulation in animals. In these studies CGRP, VIP and PACAP are most commonly upregulated with no change in substance P levels (325, 874). A summary of approaches in, or near development, for the treatment of migraine is found in Table 4.

A. Serotonin (5-HT)

The initial involvement of serotonin (5-HT) in migraine was postulated more than 50 years ago with seminal observations of increased 5-hydroxyindoleacetic acid (metabolite of 5-HT) associated with migraine attacks (191, 734). Further evidence was gained from two key studies identifying reductions in platelet 5-HT during attack onset (50) and that infusion of 5-HT could abort both reserpine-induced (468) and spontaneous headache (503). In response to these seminal studies the 5-HT receptor system gained much attention culminating in the discovery of the triptans, serotonin, 5-HT_{1B/1D} receptor agonists (434).

1. Triptans- Serotonin, 5-HT_{1B/1D} receptor agonists

Of the fourteen 5-HT receptors identified all except 5-HT₃ (ligand-gated ion channel) are G protein-coupled receptors (430). While the triptans are classed as 5-HT_{1B/1D} receptor agonists, most also activate to a lesser extent the 5-HT_{1A}, 5-HT_{1E} or 5-HT_{1F} receptors (310, 434). Originally the triptans were developed to act on the craniovasculature, an idea supported by their clear vasoconstrictive actions (174, 177, 264, 265) and the preferential expression of the 5-HT_{1B} receptor on cranial rather than peripheral vessels (809). In conjunction with progress in theories of migraine (section XI), understanding of the mechanism of action of the triptans has evolved, largely due to the discovery that triptans are not selective cerebral vasoconstrictors and the presence of central effects. Both sumatriptan and dihydroergotamine, a less specific 5-HT_{1B/1D} receptor agonist (86), were demonstrated to inhibit trigeminal afferents by an exclusively neural mechanism, without effect of vessels, that is also acting on central trigeminal neurons (419, 420, 462). A neural mechanism of triptans on peripheral trigeminal nerve endings could inhibit proinflammatory neuropeptide release and neurogenic dural vasodilation (853, 854), which was consistent with the developing theme of migraine as a neurovascular disease.

It is now clear that the triptans may be acting within the TCC to modulate trigeminovascular nociceptive neurons which express 5-HT_{1D} and 5-HT_{1F} receptors (170, 426, 552). It has been demonstrated that TCC neuronal activity can be inhibited by more centrally active triptans (314, 322, 331, 333, 334) and this effect is mediated predominantly by 5-HT_{1B/1D} receptors (332). The growing interest in possible CNS sites of action for the triptans led to more focused approaches relying upon direct delivery to discrete areas combined with detailed electrophysiological

approaches. Microiontophoresis of 5-HT_{1B/1D} agonists on trigeminovascular neurons in the TCC results in a clear reversible inhibition of trigeminal activity (763), highlighting this key relay center as a major site of action. However, as discussed earlier, multiple CNS sites of action have now been established including the PAG (77), PVN (688) and thalamus (730). The diversity of the target sites raises an intriguing scenario where modulation of 5-HT_{1B/1D} receptors could influence ascending trigeminothalamic projections in tandem with actions on descending pain modulatory structures.

2. Ditans- Serotonin, 5-HT_{1F} receptor agonists

Despite the clear pharmacology of the triptans in the treatment of migraine their use is limited in patients with cardiac risk factors (223), resulting in the need to target receptors lacking vasoconstrictive actions. One such target is the 5-HT_{1F} receptor which is activated to a degree by some triptans, such as naratriptan, and not by others, such as rizatriptan (310). 5-HT_{1F} receptors are found in the TCC and trigeminal ganglion (42, 115, 124, 170), and their activation inhibits trigeminal activity in the rat and cat (728, 762). Indeed it can be shown that after blockade of 5-HT_{1B} and 5-HT_{1D} receptors with SB224289 (724) and BRL-15572 (670), respectively, naratriptan retains an inhibitory effect on trigeminocervical responses evoked from superior sagittal sinus (316), while a 5-HT_{1F} receptor agonist LY344864 (663) has inhibitory TCC effects and no effect on the cat carotid circulation (316). Moreover, the inhibitory effect of alniditan, a 5-HT_{1B/1D} receptor agonist with no 5-HT_{1F} effects (528) and proven anti-migraine effects (352), is completely blocked by the combination of SB224289 and BRL-15572 (316). Evidence for a neural mechanism which may be devoid of vascular effects (114) is further

supported by selective 5-HT_{1F} inhibition of dural extravasation and inhibition of TCC neuronal activation following trigeminovascular activation (449, 604, 605, 624, 663). While the development of specific 5-HT_{1F} receptor agonists has not been without complication (350), successful phase II randomized clinical trials with lasmiditan (624) highlight the potential of targeting specific neuronal targets (260, 267).

B. Calcitonin gene-related peptide (CGRP)

CGRP is a 37 amino acid neuropeptide with potent vasodilator effects (486, 852) that is produced by alternative splicing of the calcitonin gene (35, 692). Other members of the gene family are amylin, adrenomedullin and adrenomedullin 2 (intermedin) (694). With respect to the nervous system α CGRP is predominantly expressed, while β CGRP is associated with the enteric sensory system (617). CGRP acts at two receptors, one the so-called canonical CGRP-receptor complex is made up of a G-protein-coupled receptor consisting of a seven transmembrane spanning protein (calcitonin receptor-like receptor; CLR) and a single transmembrane receptor modifying protein (RAMP) 1 (16, 593). RAMP 1 is critical for the transport and cell surface expression of the CGRP receptor complex (593) and its overexpression results in migraine like phenotypes including light aversion and CGRP induced allodynia (453, 680, 681, 696). The second CGRP receptor has been called the amylin receptor (AMY₁) and consists of the calcitonin receptor (CTR) and RAMP 1 (382). It has now been clearly shown that CGRP activates this receptor (831). Amylin is a glucoregulatory hormone and has additional bone metabolism effects.

CGRP is widely distributed including in the striatum, amygdale, hypothalamus, thalamus, brainstem and TCC (404, 816, 868). Within the primary afferent trigeminovascular pathways CGRP expression is highest in the sensory trigeminal ganglion and its A δ and C-fiber projections to cerebral and dural blood vessels as well as centrally to the spinal cord (242, 246, 780), where it can impact second order ascending projections. Functional CGRP receptors and binding sites have been identified on dural artery smooth muscle cells and in the trigeminal ganglia, thalamus, hypothalamus, amygdale, cortex and brainstem (238, 246, 523, 643, 769). Interestingly in the TCC CGRP receptors are thought to co-localise with CGRP in terminals of primary afferents and not ascending fibers (523).

CGRP is a potent vasodilator which when given to migraine sufferers is known to trigger attacks (508); however, the exact triggering mechanism is not clear since VIP another potent vasodilator fails to initiate attacks (674) suggesting a non-vascular mechanism. As discussed earlier CGRP is released during spontaneous (325) or triggered attacks (289), which can be inhibited by triptan treatment (323). Experimental activation of trigeminal ganglion cells is known to result in the release of CGRP, which is dose dependently inhibited by 5-HT_{1B/1D} agonists (231), highlighting the trigeminal ganglion as a key site that may be a target of CGRP receptor antagonism and triptan response (245, 247). In addition to its vascular effects, CGRP has emerged as a key modulator of neuronal function which has important effects on neurotransmitter systems such as the glutamatergic system (760). Local administration of CGRP facilitates dorsal horn and TCC nociceptive neurons, while CGRP antagonism points towards a

tonic facilitatory role as blockade with the truncated CGRP₈₋₃₇ reduced neuronal responses below baseline levels (760). Similarly targeted administration of CGRP to the ventrolateral PAG facilitates trigeminovascular processing via descending modulatory mechanisms (668), while thalamic modulation identified a clear inhibitory action of CGRP antagonism, both on nociceptive signaling and spontaneous background activity (769).

1. Gepants- CGRP receptor antagonists

Based on the available bench and clinical data (395), an effort was commenced to develop CGRP receptor antagonists (226). Olcegepant (BIBN4096BS) demonstrated excellent efficacy in animal models of CGRP-induced vasodilation (610), and interestingly reversed spinal morphine tolerance (667). In a proof-of-principle phase II study using an Up/Down design rule, it was effective at a dose of 2mg intravenously (638). It was never commercialized due to formulation issues. Subsequently telgecepant (MK-0974) also demonstrated efficacy in better than placebo and comparable to triptans (179, 393, 396), as the first oral CGRP receptor antagonist. It had excellent long term tolerability (178), and was also well tolerated in patients being investigated for coronary artery disease (397). However, the development of telcagepant and its follow-on MK-3207 (391) was halted when liver enzyme problems emerged in a preventive study, which was interestingly enough positive (394). It has been generally considered as an off-target effect of a metabolite of the compounds, which has not been reported with rimagepant (562) or BI44370 TA (216). Most recently a further compound ubrogepant has been identified, again it was effective in a placebo-controlled trial as an acute migraine treatment (828), and along with

AGN-241689, which will be developed as a preventive (Table 4), this class of therapies has much promise.

2. CGRP peptide and receptor monoclonal antibodies (-numab & -nezumabs)

In order to capitalize on the proven anti-migraine effects of blocking CGRP mechanisms in migraine, monoclonal antibodies have been developed as novel preventive treatments. Three antibodies to the CGRP peptide, ALD-403 (224), galcanezumab (LY2951742, 225) and TEV-48125 (96), have each published a positive randomized, placebo-controlled trial in episodic migraine prevention that has been positive. One CGRP ligand monoclonal antibody has published positive data for chronic migraine (97), and the CGRP receptor (CLR/RAMP1 complex) antibody, erenumab, has also presented positive placebo-controlled trial data in episodic migraine (770). These antibodies seem well tolerated with no significant adverse events across the studies, and no issues emerging from phase I studies (98, 103, 204). These compounds represent a truly innovative, immunopharmacological approach to blocking CGRP mechanisms that is now in phase III development.

C. Nitric Oxide Synthase

Nitric oxide (NO) is an abundant gaseous signaling molecule which like the previously mentioned neuropeptides is involved in a variety of functions including endothelial dependent vasodilation (441). Nitric oxide donors, such as glyceryltrinitrate/nitroglycerin, like CGRP (508) and PACAP (720), are used for the experimental induction of migraines (439, 441) and

premonitory symptoms (11). Given the clear role of NO donors in triggering attacks it is unsurprising that they have received similar attention in preclinical models where they produce vasodilation (30, 767) and trigeminovascular activation (480, 495, 783). Perhaps the most interesting feature of experimental NO use is the biphasic nature of the TCC activation with an initial acute activation and a delayed general activation (20, 480) which appears to mirror the acute throbbing and delayed migraine seen in patients. NO donors clearly facilitate trigeminovascular activation resulting in activation of the TCC with resultant increases in CGRP and neuronal nitric oxide synthase (nNOS)(652, 653) and NOS inhibitors have also proven preclinical efficacy. Nitric oxide synthases are a family of enzymes which catalyze the production of NO consisting of endothelial (eNOS), neuronal (nNOS) and inducible (iNOS). Non-specific blockade of NOS prevents neurogenic dural vasodilation (31) and TCC neuronal activation (417, 634). Interestingly and in support of the current theme of migraine as a neurovascular disorder specific nNOS inhibitors mimic the effects of non-specific blockers (31, 93).

The available clinical and preclinical data highlighted NOS inhibitors as a reasonable target for anti-migraine therapy and while early studies showed beneficial outcomes (507) they were not without issue. Given the unwanted side effects of eNOS actions current research has focused towards other specific NOS inhibitors, with the initial study of a specific iNOS inhibitor failing to reach its clinical end point in both an acute (649) and preventive study (403). A mixed triptan and nNOS inhibitor NXN-188 was also found to be ineffective in both migraine without aura

(595) and specifically in the aura phase (428). The issue of a possible effect of a specific nNOS inhibitor is unresolved.

D. Pituitary adenylate cyclase-activating peptide (PACAP)

PACAP like CGRP is released during migraine (803, 874, 875) and can trigger attacks (720) in patients leading to its exploration as a possible anti-migraine target. It is a member of the VIP-glucagon growth hormone releasing factor-secretin superfamily which comes in two forms; PACAP-38 accounts for approximately 90%, whereas PACAP-27 is relatively poorly expressed (57). Like the majority of neuropeptides targets PACAP is widespread throughout the CNS and peripheral tissue (574, 806, 808) where it has potent vasodilator effects. PACAP is known to have a specific uptake mechanism into the brain (70). The pharmacology of PACAP is slightly more complex due to its binding affinities to three G-protein coupled receptors which also bind VIP. It should be highlighted again that VIP does not induce migraine unlike PACAP and CGRP, highlighting the importance of non-vascular targets. VPAC1 and 2 bind VIP, PACAP-38 and PACAP-27 in order of descending affinity while PAC1 is relatively specific for PACAP (492). It is expressed in the TCC, spinal cord, trigeminal ganglia, sphenopalatine ganglia and CNS structures including the thalamus, hypothalamus and brainstem (186, 450, 574, 779, 808). It is likely the central expression pattern underlies the proposed role in migraine, and like CGRP, PACAP has been linked to sensitization and light aversion (564). This facilitatory role has recently been demonstrated in the hypothalamus where PACAP administration facilitated trigeminovascular nociception via a PAC1 mechanism (688).

Recently, in a rodent model of nociceptive trigeminovascular activation it has been shown that VIP and PACAP-38 caused short-lived meningeal vasodilation mediated by VPAC2 receptors, without activation of central trigeminovascular neurons (17). PACAP-38 and not VIP caused a delayed activation and sensitization of central trigeminovascular neurons. In this context behaving as it does in triggering migraine (720). Intravenous delivery of a PAC1 receptor antagonist inhibited the peripheral meningeal vasodilatory effects of dural trigeminovascular nociception, whereas only central (intracerebroventricular) administration of the PAC1 receptor antagonist inhibited dural nociceptive trigeminovascular activation (17), suggesting a central PAC1 receptor as an important target. While not as advanced as CGRP targeting, it is clear that PACAP has a role to play in the pathogenesis of migraine and as such will continue to progress as a therapeutic target.

XII. Theories of migraine

Theories of migraine have changed greatly over the years, often turning full circle and returning to the original theories from 250 years ago. However the last 60-70 years has seen the largest development of theories as a consequence of medical research and advancing scientific technologies. Certainly since the observations of Harold Wolff and colleagues in the 1940s, where mechanical stimulation and distension of cranial blood vessels resulting in headache-type pain in patients undergoing cranial surgery, a '*vascular theory of migraine*' took on momentum. The theory is driven by the idea that vasodilation of extracranial arteries and also intracranial blood vessels produce mechanical activation of perivascular nerve fibers that

innervate the vessels, resulting in headache pain (861). This concept was supported by the observation that migraine headache commonly has a pulsating quality, as well as by more recent studies showing that nitric oxide and CGRP are able to trigger migraine attacks and the vasoconstrictive and therapeutic effect of triptans support this. However, recent preclinical and clinical data in these same areas demonstrate that this concept was based on misinterpretations. In contrast to the common assumption, the experienced pulsations during a migraine attack are not synchronized with cardiac contractions as the painful pulsations have a lower frequency (14, 603). Furthermore, arterial vasodilation produced by VIP does not trigger migraine headache in patients (674) and arterial vasodilation that has been reported during CGRP-evoked migraine (58) is modest and unlikely to be sufficient to activate perivascular nociceptive afferents. In addition, Amin and colleagues (40) demonstrated in a study using state-of-the-art MR-angiography techniques that meningeal vessels do not dilate during spontaneous migraine attacks (40), something which has been previously demonstrated during experimentally triggered migraine (713). The results further indicate that intracranial vessels show only a slight dilation that is not affected by sumatriptan, making the vascular theory obsolete (40).

The importance of the intracranial vasculature, or its nerve fiber innervation, still remains significant. The studies of Ray and Wolff demonstrated that headache-like pain and nausea can be generated by stimulation of the dura mater, particularly surrounding the dural and cerebral blood vessels, whereas stimulation away from the vessels was not effective at inducing pain (679). As described above the dural blood vessels are richly innervated by nociceptive

unmyelinated (C-fiber) and myelinated (A δ -fiber) axons that originate in the trigeminal ganglion, and contain vasoactive neuropeptides (Table 2). These data consolidate the theory that headache in migraine may be mediated by activation of nociceptive nerve fibers that innervate the meningeal blood vessels. The key question is what causes these fibers to become activated during migraine. One proposal in the 1980s was that a '*sterile neurogenic inflammation*' of the dural meninges may result in activating the perivascular innervation to trigger migraine (612). Activation is driven by local dural release of endogenous inflammatory mediators such as CGRP, substance P, neurokinin A and prostaglandins, which increase local blood flow (predominately driven by CGRP), leakage of plasma proteins from blood vessels, mast cell degranulation and platelet aggregation. It is induced experimentally in rats by trigeminal ganglion stimulation, a process that also induces similar responses in the retina (565, 566). The success of acute migraine treatments including ergot alkaloids, sumatriptan and non-steroidal anti-inflammatory drugs in blocking these effects (138, 139, 567) has added support to this theory.

However, over the last two decades an overwhelming volume of data has been generated which make this theory seem implausible, and in some respects impossible. Firstly, only CGRP has been shown to be released during migraine, with no evidence of substance P or neurokinin A release (289, 325). Furthermore, of all the inflammatory molecules shown to induce dural and retinal plasma protein extravasation, only CGRP, a marker of a migraine attack, failed to produce a response (566). It has proven very difficult to induce plasma protein extravasation in human skin, a process that is readily induced in guinea pigs, implying there may be a clear

species difference that negates these preclinical studies (660). Also retinal plasma protein extravasation is not present during migraine (587) and there is little evidence of inflammatory pathology in migraineurs. Further, a plethora of molecules developed to block extravasation without the vasoconstrictive effects of triptans, including neurokinin 1 receptor antagonists (349, 351) and extravasation inhibitors (233, 691) failed as both acute and preventive treatments of migraine. These data indicate that it is unlikely that neurogenic dural inflammation plays a significant role in the pathophysiology of migraine, and the fact migraine can be so frequent and debilitating, and occur over many years, such an inflammatory insult would likely leave a pathology that is picked up on imaging, but nothing has been found (648).

Today migraine is more commonly described as a '*neurovascular disorder*', and specifically a disorder of the brain. One theory that has grown in significance over the last 15 years extolling this view, and has served to explain many features of migraine previously unexplored or simply not clear is '*peripheral and central sensitization*'. Sensitization is a common feature of many chronic pain disorders and is hypothesized to also be present during migraine. It is long-lasting activation and sensitization of peripheral nociceptors and central nociceptive neurons, and it may explain the longevity of the migraine attack, and the transition to chronic migraine, as well as specific related symptoms. This theory was borne out of experimental studies on rodents using an inflammatory soup placed upon the dura mater to induce peripheral and central sensitization of trigeminovascular neurons (766). Within the inflammatory soup are chemical mediators; histamine, serotonin and cytokines, that are believed to be released as a consequence of the dural inflammation and plasma protein extravasation, which complicates

the efficacy of this theory given the data regarding neurogenic dural inflammation. Certainly, peripheral sensitization of trigeminal nociceptive afferents that innervate the dural meninges has gone some way to explain the likely exacerbation of intracranial headache pain due to physical activity and movement, as well as the throbbing nature of pain during migraine (766). Central sensitization of trigeminovascular neurons has aided our understanding of the neural basis for extracranial hypersensitivity in migraine; the referral of pain and allodynia to peri-orbital and cutaneous facial areas (91, 135). Sensitisation of trigeminothalamic neurons is likely to account for the widespread cutaneous allodynia to extracephalic regions (128, 132).

A major tenet of this theory is that the primary trigger of migraine comes from the periphery, in the dural blood vessels, with activation of the trigeminovascular system coming from firing of first-order peripheral trigeminal neurons in response to nociceptive injury or signals coming from the meninges that release neuro-inflammatory mediators. Sustained activation of dural meningeal nociceptive neurons causes sequential activation and sensitization of first (peripheral nociceptors), second (at the level of the TCC) and third-order (trigeminothalamic) trigeminovascular neurons, as well as ascending activation of brainstem and other diencephalic structures (91). This sequential activation is thought to explain the throbbing nature of pain in migraine, the noxious sensory hypersensitivity, associated neurological symptoms including nausea, vomiting, altered feeding and sleep, as well as cognitive disruption. In principle the theory seems to address every symptom of migraine with the initial symptom or trigger being head pain, and everything else following as a consequence. Clinically however, there are many gaps. Premonitory symptoms in migraine can be present 24-48 hours prior to headache, and

are represented by changes in activation in midbrain and hypothalamic brain regions (300, 559). Migraine triggers such as sleep and food deprivation, and stress, are under homeostatic control, likely via the hypothalamus and midbrain structures, and they do not directly activate the meninges. They do however modulate nociceptive inputs to the TCC through descending mechanisms, and have ascending projections to the cortex, and with these as trigger it is likely headache would not be the first sign of the disease. As reported there is little evidence of vasodilation during migraine, which one would assume to be a consequence of release of inflammatory mediators and activation of nociceptive nerve fibers that innervate the meninges. Therefore while sensitization of trigeminovascular pathways is clearly important, the mechanism that drives this response is not clear.

Despite these clinical anomalies as outlined above, there remains a strong belief that CSD the experimental correlate for aura is the primary triggering event for meningeal activation (the evidence for and against has been discussed above). As mentioned, aura is only present in approximately in one third of migraineurs, although a common hallmark in the rare genetically identified forms. It is unlikely that all the different forms of migraine, (migraine with (MA) and without aura (MoA), FHM (645) and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (151, 451), are all a consequence of different pathophysiological mechanisms. Given that most MA patients also suffer MoA and FHM patients can present with MA and MoA, it would suggest that a common pathophysiology underlies the conditions with heterogeneity amongst the associated symptoms that is certainly influenced by genetic predisposition.

Stepping back from CSD, it is perhaps pertinent to explore the role of the cortex itself. There is contradictory evidence of cortical excitability in migraine, on one hand migraineurs are more susceptible to visual triggering and have heightened sensitivity to such stimuli. This may result from hyperexcitability, particularly in MA (169), with a decreased threshold to produce phosphenes (82, 122, 298). However, there are similar reports of hypoexcitability states and significantly higher phosphene thresholds (8, 182). An elegant review of the data concluded that these observed changes in cortical excitability may not actually be a predisposition factor to develop migraine, but rather that changes in neuronal excitability are a function of the chronicity process in the disease (750) and an example of when in the cycle patients were tested. It would appear more reasonable to assume that altered cortical switching between hypo and hyper-excitable states exists resulting in dysregulation of normal cortical function. Alternatively much of the evidence supporting the hyperexcitability may result from lower order trigeminovascular alterations via thalamocortical networks, such as the recently identified thalamic involvement in photophobia (reviewed earlier (632)).

In the case of MoA, if CSD is the triggering factor of attacks then patients must demonstrate cortical changes similar to CSD without the physical symptoms (silent aura). There also needs to be explanations for the examples of aura without pain, or indeed treatments that improve aura, but not pain (340), but these are limited. We know that CSD has been very difficult to demonstrate in humans *in situ* and the only unequivocal evidence has been in injured human cortex (259, 589, 768). Recent studies supporting CSD in human brain during migraine aura

(366, 702) only use blood flow evidence rather than neuronal changes, which is what technically defines CSD, and merely provide more sophisticated technology to measure the response than the original study from the 1980s (640). But there is evidence from imaging studies of unilateral occipital hypoperfusion prolonged well into the headache phase of migraine with aura (640, 702), while the aura symptoms do not persist. This could be interpreted as a demonstration of aura pathophysiology without aura symptoms and similar mechanisms could hypothetically be involved in migraine without aura. However, in MoA there is much conflicting information regarding hypoperfusion, with several studies demonstrating no perfusion changes during MoA, particularly during the headache phase (192, 702) while a more recent study demonstrated prolonged bilateral posterior cerebral hypoperfusion, and this continued beyond pain relief with sumatriptan (210). It is worth noting that global hypoperfusion has also been demonstrated simply in response to pain (173). Therefore it is unlikely that CSD can explain prolonged bilateral hypoperfusion in this case. CSD is described as a wave that requires dense populations of neurons to spread across the cortex, therefore hemispheric boundaries cannot be negotiated. Recently it has been hypothesised there may be a dissociation between the neuronal and vascular responses to CSD, with evidence that vasomotor changes spread at greater velocities to the metabolic/neuronal changes (120, 153). As such, it could be hypothesized that independent mechanisms, which do not involve CSD, but result in similar vasomotor physiology, may underlie the prolonged hypoperfusion that has been demonstrated in migraine with and without aura.

The final disparity between MA and MoA lies in the epidemiology of the conditions as risk factors for other disorders. It was recently demonstrated that FHM mice undergoing experimental stroke suffered greater brain damage and poorer outcomes than control mice. It seems migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations. Clinically, MA is a risk factor for stroke (483), especially in females although not for MoA (487, 716) which is indicative of at the very least significantly fewer CSD events in MoA. There is therefore uncertainty and continuing debate about the role of aura in the cascade of events resulting in migraine pain and accompanying symptoms, which will likely continue due to the complex nature of the disease rendering it difficult to separate the component parts in a feasible manner.

If the triggering of migraine does not come from the periphery or cortical spreading depression, how can the provocation of a migraine attack be explained?

While migraine pain is undoubtedly a consequence of activation, or the perception of activation of neurovascular mechanisms, as a disorder it is now being thought of by some as a purely neuronal disorder. Much evidence indicates that the brains of migraineurs may be different in how they respond to sensory stimulation, even interictally (116, 158, 182, 749). An alternative and all-encompassing hypothesis is that the brain is at the heart of triggering migraine. Rather than a sequential activation of different brain regions, migraine is a disorder of the brain and therefore considered a '*brain state*', and is a consequence of changes, or dysfunction, in brainstem and hypothalamic regions, which contribute to changes in cellular and vascular

function in many regions of the brain. This hypothesis states that migraine may be best described as a consequence of dysfunction in the brainstem and hypothalamic nuclei that normally modulate or gate sensory inputs, including touch, light, sounds, and smells. These brainstem and hypothalamic nuclei can be considered '*migraine mediators*' and their dysfunction can lead to the failure of brain integration and filtering mechanisms, resulting in the perception of activation of sensory systems under normal conditions. The complex network of connections between regions of the brainstem, which include the PAG, RVM, locus coeruleus and SuS, and diencephalic nuclei including hypothalamus, thalamus and cortex can lead to the generation of symptoms through the same core dysfunction. Dysfunction in these regions, through descending control of trigeminovascular nociceptive traffic, can lead to the perception of head pain through normal vessels throbbing, and continued dysfunction can lead to central sensitization of trigeminovascular neurons and the exacerbation of pain to normal physical activity, cutaneous cephalic and extracephalic allodynia. Convergence of sensory inputs in the thalamus that project to the cortex can explain the hypersensitivity to light, sounds, and smells. The same dysfunction can lead to homeostatic changes, controlled by the hypothalamus, related to sleep, feeding, and activity. The general alteration of cortical and subcortical function can trigger events such as migraine aura, and extend to a general inability to function properly. Inherited genetic factors clearly play a role in pre-disposing migraine susceptibility, as do the role of potential migraine triggers, whose common link seems to play at the heart of brain homeostasis in the hypothalamus and brainstem.

Certainly much is still unclear about how we understand migraine. It is most likely that many of the ideas surrounding its pathophysiology are relevant, from a genetic predisposition, to brain hyperexcitability, to peripheral and central sensitization, and brainstem and hypothalamic dysfunction. They all contribute to the phenotype of the migraineur and are avenues that need to be explored further to understand the pathophysiology of migraine, and the development of novel safer and effective migraine therapeutics.

Conclusion

Migraine is a complex, basically inherited variable disorder of brain function. Its afferent pathway arises in the nociceptive durovascular afferents that seemed design to warn not localize. Their projection to the thalamus and cortex, and the regulation of this pathway, importantly at each level, and by multiple systems offers the possibility to understand the complex symptoms and target therapies. Migraine is a trait, well demonstrated by neurophysiological data that waxes and wanes to attacks. The attacks start as premonitory symptoms, such as concentration impairment, yawning, mood change, homeostatic changes-eating and fluid balance, and can include more generalized sensitivities, such as photophobia and phonophobia. The premonitory phase gives way to the pain phase with its attendant suffering and terminates in a postdromal phase of feeling washed out by the experience. Migraine aura, at least in its classical sense has some relationship to cortical spreading depression, although this is neither necessary nor sufficient for the attack, more likely acting as a parallel actor on an arguably smaller stage. A crucial advance in understanding has been the

re-appreciation of migraine as a predominantly neural disorder with the development of non-vasoactive acute and preventive strategies for treatment. Understanding migraine both offers the tangible benefit of reducing the burden of the sixth most disabling medical problem on the planet and the real opportunity to gain insights in basic aspects of human neurobiology.

Migraine pathophysiology has come a long way in the last two millennia and seems poised to accelerate the pace and deliver even more benefits in the coming decades.

Table 1: International classification for headache disorders (ICHD)-3 β (386)

Criteria for migraine without aura

- A. At least five attacks fulfilling criteria B-D
- B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
- C. Headache has at least two of the following four characteristics:
 - 1. unilateral location
 - 2. pulsating quality
 - 3. moderate or severe pain intensity
 - 4. aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs)
- D. During headache at least one of the following:
 - 1. nausea and/or vomiting
 - 2. photophobia and phonophobia
- E. Not better accounted for by another ICHD-3 diagnosis

Criteria for migraine with aura

- A. At least two attacks fulfilling criteria B and C
- B. One or more of the following fully reversible aura symptoms:
 - 1. visual
 - 2. sensory
 - 3. speech and/or language
 - 4. motor
 - 5. brainstem
 - 6. retinal
- C. At least two of the following four characteristics:
 - 1. at least one aura symptom spreads gradually over ≥ 5 minutes, and/or two or more symptoms occur in succession
 - 2. each individual aura symptom lasts 5-60 minutes
 - 3. at least one aura symptom is unilateral

- 4. the aura is accompanied, or followed within 60 minutes, by headache
- D. Not better accounted for by another ICHD-3 diagnosis, and transient ischaemic attack has been excluded.

Table 2: Summary of craniovascular nerve fibers and their vasoactive neuropeptides involved in migraine

Craniovascular nerve fiber localization	Vasoactive neuropeptide/Neurotransmitter
	<ul style="list-style-type: none"> • Calcitonin gene-related peptide (CGRP) • Substance P (SP) • Neurokinin A (NKA)
Trigeminal Sensory Nerve Fibers	<ul style="list-style-type: none"> • Pituitary adenylate cyclase-activating peptide (PACAP) • Nitric oxide synthase (NOS) • Vasoactive intestinal peptide (VIP) • PACAP
Parasympathetic Nerve Fibers	<ul style="list-style-type: none"> • Neuropeptide Y (NPY), • Acetylcholine • NOS • Noradrenaline,
Sympathetic Nerve Fibers	<ul style="list-style-type: none"> • NPY • Adenosine triphosphate (ATP)

Table 3: Summary of neuropeptides and their role in homeostatic function

Neuropeptide	Effect on appetite	Receptors	Food restriction	Refeeding	Sleep deprivation	Normal sleep	Physiological stress	Migraineurs
Leptin	Anorexigenic (reduces appetite)	ObR(a-f) leptin signaling through ObRb	↓ leptin plasma levels ↑ leptin binding in ARC	↑ leptin secretion	↓ leptin plasma levels	↑ leptin plasma levels	Leptin ↓ glucocorticoid secretion	Lower serum leptin interictally
Neuropeptide Y (NPY)	Orexigenic (increases appetite)	NPY Y(1-6) Only Y1, Y2, Y4 and Y5 physiologically relevant	↑ NPY mRNA in ARC ↑ secretion of NPY into PVN	Normalizes NPY levels in ARC ↑ NPY in PVN	↑ NPY hypothalamic mRNA levels	NPY promotes sleep	↑ NPY in the PVN ↑ ACTH and corticosterone release	ND
Orexin (OX) A and B	Orexigenic	OX ₁ R and OX ₂ R	↑ Ox release hypothalamus ↑ OX ₁ R VMH mRNA ↑ OX ₂ R ARC mRNA	↑ prepro-orexin mRNA in LH	↑ mRNA Ox levels in hypothalamic	Ox neurons stop firing during sleep	Orexin ↑ glucocorticoid secretion	Higher CSF OxA levels in CM/MOH

↑, increase; ↓ decrease; ARC, hypothalamic arcuate nucleus; PVN, paraventricular hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus; CM, chronic migraine; MOH, medication overuse headache; ND, no data

Table 4: Current developmental pipeline in migraine (modified after 306)

Mechanism/Indication	Treatment	Current Stage
Calcitonin gene-related peptide (CGRP) mechanism antagonist		
• CGRP receptor antagonist (<i>gepant</i>)	Olcegepant (638)	Phase II
	Telcagepant- acute (396)	Phase II*
	Telcagepant- preventive (394)	Phase II
	Rimagepant (561)	Phase II
	BI44370TA (216)	Phase II*
	MK-3207 (391)	Phase II
	Ubrogepant (828)	Phase II
	AGN-241689 (preventive)¶	Phase I
• CGRP antibody (<i>-nezumab</i>)	ALD-403 (224)	Phase III
	galcanezumab (225)	Phase III
	TEV-48125 (96, 97)	Phase III
• CGRP receptor antibody (<i>-numab</i>)	erenumab (770)	Phase III
Serotonin-related		
Serotonin 5-HT _{1F} receptor agonist- (<i>ditan</i>)	Lasmiditan (260, 267)	Phase III
Nitric oxide synthase (NOS) inhibition		
• Pan NOS	546C88 (507)	Phase II
• Inducible NOS	GW274150 acute (649)	Phase II (F)
	GW274150 preventive (403)	Phase II (F)
• Neuronal NOS plus triptan	NXN-188 (428, 595)	Phase II (F)
Glutamatergic targets		

• NMDA receptor migraine with prolonged aura	Ketamine (10)	Phase II
• Prevention of aura not headache	Tonabersat (326, 381)	Phase II
• AMPA/kainate	Tezampanel/LY293558 (704)	Phase II
• iGluR5 (kainate) receptor	LY466195 (448)	Phase II
• mGluR5 (glurants)	ADX10059 (839)	Phase II
• AMPA receptor antagonist	BGG492 (353)	Phase II (F)

Neuroinflammatory targets

• TRPV1	SB-705498(165)	Phase II (F) Phase II (F)
• Substance P/neurokinin-1	Dapitant (218) Lanepitant (351) GR205171 (176) L-758,298 (629) Lanepitant (349) Prevention	Phase II (F) Phase II (F) Phase II (F) Phase II (F) Phase II (F)
• Neurogenic plasma protein extravasation (PPE)	CP-122,288 (691) 4991W93 (233)	Phase II (F) Phase II (F)

Other targets

• Orexin 1 and 2 receptors (<i>rexants</i>)	Fliorexant (150)	Phase II (F)
• Angiotensin Receptor (?)	Candesartan (765, 800) Telmisartan (219)	Off-License (F)

Emerging targets

• Acid Sensing Ion Channel (ASICs)	Amiloride (406)	
• Pituitary adenylate cyclase activating peptide (PACAP)	PACAP receptor antagonists (17, 41, 874)	

Figure 1 The migrainous brain interictally

Imaging studies in the migraineurs' brain interictally demonstrates there is reduced activation of the spinal trigeminal nuclei in response to trigeminal nociceptive stimulation, which normalizes prior to the next migraine attack. This change might reflect an increased susceptibility of the brain to generate the subsequent attack in the sense of a defective top-down modulation of trigeminal input (taken with permission from 749).

Figure 2 The migrainous migraine during the premonitory phase

In nitroglycerin-induced migraine attacks $H_2^{15}O$ -PET demonstrated increased rCBF in the posterior hypothalamic region (A and B), the periaqueductal grey region (C and D), and in dorsal pons (E and F) are highlighted by circles. The color bar indicates the color coding of the Z scores. (559). From a clinical perspective, the hypothalamus might be involved in the premonitory symptoms prior to the experience of head pain. Such symptoms involve tiredness, concentration problems, yawning, appetite alterations, and frequent urination. Activation in the midbrain and PAG likely reflects a mechanism through which nociceptive head pain symptoms may be generated (Taken with permission from 559).

Figure 3 The migrainous brain during migraine head pain

Many studies have demonstrated that migraine attacks are associated with an increase of rCBF in mesencephalon and pons, which cannot be found in experimental head pain, indicating specificity for migraine attacks (842). After termination of the migraine attack with sumatriptan these changes persisted, suggesting involvement in migraine generation or sustentation, rather than specifically trigeminally-mediated pain.

Figure 4 Anatomy of the trigeminovascular system – ascending projections

The trigeminal ganglion (TG) gives rise to pseudo-unipolar trigeminal primary afferents which synapse on intra and extra-cranial structures (blood vessels) as well as the spinal cord trigeminocervical complex (TCC). Second order neurons from the TCC ascend in the quintothalamic (trigeminothalamic) tract synapsing on third order thalamocortical neurons. Direct and indirect ascending projections also exist to the locus coeruleus (LC), periaqueductal grey (PAG) and hypothalamus. The third order thalamocortical neurons in turn synapse on a diffuse network of cortical regions including the primary and secondary motor (M1/M2), somatosensory (S1/S2) and visual (V1/V2) cortices. A reflex connection from the TCC to the superior salivatory nucleus (SuS) exists, which projects via the sphenopalantine ganglion (SPG) providing parasympathetic innervation to the extra and intra-cranial structures. Insula; Ins, Parietal Association; PtA, Retrosplenial; RS, Auditory; Au, Ectorhinal; Ect, Rostral ventromedial medulla; RVM.

Figure 5 Modulation of trigeminovascular nociceptive transmission – descending projections

The trigeminocervical complex (TCC) is subject to direct and indirect descending pain modulatory pathways arising in the cortex. Direct projections exist from primary somatosensory (S1) and Insular (Ins) cortices while indirect projections arising in S1 that project via the hypothalamus. A local corticothalamic circuit also exists which can modulate trigeminothalamic processing. Hypothalamic projections again form direct TCC modulatory projections as well as indirect projections via the locus coeruleus (LC) and periaqueductal gray (PAG) which can further pass via the rostral ventromedial medulla (RVM). This complex network of direct and indirect pathways provides potent anti- and pro-nociceptive modulation of incoming trigeminal nociceptive signaling, the dysfunction of which is thought to contribute to triggering migraine attacks. Sphenopalantine ganglion; SPG, superior salivatory nucleus; SuS, trigeminal ganglion; TG.

Figure 6 Anatomy of the trigemino-autonomic pathway believed to contribute to head pain and cranial autonomic symptoms in migraine.

A) Schematic representation of trigemino-autonomic pathway includes the peripheral and central projections of the trigeminovascular system (black neurons). There is also a trigemino-autonomic reflex connection from the trigeminocervical complex (TCC; grey neuron), to the superior salivatory nucleus (green cell; SuS) and its parasympathetic projection to the cranial vasculature, predominantly via the greater petrosal nerve (green projection) and its synapse with the pterygopalatine ganglion (PG), as well as via the facial (VIIth cranial) nerve (purple neuron). **B)** Electrophysiological recording of neurons in the rat TCC is activated by SuS stimulation, firstly there is a shorter latency response **(C)** believed to be activated by antidromic activation of the trigemino-autonomic reflex, and a longer latency response **(C and D)** caused by activation of the parasympathetic outflow to the cranial vasculature; a signal which traverses the nociceptive meninges, which subsequently causes activation of the central trigeminovascular projection to the TCC. **E)** Lacrimal gland/duct (yellow cell in **B**) blood flow also increases concurrent with SuS stimulation, as a result of the parasympathetic projection to the lacrimal gland. TG; trigeminal ganglion. (Parts C-E are modified from 25, 26).

Figure 7 Proposed mechanism of descending modulation of trigeminovascular nociceptive transmission through brainstem nuclei, mediated by 5-HT and endocannabinoids

A) The spontaneous firing of neurons in the TCC is modulated by micro-injection of CB₁-mediated endocannabinoids (ACPA) in the ventrolateral periaqueductal grey (vlPAG), with transient inhibition of firing. **B)** ACPA micro-injection in the vlPAG also inhibits dural-evoked nociceptive firing in the TCC, an effect that is replicated by naratriptan micro-injection. We propose that the mechanism of action of this inhibitory effect is by modulating descending GABAergic projections **C and D)**. At the level of the vlPAG GABAergic projection (blue) neurons synapse with glutamatergic projections (purple) to 'OFF' and 'ON' cells in the rostral ventromedial medulla (RVM). Tonic release of GABA (blue circles) controls the level of descending inhibition to the TCC, via 'OFF' and 'ON' cell activity in the RVM. Cannabinoid (CB₁, green) and triptan (5-HT_{1B/1D}, orange) receptors are located pre-synaptically on these GABAergic projections. Orexin 1 (Ox1, red) receptors are also located post-synaptically on the glutamatergic projections. Endogenous release or exogenous administration of ECs (green circles) and 5-HT agonists (yellow circles) activate pre-synaptic receptors inhibiting the release of GABA, increasing the likelihood of activation of the descending glutamatergic projections to 'OFF' cells in the rostral ventromedial medulla (RVM). Activation of post-synaptic Ox1 receptors are also thought to stimulate the production and release of ECs from the post-synaptic cell, activating pre-synaptic CB₁ receptors and inhibiting GABA release, disinhibiting, and thus activating glutamatergic projections to 'OFF' cells in the RVM. This implies that orexin peptides may also be involved in this mechanism of descending control. **D)** At the same time a hypothesized projection (dashed lines) from the descending glutamatergic projection also

synapses with an inhibitory interneuron (light blue neuron-dashed lines) in RVM, which inhibits activity of 'ON' cells. Activation of RVM 'OFF' cells and inhibition of 'ON' cell results in switching off activity at the level of the trigeminocervical complex (TCC) second order neuron.

D) Additionally at the level of the RVM CB₁ receptors situated pre-synaptically on GABAergic projections to 'OFF' cells, when activated by endogenous or exogenous ECs, inhibit the release of GABA, increasing 'OFF' cell activity by disinhibition, likewise we propose that pre-synaptic CB₁ receptors on glutamatergic projections to 'ON' cells inhibit the release of glutamate blocking 'ON' cell activation, and thus reducing activity at the level of the TCC. 'ON' cell activity may also be inhibited by CB₁ receptor-mediated inhibition of pre-synaptic release of GABA from neurons that synapse on inhibitory interneurons (light blue neuron-dashed lines). There is also thought to be a state-dependent and bidirectional control of pain modulation through serotonergic projections from the RVM to the TCC that is distinct to 'ON' and 'OFF' cell modulation. (Data in A and B adapted from²⁴).

Figure 8 Proposed mechanisms for the neural basis of photophobia in migraine

A) It is proposed that there is convergence of photic signals from the retina, via an intact optic nerve, onto posterior thalamic neurons that also receive nociceptive inputs from the dura mater, via the trigeminothalamic tract. These inputs subsequently project to nociceptive areas of the cortex (S1 and S2) resulting in the exacerbation of migraine headache by light, and areas of the visual cortex that cause hypersensitivity to light itself. **B)** PET imaging during the interictal phase of migraine demonstrates that 600-1800 Cd/m² light causes activation in the visual cortex in migraineurs, whereas in controls there is no activation (lower panel). During pain in the trigeminal distribution light does causes activation in the visual cortex of control subjects, and a hypersensitive response in the visual cortex of migraineurs. **C).** During migraine low intensity light (240 Cd/m²) also causes activation in the visual cortex which is significantly greater compared to that after headache relief with sumatriptan and headache-free interval. Also activation of the visual cortex to the low level light after headache relief is still greater than that during headache-free interval. These data indicate that further physiological mechanism may contribute to the hypersensitivity to light as it appears to be not dependent on a trigeminovascular nociceptive input. (Parts B and C are taken and adapted from 116, 208).

Figure 9 Anatomy and pharmacology of the hypothalamic nuclei and brainstem nuclei involved in energy homeostasis and pain modulation in the context of migraine

Projections to and from specific nuclei within the hypothalamus are involved in the complex neural circuitry of energy homeostasis, including the arcuate (ARC), paraventricular (PVN), ventromedial (VMH), dorsomedial (DMH) and lateral (LH) hypothalamic neurons. In the ARC energy homeostasis is controlled by orexigenic neuropeptides (stimulating (+) food intake and decrease energy expenditure) neuropeptide Y (NPY) and agouti-related peptide (AgRP) and anorexigenic peptides (inhibit (-) food intake and increase energy expenditure) proopiomelanocortin (POMC) and cocaine-and amphetamine-regulated transcript (CART). Peripheral circulating hormones insulin and leptin inhibit NPY/AgRP and stimulate POMC/CART neurons. Communication amongst these neural circuits is further controlled by the release of orexin A and B, corticotropin-releasing factor (CRF), melanin-concentrating hormone (MCH), γ -aminobutyric acid (GABA), glutamate (GLU) and brain-derived neurotrophic factor (BDNF), amongst others. The role these nuclei have in potentially triggering migraine, as a consequence of altered feeding and changes in energy homeostasis, is through their descending projections to brainstem nuclei known to be involved in the modulation of pain processing related to headache. These include direct PVN projections to the trigeminocervical complex (TCC), VMH projections the periaqueductal grey (PAG) and the locus coeruleus (LC), and indirect communication through the ventral tegmental area (VTA) and nucleus tractus solitarius (NTS). Hypothetically altered feeding will affect neuronal processing in the ARC, and subsequently in other hypothalamic nuclei through its connections to them, including the PVN, VMH and LH. Their control of transmission of nociceptive inputs to the trigeminovascular system may be

altered, which ultimately produces the perception of noxious input from the craniofacial region and activation of trigeminovascular system, with a specific injury or insult.

NPY receptors, NPY1R and NPY5R; orexin receptors, OX1R and OX2R, long 'signaling' isoform of the leptin receptor, ObRb; insulin receptor, INSR and 3rd ventricle, 3V

Acknowledgements

The authors thank Michele Lasalandra for excellent technical assistance with many of the studies over a long period.

Work reported herein has been supported by the Sandler Foundation, The European Union (EUROHEADPAIN- EU 602633), The Wellcome Trust and the Department of Defense. Margarida Martins Oliveira was funded by the Portuguese Fundação para a Ciência e Tecnologia (FCT) with an individual PhD grant (SFRH/BD/ 77127/2011).

Some parts of the King's CRF are funded by the South London and the Maudsley Mental Health BRC. The views expressed are those of the author(s) and not necessarily those of the UK NHS, the NIHR or the Department of Health.

References

1. **Abdallah K, Artola A, Monconduit L, Dallel R, and Luccarini P.** Bilateral descending hypothalamic projections to the spinal trigeminal nucleus caudalis in rats. *PLoS One* 8: e73022, 2013.
2. **Abe J, Hosokawa H, Okazawa M, Kandachi M, Sawada Y, Yamanaka K, Matsumura K, and Kobayashi S.** TRPM8 protein localization in trigeminal ganglion and taste papillae. *Brain Res Mol Brain Res* 136: 91-98, 2005.
3. **Abizaid A.** Ghrelin and dopamine: new insights on the peripheral regulation of appetite. *J Neuroendocrinol* 21: 787-793, 2009.
4. **Abizaid A, and Horvath TL.** Ghrelin and the central regulation of feeding and energy balance. *Indian J Endocrinol Metab* 16: S617-626, 2012.
5. **Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA, and Greve JW.** Decreased plasma orexin-A levels in obese individuals. *Int J Obes Relat Metab Disord* 26: 274-276, 2002.
6. **Adamantidis A, Salvert D, Goutagny R, Lakaye B, Gervasoni D, Grisar T, Luppi PH, and Fort P.** Sleep architecture of the melanin-concentrating hormone receptor 1-knockout mice. *Eur J Neurosci* 27: 1793-1800, 2008.
7. **Adrian TE, Allen JM, Bloom SR, Ghatei MA, Rossor MN, Roberts GW, Crow TJ, Tatemoto K, and Polak JM.** Neuropeptide Y distribution in human brain. *Nature* 306: 584-586, 1983.
8. **Afra J.** Intensity dependence of auditory evoked cortical potentials in migraine. Changes in the peri-ictal period. *Funct Neurol* 20: 199-200, 2005.
9. **Afridi S, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RSJ, and Goadsby PJ.** A PET study in spontaneous migraine. *Archives of Neurology* 62: 1270-1275, 2005.
10. **Afridi S, Giffin NJ, Kaube H, and Goadsby PJ.** A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. *Neurology* 80: 642-647, 2013.
11. **Afridi S, Kaube H, and Goadsby PJ.** Glyceryl trinitrate triggers premonitory symptoms in migraineurs. *Pain* 110: 675-680, 2004.
12. **Afridi S, Kaube H, and Goadsby PJ.** Occipital activation in glyceryl trinitrate-induced migraine with visual aura. *Journal of Neurology, Neurosurgery and Psychiatry* 76: 1158-1160, 2005.
13. **Afridi S, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowiak RSJ, and Goadsby PJ.** A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. *Brain* 128: 932-939, 2005.
14. **Ahn AH.** On the temporal relationship between throbbing migraine pain and arterial pulse. *Headache* 50: 1507-1510, 2010.
15. **Airy H.** On a distinct form of transient hemiopia. *Philosophical Transactions of the Royal Society of London* 160: 247, 1870.

16. **Aiyar N, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, Bergsma DJ, and Li Y.** A cDNA encoding the calcitonin gene-related peptide type 1 receptor. *J Biol Chem* 271: 11325-11329, 1996.
17. **Akerman S, and Goadsby PJ.** Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. *Science Translational Medicine* 7: 1-11, 2015.
18. **Akerman S, and Goadsby PJ.** The role of dopamine in a model of trigeminovascular nociception. *Journal of Pharmacology and Experimental Therapeutics* 314: 162-169, 2005.
19. **Akerman S, and Goadsby PJ.** Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. *Neuroreport* 16: 1383-1387, 2005.
20. **Akerman S, Hoffmann J, and Goadsby PJ.** A Translational Approach to Studying Triptan-Induced Reversal of Established Central Sensitization of Trigemino-vascular Neurons. *Cephalalgia* 33: 211, 2013.
21. **Akerman S, Holland P, and Goadsby PJ.** Diencephalic and brainstem mechanisms in migraine. *Nature Reviews Neuroscience* 12: 570-584, 2011.
22. **Akerman S, Holland PR, and Goadsby PJ.** Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. *Journal of Pharmacology and Experimental Therapeutics* 320: 64-71, 2007.
23. **Akerman S, Holland PR, and Goadsby PJ.** Mechanically-induced cortical spreading depression associated regional cerebral blood flow changes are blocked by Na⁺ ion channel blockade. *Brain Research* 1229: 27-36, 2008.
24. **Akerman S, Holland PR, Lasalandra M, and Goadsby PJ.** Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and 'triptan' receptors: implications in migraine. *Journal of Neuroscience* 33: 14869-14877, 2013.
25. **Akerman S, Holland PR, Lasalandra MP, and Goadsby PJ.** Oxygen inhibits neuronal activation in the trigeminocervical complex after stimulation of trigeminal autonomic reflex, but not via direct dural activation of trigeminal afferents. *Headache* 49: 1131-1143, 2009.
26. **Akerman S, Holland PR, Summ O, Lasalandra MP, and Goadsby PJ.** A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization. *Brain* 135: 3664-3675, 2012.
27. **Akerman S, Kaube H, and Goadsby PJ.** Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. *British Journal of Pharmacology* 142: 1354-1360, 2004.
28. **Akerman S, Kaube H, and Goadsby PJ.** Anandamide is able to inhibit trigeminal neurons using an *in vivo* model of trigeminovascular-mediated nociception. *Journal of Pharmacology and Experimental Therapeutics* 309: 56-63, 2004.
29. **Akerman S, Williamson DJ, Kaube H, and Goadsby PJ.** The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. *Eur J Pharmacol* 452: 223-228, 2002.
30. **Akerman S, Williamson DJ, Kaube H, and Goadsby PJ.** Nitric oxide synthase inhibitors can antagonise neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. *British Journal of Pharmacology* 137: 62-68, 2002.
31. **Akerman S, Williamson DJ, Kaube H, and Goadsby PJ.** Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. *Br J Pharmacol* 137: 62-68, 2002.

32. **Albers HE, Ottenweller JE, Liou SY, Lumpkin MD, and Anderson ER.** Neuropeptide Y in the hypothalamus: effect on corticosterone and single-unit activity. *Am J Physiol* 258: R376-382, 1990.
33. **Alstadhaug K, Salvesen R, and Bekkelund S.** Insomnia and circadian variation of attacks in episodic migraine. *Headache* 47: 1181-1188, 2007.
34. **Altier N, and Stewart J.** Intra-VTA infusions of the substance P analogue, DiMe-C7, and intra-accumbens infusions of amphetamine induce analgesia in the formalin test for tonic pain. *Brain Res* 628: 279-285, 1993.
35. **Amara SG, Jonas V, Rosenfeld MG, Ong ES, and Evans RM.** Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. *Nature* 298: 240-244, 1982.
36. **Amaral DG, and Sinnamon HM.** The locus coeruleus: neurobiology of a central noradrenergic nucleus. *Progress in Neurobiology* 9: 147-196, 1977.
37. **Ambrosini A, Rossi P, De Pasqua V, Pierelli F, and Schoenen J.** Lack of habituation causes high intensity dependence of auditory evoked cortical potentials in migraine. *Brain* 126: 2009-2015, 2003.
38. **Ambrosini A, and Schoenen J.** The electrophysiology of migraine. *Current Opinion in Neurology* 16: 327-331, 2003.
39. **Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, van der Geest RJ, de Koning PJ, Larsson HB, Olesen J, and Ashina M.** Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. *Cephalalgia* 32: 140-149, 2012.
40. **Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJ, Larsson HB, Olesen J, and Ashina M.** Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. *Lancet Neurol* 12: 454-461, 2013.
41. **Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI, de Koning PJ, Andersen MR, Larsson HB, Fahrenkrug J, Olesen J, and Ashina M.** Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. *Brain* 137: 779-794, 2014.
42. **Amrutkar DV, Ploug KB, Hay-Schmidt A, Porreca F, Olesen J, and Jansen-Olesen I.** mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. *Pain* 153: 830-838, 2012.
43. **Andlin-Sobocki P, Jonsson B, Wittchen HU, and Olesen J.** Cost of disorders of the brain in Europe. *Eur J Neurol* 12: 1-27, 2005.
44. **Andreou AP, and Goadsby PJ.** Topiramate in the treatment of migraine: A kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. *Cephalalgia* 31: 1343-1358, 2011.
45. **Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, and Goadsby PJ.** Transcranial Magnetic Stimulation and Potential Cortical and Trigeminothalamic Mechanisms in Migraine. *Brain* in press, 2016.
46. **Andreou AP, Holland PR, Lasalandra M, and Goadsby PJ.** Modulation of nociceptive dural input to the trigeminocervical complex via GluK1 kainate receptors. *Pain* 156: 439-450, 2015.

47. **Andreou AP, Shields KG, and Goadsby PJ.** GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus. *Neurobiology of Disease* 37: 314-323, 2010.
48. **Andres-Enguix I, Shang L, Stansfeld PJ, Morahan JM, Sansom MS, Lafreniere RG, Roy B, Griffiths LR, Rouleau GA, Ebers GC, Cader ZM, and Tucker SJ.** Functional analysis of missense variants in the TRESK (KCNK18) K channel. *Scientific reports* 2: 237, 2012.
49. **Angelini L, de Tommaso M, Guido M, Hu K, Ivanov P, Marinazzo D, Nardulli G, Nitti L, Pellicoro M, Pierro C, and Stramaglia S.** Steady-state visual evoked potentials and phase synchronization in migraine patients. *Phys Rev Lett* 93: 038103-038101-038103-038104, 2004.
50. **Anthony M, Hinterberger H, and Lance JW.** Plasma serotonin in migraine and stress. *Archives of Neurology* 16: 544-552, 1967.
51. **Antonijevic IA, Murck H, Bohlhalter S, Frieboes RM, Holsboer F, and Steiger A.** Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. *Neuropharmacology* 39: 1474-1481, 2000.
52. **Antonova M, Wienecke T, Olesen J, and Ashina M.** Prostaglandin E(2) induces immediate migraine-like attack in migraine patients without aura. *Cephalalgia* 32: 822-833, 2012.
53. **Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, Calafato MS, Nyholt DR, Dimas AS, Freilinger T, Muller-Myhsok B, Artto V, Inouye M, Alakurtti K, Kaunisto MA, Hamalainen E, de Vries B, Stam AH, Weller CM, Heinze A, Heinze-Kuhn K, Goebel I, Borck G, Gobel H, Steinberg S, Wolf C, Bjornsson A, Gudmundsson G, Kirchmann M, Hauge A, Werge T, Schoenen J, Eriksson JG, Hagen K, Stovner L, Wichmann HE, Meitinger T, Alexander M, Moebus S, Schreiber S, Aulchenko YS, Breteler MM, Uitterlinden AG, Hofman A, van Duijn CM, Tikka-Kleemola P, Vepsalainen S, Lucae S, Tozzi F, Muglia P, Barrett J, Kaprio J, Farkkila M, Peltonen L, Stefansson K, Zwart JA, Ferrari MD, Olesen J, Daly M, Wessman M, van den Maagdenberg AM, Dichgans M, Kubisch C, Dermitzakis ET, Frants RR, and Palotie A.** Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. *Nat Genet* 42: 869-873, 2010.
54. **Anttila V, Winsvold BS, Gormley P, Kurth T, Bettella F, McMahon G, Kallela M, Malik R, de Vries B, Terwindt G, Medland SE, Todt U, McArdle WL, Quaye L, Koironen M, Ikram MA, Lehtimäki T, Stam AH, Ligthart L, Wedenoja J, Dunham I, Neale BM, Palta P, Hamalainen E, Schurks M, Rose LM, Buring JE, Ridker PM, Steinberg S, Stefansson H, Jakobsson F, Lawlor DA, Evans DM, Ring SM, Farkkila M, Artto V, Kaunisto MA, Freilinger T, Schoenen J, Frants RR, Pelzer N, Weller CM, Zielman R, Heath AC, Madden PA, Montgomery GW, Martin NG, Borck G, Gobel H, Heinze A, Heinze-Kuhn K, Williams FM, Hartikainen AL, Pouta A, van den Ende J, Uitterlinden AG, Hofman A, Amin N, Hottenga JJ, Vink JM, Heikkila K, Alexander M, Muller-Myhsok B, Schreiber S, Meitinger T, Wichmann HE, Aromaa A, Eriksson JG, Traynor BJ, Trabzuni D, Rossin E, Lage K, Jacobs SB, Gibbs JR, Birney E, Kaprio J, Penninx BW, Boomsma DI, van Duijn C, Raitakari O, Jarvelin MR, Zwart JA, Cherkas L, Strachan DP, Kubisch C, Ferrari MD, van den Maagdenberg AM, Dichgans M, Wessman M, Smith GD, Stefansson K, Daly MJ, Nyholt DR, Chasman DI, Palotie A, North American Brain Expression C, Consortium UKBE, and International Headache Genetics C.** Genome-wide meta-analysis identifies new susceptibility loci for migraine. *Nat Genet* 45: 912-917, 2013.
55. **Aponte Y, Atasoy D, and Sternson SM.** AGRP neurons are sufficient to orchestrate feeding behavior rapidly and without training. *Nat Neurosci* 14: 351-355, 2011.

56. **Argiolas A, and Melis MR.** The neuropharmacology of yawning. *Eur J Pharmacol* 343: 1-16, 1998.
57. **Arimura A.** Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. *Regulatory Peptides* 37: 287-303, 1992.
58. **Asghar MS, Hansen AE, Amin FM, van der Geest RJ, Koning P, Larsson HB, Olesen J, and Ashina M.** Evidence for a vascular factor in migraine. *Ann Neurol* 69: 635-645, 2011.
59. **Asghar MS, Hansen AE, Kapijimpanga T, van der Geest RJ, van der Koning P, Larsson HB, Olesen J, and Ashina M.** Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. *Neurology* 75: 1520-1526, 2010.
60. **Aurora SK, Al-Sayeed F, and Welch KMA.** The cortical silent period is shortened in migraine with aura. *Cephalalgia* 19: 708-712, 1999.
61. **Aurora SK, Cao Y, Bowyer SM, and Welch KMA.** The occipital cortex is hyperexcitable in migraine: experimental evidence. *Headache* 39: 469-476, 1999.
62. **Ayata C.** Cortical spreading depression triggers migraine attack: pro. *Headache* 50: 725-730, 2010.
63. **Ayata C, Jin H, Kudo C, Dalkara T, and Moskowitz MA.** Suppression of cortical spreading depression in migraine prophylaxis. *Ann Neurol* 59: 652-661, 2006.
64. **Azhdari-Zarmehri H, Reisi Z, Vaziri A, Haghparast A, and Shaigani P.** Involvement of orexin-2 receptors in the ventral tegmental area and nucleus accumbens in the antinociception induced by the lateral hypothalamus stimulation in rats. *Peptides* 47: 94-98, 2013.
65. **Baez MA, Brink TS, and Mason P.** Roles for pain modulatory cells during micturition and continence. *J Neurosci* 25: 384-394, 2005.
66. **Bahra A, Matharu MS, Buchel C, Frackowiak RS, and Goadsby PJ.** Brainstem activation specific to migraine headache. *Lancet* 357: 1016-1017, 2001.
67. **Bai FL, Yamano M, Shiotani Y, Emson PC, Smith AD, Powell JF, and Tohyama M.** An arcuate-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat. *Brain Res* 331: 172-175, 1985.
68. **Banarer S, and Cryer PE.** Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. *Diabetes* 52: 1195-1203, 2003.
69. **Banks WA, Kastin AJ, Komaki G, and Arimura A.** Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. *J Pharmacol Exp Ther* 267: 690-696, 1993.
70. **Banks WA, Kastin AJ, Komaki G, and Arimura A.** Pituitary adenylate cyclase activating polypeptide (PACAP) can cross the vascular component of the blood-testis barrier in the mouse. *J Androl* 14: 170-173, 1993.
71. **Barbanti P, Fabbrini G, Aurilia C, Vanacore N, and Cruccu G.** A case-control study on excessive daytime sleepiness in episodic migraine. *Cephalalgia* 27: 1115-1119, 2007.
72. **Barriere G, Cazalets JR, Bioulac B, Tison F, and Ghorayeb I.** The restless legs syndrome. *Progress in Neurobiology* 77: 139-165, 2005.
73. **Barsh GS, and Schwartz MW.** Genetic approaches to studying energy balance: perception and integration. *Nat Rev Genet* 3: 589-600, 2002.
74. **Bartsch T, and Goadsby PJ.** Anatomy and physiology of pain referral in primary and cervicogenic headache disorders. *Headache Currents* 2: 42-48, 2005.
75. **Bartsch T, and Goadsby PJ.** Increased responses in trigeminocervical nociceptive neurones to cervical input after stimulation of the dura mater. *Brain* 126: 1801-1813, 2003.

76. **Bartsch T, and Goadsby PJ.** Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. *Brain* 125: 1496-1509, 2002.
77. **Bartsch T, Knight YE, and Goadsby PJ.** Activation of 5-HT_{1B/1D} receptors in the periaqueductal grey inhibits meningeal nociception. *Annals of Neurology* 56: 371-381, 2004.
78. **Bartsch T, Levy MJ, Knight YE, and Goadsby PJ.** Differential modulation of nociceptive dural input to [hypocretin] Orexin A and B receptor activation in the posterior hypothalamic area. *Pain* 109: 367-378, 2004.
79. **Bartsch T, Levy MJ, Knight YE, and Goadsby PJ.** Inhibition of nociceptive dural input in the trigeminal nucleus caudalis by somatostatin receptor blockade in the posterior hypothalamus. *Pain* 117: 30-39, 2005.
80. **Basbaum AI, and Fields HL.** Endogenous pain control mechanisms: review and hypothesis. *Annals of Neurology* 4: 451-462, 1978.
81. **Baskin DG, Hahn TM, and Schwartz MW.** Leptin sensitive neurons in the hypothalamus. *Horm Metab Res* 31: 345-350, 1999.
82. **Battelli L, Black KR, and Wray SH.** Transcranial magnetic stimulation of visual area V5 in migraine. *Neurology* 58: 1066-1069, 2002.
83. **Baun M, Hay-Schmidt A, Edvinsson L, Olesen J, and Jansen-Olesen I.** Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat. *Eur J Pharmacol* 670: 186-194, 2011.
84. **Bautista DM, Siemens J, Glazer JM, Tsuruda PR, Basbaum AI, Stucky CL, Jordt SE, and Julius D.** The menthol receptor TRPM8 is the principal detector of environmental cold. *Nature* 448: 204-208, 2007.
85. **Benjamin L, Levy MJ, Lasalandra MP, Knight YE, Akerman S, Classey JD, and Goadsby PJ.** Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: a Fos study. *Neurobiology of Disease* 16: 500-505, 2004.
86. **Berde B, and Schild HO.** *Ergot alkaloids and related compounds*. Berlin: Springer-Verlag, 1978.
87. **Bergendahl M, Vance ML, Iranmanesh A, Thorner MO, and Veldhuis JD.** Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. *J Clin Endocrinol Metab* 81: 692-699, 1996.
88. **Bergerot A, Holland PR, Akerman S, Bartsch T, Ahn AH, MaassenVanDenBrink A, Reuter U, Tassorelli C, Schoenen J, Mitsikostas DD, van den Maagdenberg AMJM, and Goadsby PJ.** Animal models of migraine. Looking at the component parts of a complex disorder. *European Journal of Neuroscience* 24: 1517-1534, 2006.
89. **Bergerot A, Storer RJ, and Goadsby PJ.** Dopamine inhibits trigeminovascular transmission in the rat. *Annals of Neurology* 61: 251-262, 2007.
90. **Bernecker C, Pailer S, Kieslinger P, Horejsi R, Möller R, Lechner A, Wallner-Blazek M, Weiss S, Fazekas F, Truschnig-Wilders M, and Gruber HJ.** GLP-2 and leptin are associated with hyperinsulinemia in non-obese female migraineurs. *Cephalalgia* 30: 1366-1374, 2010.
91. **Bernstein C, and Burstein R.** Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. *J Clin Neurol* 8: 89-99, 2012.
92. **Bes A, Dupui P, Guell A, Bessoles G, and Geraud G.** Pharmacological exploration of dopamine hypersensitivity in migraine patients. *Int J Clin Pharmacol Res* 6: 189-192, 1986.

93. **Bhatt DK, Gupta S, Jansen-Olesen I, Andrews JS, and Olesen J.** NXN-188, a selective nNOS inhibitor and a 5-HT_{1B/1D} receptor agonist, inhibits CGRP release in preclinical migraine models. *Cephalalgia* 33: 87-100, 2013.
94. **Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, and Goadsby PJ.** Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: Evaluation of outcome data for the UK post market pilot program. *Journal of Headache and Pain* 16: 51, 2015.
95. **Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, and Lipton RB.** Prevalence and characteristics of allodynia in headache sufferers: a population study. *Neurology* 70: 1525-1533, 2008.
96. **Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, and Lipton RB.** Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. *Lancet Neurology* 14: 1081-1090, 2015.
97. **Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings ELH, Diener H-C, Burstein R, Loupe PS, Ma Y, Yang R, and Silberstein SD.** Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. *Lancet Neurology* 14: 1091-1100, 2015.
98. **Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, and Garzone P.** Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. *Cephalalgia* 34: 483-492, 2013.
99. **Bigal ME, Liberman JN, and Lipton RB.** Obesity and migraine: a population study. *Neurology* 66: 545-550, 2006.
100. **Bigal ME, and Lipton RB.** Clinical course in migraine: conceptualizing migraine transformation. *Neurology* 71: 848-855, 2008.
101. **Bigal ME, Lipton RB, Holland PR, and Goadsby PJ.** Obesity, migraine and chronic migraine. Possible mechanisms of interaction. *Neurology* 68: 1851-1861, 2007.
102. **Bigal ME, Tsang A, Loder E, Serrano D, Reed ML, and Lipton RB.** Body mass index and episodic headaches: a population-based study. *Arch Intern Med* 167: 1964-1970, 2007.
103. **Bigal ME, Walter S, Bronson M, Alibhoy A, and Escandon R.** Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. *Cephalalgia* 34: 968-976, 2014.
104. **Bittencourt JC, and Elias CF.** Diencephalic origins of melanin-concentrating hormone immunoreactive projections to medial septum/diagonal band complex and spinal cord using two retrograde fluorescent tracers. *Ann N Y Acad Sci* 680: 462-465, 1993.
105. **Blau J.** Migraine postdromes: symptoms after attacks. *Cephalalgia* 11: 229-231, 1991.
106. **Blau JN.** Migraine prodromes separated from the aura; complete migraine. *British Medical Journal* 21.: 658-660, 1980.
107. **Blau JN.** Sleep deprivation headache. *Cephalalgia* 10: 157-160, 1990.
108. **Blau JN, and Cumings JN.** Method of precipitating and preventing migraine attacks. *British Medical Journal* II: 1242-1243, 1966.
109. **Blin O, Azulay J, Masson G, Aubrespey G, and Serratrice G.** Apomorphine-induced yawning in migraine patients: enhanced responsiveness. *Clinical Neuropharmacology* 14: 91-95, 1991.

110. **Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, and Moskowitz MA.** Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. *Nature Medicine* 8: 136-142, 2002.
111. **Boni LJ, Ploug KB, Olesen J, Jansen-Olesen I, and Gupta S.** The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. *Cephalalgia* 29: 837-847, 2009.
112. **Borbély AA.** Sleep in the rat during food deprivation and subsequent restitution of food. *Brain Res* 124: 457-471, 1977.
113. **Bornstein SR, Uhlmann K, Haidan A, Ehrhart-Bornstein M, and Scherbaum WA.** Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: leptin inhibits cortisol release directly. *Diabetes* 46: 1235-1238, 1997.
114. **Bouchelet I, Case B, Olivier A, and Hamel E.** No contractile effect for 5-HT_{1D} and 5-HT_{1F} receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. *British Journal of Pharmacology* 129: 501-508, 2000.
115. **Bouchelet I, Cohen Z, Case B, and Hamel E.** Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. *Molecular Pharmacology* 50: 219-223, 1996.
116. **Boulloche N, Denuelle M, Payoux P, Fabre N, Trotter Y, and Geraud G.** Photophobia in migraine: an interictal PET study of cortical hyperexcitability and its modulation by pain. *J Neurol Neurosurg Psychiatry* 81: 978-984, 2010.
117. **Bourgin P, Huitron-Resendiz S, Spier AD, Fabre V, Morte B, Criado JR, Sutcliffe JG, Henriksen SJ, and de Lecea L.** Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. *J Neurosci* 20: 7760-7765, 2000.
118. **Brady LS, Smith MA, Gold PW, and Herkenham M.** Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats. *Neuroendocrinology* 52: 441-447, 1990.
119. **Brennan KC, Bates EA, Shapiro RE, Zyuzin J, Hallows WC, Huang YH, Lee H-Y, Jones CR, Fu Y-H, Charles AC, and Ptacek LJ.** Casein Kinase Id Mutations in Familial Migraine and Advanced Sleep Phase. *Science Translational Medicine* 5: 183ra156, 2013.
120. **Brennan KC, Beltran-Parrazal L, Lopez Valdes HE, Theriot J, Toga A, and Charles AC.** Distinct vascular conduction with cortical spreading depression. *J Neurophysiol* 97: 4143-4151, 2007.
121. **Brennan KC, Romero-Reyes M, Lopez Valdes HE, Arnold AP, and Charles AC.** Reduced threshold for cortical spreading depression in female mice. *Ann Neurol* 61: 603-606, 2007.
122. **Brighina F, Piazza A, Daniele O, and Fierro B.** Modulation of visual cortical excitability in migraine with aura: effects of 1 Hz repetitive transcranial magnetic stimulation. *Exp Brain Res* 145: 177-181, 2002.
123. **Broberger C, De Lecea L, Sutcliffe JG, and Hökfelt T.** Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems. *J Comp Neurol* 402: 460-474, 1998.
124. **Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Branchek TA, Hoyer D, and Palacios JM.** Localization of 5-HT_{1B}, 5-HT_{1D} alpha, 5-HT_{1E} and 5-HT_{1F} receptor messenger RNA in rodent and primate brain. *Neuropharmacology* 33: 367-386, 1994.

125. **Burdakov D, Gerasimenko O, and Verkhatsky A.** Physiological changes in glucose differentially modulate the excitability of hypothalamic melanin-concentrating hormone and orexin neurons in situ. *J Neurosci* 25: 2429-2433, 2005.
126. **Burstein R, Cliffer KD, and Giesler GJ, Jr.** Direct somatosensory projections from the spinal cord to the hypothalamus and telencephalon. *J Neurosci* 7: 4159-4164, 1987.
127. **Burstein R, Collins B, and Jakubowski M.** Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. *Annals of Neurology* 55: 19-26, 2004.
128. **Burstein R, Cutrer MF, and Yarnitsky D.** The development of cutaneous allodynia during a migraine attack. *Brain* 123: 1703-1709, 2000.
129. **Burstein R, Dado RJ, and Giesler GJ, Jr.** The cells of origin of the spinothalamic tract of the rat: a quantitative reexamination. *Brain Res* 511: 329-337, 1990.
130. **Burstein R, and Jakubowski M.** Neural substrate of depression during migraine. *Neurol Sci* 30 Suppl 1: S27-31, 2009.
131. **Burstein R, and Jakubowski M.** Unitary hypothesis for multiple triggers of the pain and strain of migraine. *J Comp Neurol* 493: 9-14, 2005.
132. **Burstein R, Jakubowski M, Garcia-Nicas E, Kainz V, Bajwa Z, Hargreaves R, Becerra L, and Borsook D.** Thalamic sensitization transforms localized pain into widespread allodynia. *Ann Neurol* 68: 81-91, 2010.
133. **Burstein R, Jakubowski M, and Levy D.** Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors. *Pain* 115: 21-28, 2005.
134. **Burstein R, Strassman A, and Moskowitz M.** Can cortical spreading depression activate central trigeminovascular neurons without peripheral input? Pitfalls of a new concept. *Cephalalgia* 32: 509-511, 2012.
135. **Burstein R, Yamamura H, Malick A, and Strassman AM.** Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. *Journal of Neurophysiology* 79: 964-982, 1998.
136. **Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, and Bajwa ZH.** An association between migraine and cutaneous allodynia. *Annals of Neurology* 47: 614-624, 2000.
137. **Buse DC, Manack A, Serrano D, Turkel C, and Lipton RB.** Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. *J Neurol Neurosurg Psychiatry* 81: 428-432, 2010.
138. **Buzzi MG, and Moskowitz MA.** The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. *British Journal of Pharmacology* 99: 202-206, 1990.
139. **Buzzi MG, Sakas DE, and Moskowitz MA.** Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. *European Journal of Pharmacology* 165: 251-258, 1989.
140. **Cahill GF.** Starvation in man. *N Engl J Med* 282: 668-675, 1970.
141. **Cai XJ, Evans ML, Lister CA, Leslie RA, Arch JR, Wilson S, and Williams G.** Hypoglycemia activates orexin neurons and selectively increases hypothalamic orexin-B levels: responses inhibited by feeding and possibly mediated by the nucleus of the solitary tract. *Diabetes* 50: 105-112, 2001.
142. **Cai XJ, Widdowson PS, Harrold J, Wilson S, Buckingham RE, Arch JR, Tadayyon M, Clapham JC, Wilding J, and Williams G.** Hypothalamic orexin expression: modulation by blood glucose and feeding. *Diabetes* 48: 2132-2137, 1999.

143. **Cailotto C, La Fleur SE, Van Heijningen C, Wortel J, Kalsbeek A, Feenstra M, Pévet P, and Buijs RM.** The suprachiasmatic nucleus controls the daily variation of plasma glucose via the autonomic output to the liver: are the clock genes involved? *Eur J Neurosci* 22: 2531-2540, 2005.
144. **Calzá L, Giardino L, Battistini N, Zanni M, Galetti S, Protopapa F, and Velardo A.** Increase of neuropeptide Y-like immunoreactivity in the paraventricular nucleus of fasting rats. *Neurosci Lett* 104: 99-104, 1989.
145. **Canteras NS, Simerly RB, and Swanson LW.** Organization of projections from the ventromedial nucleus of the hypothalamus: a Phaseolus vulgaris-leucoagglutinin study in the rat. *J Comp Neurol* 348: 41-79, 1994.
146. **Caproni S, Corbelli I, Pini LA, Cupini ML, Calabresi P, and Sarchielli P.** Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: the results of a pilot study. *Cephalalgia* 31: 543-549, 2011.
147. **Casse F, Bardou I, Danglot L, Briens A, Montagne A, Parcq J, Alahari A, Galli T, Vivien D, and Docagne F.** Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. *J Neurosci* 32: 5186-5199, 2012.
148. **Cavestro C, Rosatello A, Micca G, Ravotto M, Marino MP, Asteggiano G, and Beghi E.** Insulin metabolism is altered in migraineurs: a new pathogenic mechanism for migraine? *Headache* 47: 1436-1442, 2007.
149. **Cerbo R, Barbanti P, Buzzi MG, Fabbrini G, Brusa L, and Roberti C.** Dopamine hypersensitivity in migraine: role of the apomorphine test. *Clinical Neuropharmacology* 20: 36-41, 1997.
150. **Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, Connor KM, and Michelson D.** Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. *Cephalalgia* 35: 379-388, 2015.
151. **Chabriat H, Tournier-Lasserre E, Vahedi K, Leys D, Joutel A, Nibbio A, Escaillas JP, Iba-Zizen MT, Bracard S, Tehindrazanarivelo A, Gastaut JL, and Bousser MG.** Autosomal dominant migraine with MRI white-matter abnormalities mapping to the CADASIL locus. *Neurology* 45: 1086-1091, 1995.
152. **Chai NC, Shapiro RE, and Rapoport AM.** Why does vomiting stop a migraine attack? *Curr Pain Headache Rep* 17: 362, 2013.
153. **Chang JC, Shook LL, Biag J, Nguyen EN, Toga AW, Charles AC, and Brennan KC.** Biphasic direct current shift, haemoglobin desaturation and neurovascular uncoupling in cortical spreading depression. *Brain* 133: 996-1012, 2010.
154. **Chaput JP, Després JP, Bouchard C, and Tremblay A.** Short sleep duration is associated with reduced leptin levels and increased adiposity: Results from the Quebec family study. *Obesity (Silver Spring)* 15: 253-261, 2007.
155. **Charbit AR, Akerman S, and Goadsby PJ.** Trigemino-cervical complex responses after lesioning dopaminergic A11 nucleus are modified by dopamine and serotonin mechanisms. *Pain* 152: 2365-2376, 2011.
156. **Charbit AR, Akerman S, Holland PR, and Goadsby PJ.** Neurons of the dopaminergic/Calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigemino-cervical complex: an electrophysiological and immunohistochemical study. *Journal of Neuroscience* 29: 12532-12541, 2009.
157. **Charles A.** Does cortical spreading depression initiate a migraine attack? Maybe not. *Headache* 50: 731-733, 2010.

158. **Charles A.** Migraine: a brain state. *Curr Opin Neurol* 26: 235-239, 2013.
159. **Chasman DI, Anttila V, Buring JE, Ridker PM, Schurks M, Kurth T, and International Headache Genetics Consortium.** Selectivity in genetic association with sub-classified migraine in women. *PLoS Genet* 10: e1004366, 2014.
160. **Chasman DI, Schurks M, Anttila V, de Vries B, Schminke U, Launer LJ, Terwindt GM, van den Maagdenberg AM, Fendrich K, Volzke H, Ernst F, Griffiths LR, Buring JE, Kallela M, Freilinger T, Kubisch C, Ridker PM, Palotie A, Ferrari MD, Hoffmann W, Zee RY, and Kurth T.** Genome-wide association study reveals three susceptibility loci for common migraine in the general population. *Nat Genet* 43: 695-698, 2011.
161. **Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong YM, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, and Yanagisawa M.** Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. *Cell* 98: 437-451, 1999.
162. **Chen L, Philippe J, and Unger RH.** Glucagon responses of isolated alpha cells to glucose, insulin, somatostatin, and leptin. *Endocr Pract* 17: 819-825, 2011.
163. **Chen SP, Ay I, Lopes de Moraes A, Qin T, Zheng Y, Sadeghian H, Oka F, Simon B, Eikermann-Haerter K, and Ayata C.** Vagus nerve stimulation inhibits cortical spreading depression. *Pain* 157: 797-805, 2016.
164. **Chergui K, Svenningsson P, and Greengard P.** Physiological role for casein kinase 1 in glutamatergic synaptic transmission. *J Neurosci* 25: 6601-6609, 2005.
165. **Chizh B, Palmer J, Lai R, Guillard F, Bullman J, Baines A, Napolitano A, and Appleby J.** A randomised, two-period cross-over study to investigate the efficacy of the Trpv1 antagonist SB-705498 in acute migraine. *Eur J Pain* 13: S202a-S202, 2009.
166. **Chong CD, Gaw N, Fu Y, Li J, Wu T, and Schwedt TJ.** Migraine classification using magnetic resonance imaging resting-state functional connectivity data. *Cephalalgia* 2016.
167. **Chou TC, Scammell TE, Gooley JJ, Gaus SE, Saper CB, and Lu J.** Critical role of dorsomedial hypothalamic nucleus in a wide range of behavioral circadian rhythms. *J Neurosci* 23: 10691-10702, 2003.
168. **Christensen AF, Esserlind AL, Werge T, Stefansson H, Stefansson K, and Olesen J.** The influence of genetic constitution on migraine drug responses. *Cephalalgia* 36: 624-639, 2016.
169. **Chronicle EP, and Mulleners WM.** Visual system dysfunction in migraine: a review of clinical and psychophysical findings. *Cephalalgia* 16: 525-535; discussion 523, 1996.
170. **Classey JD, Bartsch T, and Goadsby PJ.** Distribution of 5-HT_{1B}, 5-HT_{1D} and 5-HT_{1F} receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans. *Brain Research* 1361: 76-85, 2010.
171. **Classey JD, Knight YE, and Goadsby PJ.** The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat. *Brain Research* 907: 117-124, 2001.
172. **Clemens S, Rye D, and Hochman S.** Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. *Neurology* 67: 125-130, 2006.
173. **Coghill RC, Sang CN, Berman KF, Bennett GJ, and Iadarola MJ.** Global cerebral blood flow decreases during pain. *Journal of Cerebral Blood Flow and Metabolism* 18: 141-147, 1998.
174. **Cohen ML, Johnson KW, Schenck KW, and Phebus LA.** Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries. *Cephalalgia* 17: 631-638, 1997.

175. **Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, Mombaerts P, and Friedman JM.** Selective deletion of leptin receptor in neurons leads to obesity. *J Clin Invest* 108: 1113-1121, 2001.
176. **Connor HE, Bertin L, Gillies S, Beattie DT, Ward P, and The GR205171 Clinical Study Group.** Clinical evaluation of a novel, potent, CNS penetrating NK₁ receptor antagonist in the acute treatment of migraine. *Cephalalgia* 18: 392, 1998.
177. **Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA, and Humphrey PPA.** Naratriptan: biological profile in animal models relevant to migraine. *Cephalalgia* 17: 145-152, 1997.
178. **Connor KM, Aurora SK, Loeys T, Ashina M, Jones C, Giezek H, Massaad R, Williams-Diaz A, Lines C, and Ho TW.** Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. *Headache* 51: 73-84, 2011.
179. **Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, Fan X, Fei K, Assaid C, Lines C, and Ho TW.** Randomized, controlled trial of telcagepant for the acute treatment of migraine. *Neurology* 73: 970-977, 2009.
180. **Coppola G, Di Renzo A, Tinelli E, Iacovelli E, Lepre C, Di Lorenzo C, Di Lorenzo G, Di Lenola D, Parisi V, Serrao M, Pauri F, Fiermonte G, Bianco F, and Pierelli F.** Evidence for brain morphometric changes during the migraine cycle: a magnetic resonance-based morphometry study. *Cephalalgia* 35: 783-791, 2015.
181. **Coppola G, Pierelli F, and Schoenen J.** Habituation and migraine. *Neurobiol Learn Mem* 92: 249-259, 2009.
182. **Coppola G, Pierelli F, and Schoenen J.** Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? *Cephalalgia* 27: 1427-1439, 2007.
183. **Coppola G, Pierelli F, and Schoenen J.** Reply to the topical review entitled "the phenomenon of changes in cortical excitability in migraine is not migraine-specific--a unifying thesis" by Anne Stankewitz and Arne May published in *Pain* 2009;145:14-7. *Pain* 149: 407-408; author reply 408-409, 2010.
184. **Coppola G, Tinelli E, Lepre C, Iacovelli E, Di Lorenzo C, Di Lorenzo G, Serrao M, Pauri F, Fiermonte G, Bianco F, and Pierelli F.** Dynamic changes in thalamic microstructure of migraine without aura patients: a diffusion tensor magnetic resonance imaging study. *Eur J Neurol* 21: 287-e213, 2014.
185. **Coppola G, Vandenheede M, Di Clemente L, Ambrosini A, Fumal A, De Pasqua V, and Schoenen J.** Somatosensory evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in migraine patients between attacks. *Brain* 128: 98-103, 2005.
186. **Csati A, Tajti J, Kuris A, Tuka B, Edvinsson L, and Warfvinge K.** Distribution of vasoactive intestinal polypeptide, pituitary adenylate cyclase activating peptide, nitric oxide synthase and their receptors in human and rat sphenopalatine ganglion. *Neuroscience* 202: 158-168, 2012.
187. **Cumberbatch MJ, Hill RG, and Hargreaves RJ.** Differential effects of the 5HT_{1B/1D} receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. *Cephalalgia* 18: 659-664, 1998.
188. **Cumberbatch MJ, Williamson DJ, Mason GS, Hill RG, and Hargreaves RJ.** Dural vasodilatation causes a sensitization of rat caudal trigeminal neurones *in vivo* that is blocked by a 5-HT_{1B/1D} agonist. *British Journal of Pharmacology* 126: 1478-1486, 1999.

189. **Cunningham ET, Bohn MC, and Sawchenko PE.** Organization of adrenergic inputs to the paraventricular and supraoptic nuclei of the hypothalamus in the rat. *J Comp Neurol* 292: 651-667, 1990.
190. **Cunningham ET, and Sawchenko PE.** Anatomical specificity of noradrenergic inputs to the paraventricular and supraoptic nuclei of the rat hypothalamus. *J Comp Neurol* 274: 60-76, 1988.
191. **Curran DA, Hinterberger H, and Lance JW.** Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. *Brain* 88: 997-1010, 1965.
192. **Cutrer FM, Sorensen AG, Weisskoff RM, Ostergaard L, Sanchez del Rio M, Lee J, Rosen BR, and Moskowitz MA.** Perfusion-weighted imaging defects during spontaneous migrainous aura. *Annals of Neurology* 43: 25-31, 1998.
193. **Dahlstrom A, and Fuxe K.** Evidence for the existence of monoamine-containing neurons in the central nervous system. I demonstration of monoamines in the cell bodies of Brain stem neurons (Suppl 232). *Acta Physiologica Scandinavica* 62: 1-55, 1964.
194. **Dahmen N, Kasten M, Wieczorek S, Gencik M, Epplen JT, and Ullrich B.** Increased frequency of migraine in narcoleptic patients: a confirmatory study. *Cephalalgia* 23: 14-19, 2003.
195. **Dahmen N, Querings K, Grun B, and Bierbrauer J.** Increased frequency of migraine in narcoleptic patients. *Neurology* 52: 1291-1293, 1999.
196. **Dalkara T, and Kiliç K.** How does fasting trigger migraine? A hypothesis. *Curr Pain Headache Rep* 17: 368, 2013.
197. **Dalkvist J, Ekblom K, and Waldenlind E.** Headache and mood: a time-series analysis of self-ratings. *Cephalalgia* 4: 45-52, 1984.
198. **Danguir J, and Nicolaidis S.** Dependence of sleep on nutrients' availability. *Physiol Behav* 22: 735-740, 1979.
199. **DaSilva AF, Granziera C, Tuch DS, Snyder J, Vincent M, and Hadjikhani N.** Interictal alterations of the trigeminal somatosensory pathway and periaqueductal gray matter in migraine. *Neuroreport* 18: 301-305, 2007.
200. **Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S, Kangawa K, Sakurai T, Yanagisawa M, and Nakazato M.** Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. *Proceedings of the National Academy of Sciences (USA)* 96: 748-753, 1999.
201. **Davidson AJ, Yamazaki S, Arble DM, Menaker M, and Block GD.** Resetting of central and peripheral circadian oscillators in aged rats. *Neurobiol Aging* 29: 471-477, 2008.
202. **Davis KD, and Dostrovsky JO.** Properties of feline thalamic neurons activated by stimulation of the middle meningeal artery and sagittal sinus. *Brain Research* 454: 89-100, 1988.
203. **De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L, Ballabio A, Aridon P, and Casari G.** Haploinsufficiency of ATP1A2 encoding the Na⁺/K⁺ pump α 2 subunit associated with familial hemiplegic migraine type 2. *Nature Genetics* 33: 192-196, 2003.
204. **de Hoon J, Montieth D, Vermeersch S, Van Hecken A, Abu-Raddad E, Collins E, Schuetz T, Scherer J, and Grayzel D.** Safety, Pharmacokinetics, and Pharmacodynamics of LY2951742: A Monoclonal Antibody Targeting CGRP. *Cephalalgia* 33: 247-248, 2013.
205. **de Kloet ER, Joëls M, and Holsboer F.** Stress and the brain: from adaptation to disease. *Nat Rev Neurosci* 6: 463-475, 2005.

206. **de Tommaso M, Ambrosini A, Brighina F, Coppola G, Perrotta A, Pierelli F, Sandrini G, Valeriani M, Marinazzo D, Stramaglia S, and Schoenen J.** Altered processing of sensory stimuli in patients with migraine. *Nat Rev Neurol* 10: 144-155, 2014.
207. **Demarquay G, Royet JP, Mick G, and Ryvlin P.** Olfactory hypersensitivity in migraineurs: a H(2)(15)O-PET study. *Cephalalgia* 28: 1069-1080, 2008.
208. **Denuelle M, Bouloche N, Payoux P, Fabre N, Trotter Y, and Geraud G.** A PET study of photophobia during spontaneous migraine attacks. *Neurology* 76: 213-218, 2011.
209. **Denuelle M, Fabre N, Payoux P, Chollet F, and Geraud G.** Hypothalamic activation in spontaneous migraine attacks. *Headache* 47: 1418-1426, 2007.
210. **Denuelle M, Fabre N, Payoux P, Chollet F, and Geraud G.** Posterior cerebral hypoperfusion in migraine without aura. *Cephalalgia* 28: 856-862, 2008.
211. **Derbyshire SWG, Jones AKP, Gyulai F, Clark S, Townsend D, and Firestone LL.** Pain processing during three levels of noxious stimulation produces differential patterns of central activity. *Pain* 73: 431-445, 1997.
212. **Dhaka A, Earley TJ, Watson J, and Patapoutian A.** Visualizing cold spots: TRPM8-expressing sensory neurons and their projections. *J Neurosci* 28: 566-575, 2008.
213. **Di Clemente L, Coppola G, Magis D, Fumal A, De Pasqua V, Di Piero V, and Schoenen J.** Interictal habituation deficit of the nociceptive blink reflex: an endophenotypic marker for presymptomatic migraine? *Brain* 130: 765-770, 2007.
214. **Diano S, Horvath B, Urbanski HF, Sotonyi P, and Horvath TL.** Fasting activates the nonhuman primate hypocretin (orexin) system and its postsynaptic targets. *Endocrinology* 144: 3774-3778, 2003.
215. **Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, Ferrari MD, Herzog J, van den Maagdenberg AM, Pusch M, and Strom TM.** Mutation in the neuronal voltage-gated sodium channel *SCN1A* causes familial hemiplegic migraine. *The Lancet* 366: 371-377, 2005.
216. **Diener H-C, Barbanti P, Dahlof C, Reuter U, Habeck J, and Podhorna J.** BI 44370 TA, an oral CGRP antagonist for the acute treatment of migraine attacks: results from a phase II study. *Cephalalgia* 31: 573-584, 2011.
217. **Diener H-C, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, and Silberstein SD.** Chronic migraine-classification, characteristics and treatment. *Nature Review Neurology* 14: 162-171, 2012.
218. **Diener H-C, and The RPR100893 Study Group.** RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. *Cephalalgia* 23: 183-185, 2003.
219. **Diener HC, Gendolla A, Feuersenger A, Evers S, Straube A, Schumacher H, and Davidai G.** Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. *Cephalalgia* 29: 921-927, 2009.
220. **Dietrich MO, and Horvath TL.** Hypothalamic control of energy balance: insights into the role of synaptic plasticity. *Trends Neurosci* 36: 65-73, 2013.
221. **DiMauro S, and Schon EA.** Mitochondrial respiratory-chain diseases. *New England Journal of Medicine* 348: 2556-2668, 2004.
222. **Dimitrov EL, DeJoseph MR, Brownfield MS, and Urban JH.** Involvement of neuropeptide Y Y1 receptors in the regulation of neuroendocrine corticotropin-releasing hormone neuronal activity. *Endocrinology* 148: 3666-3673, 2007.
223. **Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S,**

- Matchar D, Silberstein S, Smith TR, Purdy RA, and Saiers J.** Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT_{1B/1D} Agonists) in the Acute Treatment of Migraine. *Headache* 44: 414-425, 2004.
224. **Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, and Smith J.** Randomized, Double-blind, Placebo-controlled, Phase II Trial of ALD403, an anti-CGRP peptide antibody in the prevention of frequent episodic migraine. *Lancet Neurology* 13: 1100-1107, 2014.
225. **Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, and Grayzel DS.** CGRP Monoclonal Antibody LY2951742 for the Prevention of Migraine: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. *Lancet Neurology* 13: 885-892, 2014.
226. **Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, and Eberlein W.** Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. *British Journal of Pharmacology* 129: 420-423, 2000.
227. **Drummond PD.** Predisposing, precipitating and relieving factors in different categories of headache. *Headache* 25: 16-22, 1985.
228. **Drummond PD, and Lance JW.** Neurovascular disturbances in headache patients. *Clinical and Experimental Neurology* 20: 93-99, 1984.
229. **Dube MG, Sahu A, Kalra PS, and Kalra SP.** Neuropeptide Y release is elevated from the microdissected paraventricular nucleus of food-deprived rats: an in vitro study. *Endocrinology* 131: 684-688, 1992.
230. **Dunckley P, Wise RG, Fairhurst M, Hobden P, Aziz Q, Chang L, and Tracey I.** A comparison of visceral and somatic pain processing in the human brainstem using functional magnetic resonance imaging. *J Neurosci* 25: 7333-7341, 2005.
231. **Durham PL, and Russo AF.** Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. *Journal of Neuroscience* 19: 3423-3429, 1999.
232. **Eadie MJ.** A History of Migraine. In: *The Migraine Brain*, edited by Borsook D, May A, Goadsby PJ, and Hargreaves R. New York: Oxford University Press, 2012, p. 3-16.
233. **Earl NL, McDonald SA, Lowy MT, and 4991W93 Investigator Group.** Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine. *Cephalalgia* 19: 357, 1999.
234. **Ebersberger A, Averbeck B, Messlinger K, and Reeh PW.** Release of substance P, calcitonin gene-related peptide and prostaglandin E₂ from rat dura mater encephali following electrical and chemical stimulation *in vitro*. *Neuroscience* 89: 901-907, 1999.
235. **Ebersberger A, Schaible H-G, Averbeck B, and Richter F.** Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? *Annals Neurology* 41: 7-13, 2001.
236. **Edelmayer RM, Vanderah TW, Majuta L, Zhang ET, Fioravanti B, De Felice M, Chichorro JG, Ossipov MH, King T, Lai J, Kori SH, Nelsen AC, Cannon KE, Heinricher MM, and Porreca F.** Medullary pain facilitating neurons mediate allodynia in headache-related pain. *Ann Neurol* 65: 184-193, 2009.
237. **Edvinsson L, Brodin E, Jansen I, and Uddman R.** Neurokinin A in cerebral vessels: characterization, localization and effects in vitro. *Regulatory Peptides* 20: 181-197, 1988.
238. **Edvinsson L, Eftekhari S, Salvatore CA, and Warfvinge K.** Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. *Mol Cell Neurosci* 46: 333-339, 2011.

239. **Edvinsson L, Emson P, McCulloch J, Tatemoto K, and Uddman R.** Neuropeptide Y: cerebrovascular innervation and vasomotor effects in the cat. *Neuroscience Letters* 43: 79-84, 1983.
240. **Edvinsson L, and Goadsby PJ.** Neuropeptides in headache. *European Journal of Neurology* 5: 329-341, 1998.
241. **Edvinsson L, and Goadsby PJ.** Neuropeptides in the cerebral circulation: relevance to headache. *Cephalalgia* 15: 272-278, 1995.
242. **Edvinsson L, Mulder H, Goadsby PJ, and Uddman R.** Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. *Journal of the Autonomic Nervous System* 70: 15-22, 1998.
243. **Edvinsson L, and Tfelt-Hansen P.** The blood-brain barrier in migraine treatment. *Cephalalgia* 28: 1245-1258, 2008.
244. **Edwards CM, Abusnana S, Sunter D, Murphy KG, Ghatei MA, and Bloom SR.** The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. *Journal of Endocrinology* 160: R7-12, 1999.
245. **Eftekhari S, and Edvinsson L.** Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. *Therapeutic advances in neurological disorders* 3: 369-378, 2010.
246. **Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, and Edvinsson L.** Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. *Neuroscience* 169: 683-696, 2010.
247. **Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, and Edvinsson L.** Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. *Brain Res* 2014.
248. **Eikermann-Haerter K, Dilekoz E, Kudo C, Savitz SI, Waeber C, Baum MJ, Ferrari MD, van den Maagdenberg AM, Moskowitz MA, and Ayata C.** Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. *J Clin Invest* 119: 99-109, 2009.
249. **Eikermann-Haerter K, Lee JH, Yuzawa I, Liu CH, Zhou Z, Shin HK, Zheng Y, Qin T, Kurth T, Waeber C, Ferrari MD, van den Maagdenberg AM, Moskowitz MA, and Ayata C.** Migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations. *Circulation* 125: 335-345, 2012.
250. **Eising E, de Vries B, Ferrari MD, Terwindt GM, and van den Maagdenberg AM.** Pearls and pitfalls in genetic studies of migraine. *Cephalalgia* 33: 614-625, 2013.
251. **Elias CF, Kelly JF, Lee CE, Ahima RS, Drucker DJ, Saper CB, and Elmquist JK.** Chemical characterization of leptin-activated neurons in the rat brain. *J Comp Neurol* 423: 261-281, 2000.
252. **Elias CF, Saper CB, Maratos-Flier E, Tritos NA, Lee C, Kelly J, Tatro JB, Hoffman GE, Ollmann MM, Barsh GS, Sakurai T, Yanagisawa M, and Elmquist JK.** Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. *J Comp Neurol* 402: 442-459, 1998.
253. **Ellrich J.** Brain stem reflexes: probing human trigeminal nociception. *News in the Physiological Sciences* 15: 94-97, 2000.
254. **Ellrich J, Messlinger K, Chiang CY, and Hu JW.** Modulation of neuronal activity in the nucleus raphe magnus by the 5-HT(1)-receptor agonist naratriptan in rat. *Pain* 90: 227-231, 2001.

255. **Elmquist JK, Ahima RS, Elias CF, Flier JS, and Saper CB.** Leptin activates distinct projections from the dorsomedial and ventromedial hypothalamic nuclei. *Proc Natl Acad Sci U S A* 95: 741-746, 1998.
256. **Elmquist JK, Ahima RS, Maratos-Flier E, Flier JS, and Saper CB.** Leptin activates neurons in ventrobasal hypothalamus and brainstem. *Endocrinology* 138: 839-842, 1997.
257. **Espana RA, Plahn S, and Berridge CW.** Circadian-dependent and circadian-independent behavioral actions of hypocretin/orexin. *Brain Res* 943: 224-236, 2002.
258. **Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, Saper CB, and Scammell TE.** Fos expression in orexin neurons varies with behavioral state. *J Neurosci* 21: 1656-1662, 2001.
259. **Fabrizius M, Fuhr S, Bhatia R, Boutelle M, Hashemi P, Strong AJ, and Lauritzen M.** Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. *Brain* 129: 778-790, 2006.
260. **Farkkila M, Diener HC, Geraud G, Lainez M, Schoenen J, Harner N, Pilgrim A, and Reuter U.** Efficacy and tolerability of lasmiditan, an oral 5-HT_{1F} receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. *Lancet Neurol* 11: 405-413, 2012.
261. **Fava A, Pirritano D, Consoli D, Plastino M, Casalinuovo F, Cristofaro S, Colica C, Ermio C, De Bartolo M, Opipari C, Lanzo R, Consoli A, and Bosco D.** Chronic migraine in women is associated with insulin resistance: a cross-sectional study. *Eur J Neurol* 2013.
262. **Felgenhauer K.** Protein size and cerebrospinal fluid composition. *Klinische Wochenschrift* 52: 1158-1164, 1974.
263. **Felig P, Marliss E, Owen OE, and Cahill GF.** Blood glucose and gluconeogenesis in fasting man. *Arch Intern Med* 123: 293-298, 1969.
264. **Feniuk W, Humphrey PP, and Perren MJ.** GR43175 does not share the complex pharmacology of the ergots. *Cephalalgia* 9: 35-39, 1989.
265. **Feniuk W, Humphrey PPA, and Perren MJ.** The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. *British Journal of Pharmacology* 96: 83-90, 1989.
266. **Feniuk W, Humphrey PPA, Perren MJ, Connor HE, and Whalley ET.** Rationale for the use of 5-HT₁-like agonists in the treatment of migraine. *Journal of Neurology* 238: S57-S61, 1991.
267. **Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauss M, and Diener HC.** Acute treatment of migraine with the selective 5-HT_{1F} receptor agonist lasmiditan - A randomised proof-of-concept trial. *Cephalalgia* 30: 1170-1178, 2010.
268. **Ferrari MD, Klever RR, Terwindt GM, Ayata C, and van den Maagdenberg AM.** Migraine pathophysiology: lessons from mouse models and human genetics. *Lancet Neurol* 14: 65-80, 2015.
269. **Fields H.** State-dependent opioid control of pain. *Nat Rev Neurosci* 5: 565-575, 2004.
270. **Fields HL.** Pain modulation: expectation, opioid analgesia and virtual pain. *Progress in Brain Research* 122: 245-253, 2000.
271. **Fields HL, Basbaum AI, Clanton CH, and Anderson SD.** Nucleus raphe magnus inhibition of spinal cord dorsal horn neurons. *Brain Res* 126: 441-453, 1977.
272. **Fields HL, Bry J, Hentall I, and Zorman G.** The activity of neurons in the rostral medulla of the rat during withdrawal from noxious heat. *J Neurosci* 3: 2545-2552, 1983.

273. **Fields HL, and Heinricher MM.** Anatomy and physiology of a nociceptive modulatory system. *Philosophical Transactions of the Royal Society London B Biological Sciences* 308: 361-374, 1985.
274. **Fields HL, Heinricher MM, and Mason P.** Neurotransmitters in nociceptive modulatory circuits. *Annual Review of Neuroscience* 14: 219-245, 1991.
275. **Fields HL, Vanegas H, Hentall ID, and Zorman G.** Evidence that disinhibition of brain stem neurones contributes to morphine analgesia. *Nature* 306: 684-686, 1983.
276. **Fischer MJ, Koulchitsky S, and Messlinger K.** The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. *J Neurosci* 25: 5877-5883, 2005.
277. **Fleetwood-Walker SM, Hope PJ, and Mitchell R.** Antinociceptive actions of descending dopaminergic tracts on cat and rat dorsal horn somatosensory neurones. *J Physiol* 399: 335-348, 1988.
278. **Foo H, and Mason P.** Brainstem modulation of pain during sleep and waking. *Sleep Med Rev* 7: 145-154, 2003.
279. **Foo H, and Mason P.** Sensory suppression during feeding. *Proc Natl Acad Sci U S A* 102: 16865-16869, 2005.
280. **Fox MD, and Raichle ME.** Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. *Nat Rev Neurosci* 8: 700-711, 2007.
281. **Fox MD, Snyder AZ, Vincent JL, and Raichle ME.** Intrinsic fluctuations within cortical systems account for intertrial variability in human behavior. *Neuron* 56: 171-184, 2007.
282. **Frederich RC, Löllmann B, Hamann A, Napolitano-Rosen A, Kahn BB, Lowell BB, and Flier JS.** Expression of ob mRNA and its encoded protein in rodents. Impact of nutrition and obesity. *J Clin Invest* 96: 1658-1663, 1995.
283. **Freilinger T, Anttila V, de Vries B, Malik R, Kallela M, Terwindt GM, Pozo-Rosich P, Winsvold B, Nyholt DR, van Oosterhout WP, Artto V, Todt U, Hamalainen E, Fernandez-Morales J, Louter MA, Kaunisto MA, Schoenen J, Raitakari O, Lehtimäki T, Vila-Pueyo M, Gobel H, Wichmann E, Sintas C, Uitterlinden AG, Hofman A, Rivadeneira F, Heinze A, Tronvik E, van Duijn CM, Kaprio J, Cormand B, Wessman M, Frants RR, Meitinger T, Müller-Myhsok B, Zwart JA, Farkkila M, Macaya A, Ferrari MD, Kubisch C, Palotie A, Dichgans M, van den Maagdenberg AM, and International Headache Genetics C.** Genome-wide association analysis identifies susceptibility loci for migraine without aura. *Nat Genet* 44: 777-782, 2012.
284. **Friedman BW, Garber L, Yoon A, Solorzano C, Wollowitz A, Esses D, Bijur PE, and Gallagher EJ.** Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. *Neurology (Minneapolis)* 82: 1-8, 2014.
285. **Friedman JM, and Halaas JL.** Leptin and the regulation of body weight in mammals. *Nature* 395: 763-770, 1998.
286. **Fuller PM, Saper CB, and Lu J.** The pontine REM switch: past and present. *J Physiol* 584: 735-741, 2007.
287. **Fulton S, Pissios P, Manchon RP, Stiles L, Frank L, Pothos EN, Maratos-Flier E, and Flier JS.** Leptin regulation of the mesoaccumbens dopamine pathway. *Neuron* 51: 811-822, 2006.
288. **Gais S, Born J, Peters A, Schultes B, Heindl B, Fehm HL, and Werner K.** Hypoglycemia counterregulation during sleep. *Sleep* 26: 55-59, 2003.

289. **Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Trequattrini A, and Palumbo R.** Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. *Cephalalgia* 15: 384-390, 1995.
290. **Gangwisch JE, Malaspina D, Boden-Albala B, and Heymsfield SB.** Inadequate sleep as a risk factor for obesity: analyses of the NHANES I. *Sleep* 28: 1289-1296, 2005.
291. **Gao K, and Mason P.** Physiological and anatomic evidence for functional subclasses of serotonergic raphe magnus cells. *J Comp Neurol* 439: 426-439, 2001.
292. **Gao K, and Mason P.** Serotonergic Raphe magnus cells that respond to noxious tail heat are not ON or OFF cells. *J Neurophysiol* 84: 1719-1725, 2000.
293. **Geerling JC, and Loewy AD.** Aldosterone-sensitive neurons in the nucleus of the solitary tract: efferent projections. *J Comp Neurol* 497: 223-250, 2006.
294. **Gelfand AA, and Goadsby PJ.** A neurologist's guide to acute migraine therapy in the emergency room. *The NeuroHospitalist* 2: 51-59, 2012.
295. **Gervil M, Ulrich V, Kaprio J, Olesen J, and Russell MB.** The relative role of genetic and environmental factors in migraine without aura. *Neurology* 53: 995-999, 1999.
296. **Gervil M, Ulrich V, Kaprio J, and Russell MB.** Is the genetic liability in multifactorial disorders higher in concordant than discordant monozygotic twin pairs? A population-based family twin study of migraine without aura. *Eur J Neurol* 8: 231-235, 2001.
297. **Gervil M, Ulrich V, Kyvik KO, Olesen J, and Russell MB.** Migraine without aura: a population-based twin study. *Ann Neurol* 46: 606-611, 1999.
298. **Giffin NJ, and Kaube H.** The electrophysiology of migraine. *Current Opinion in Neurology* 15: 303-309, 2002.
299. **Giffin NJ, Lipton RB, Silberstein SD, Olesen J, and Goadsby PJ.** The migraine postdrome. An electronic diary study. *Neurology (Minneapolis)* in press, 2016.
300. **Giffin NJ, Ruggiero L, Lipton RB, Silberstein S, Tvedskov JF, Olesen J, Altman J, Goadsby PJ, and Macrae A.** Premonitory symptoms in migraine: an electronic diary study. *Neurology* 60: 935-940, 2003.
301. **Glasow A, and Bornstein SR.** Leptin and the adrenal gland. *Eur J Clin Invest* 30 Suppl 3: 39-45, 2000.
302. **Glasow A, Haidan A, Hilbers U, Breidert M, Gillespie J, Scherbaum WA, Chrousos GP, and Bornstein SR.** Expression of Ob receptor in normal human adrenals: differential regulation of adrenocortical and adrenomedullary function by leptin. *J Clin Endocrinol Metab* 83: 4459-4466, 1998.
303. **Global Burden of Disease Study.** Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 386: 743-800, 2015.
304. **Goadsby PJ.** Characteristics of facial nerve elicited cerebral vasodilatation determined with laser Doppler flowmetry. *American Journal of Physiology* 260: R255-R262, 1991.
305. **Goadsby PJ.** Effect of stimulation of the facial nerve on regional cerebral blood flow and glucose utilization in cats. *American Journal of Physiology* 257: R517-R521, 1989.
306. **Goadsby PJ.** Incredible progress in migraine for an era of better care. *Nature Reviews Neurology* 11: 621-622, 2015.
307. **Goadsby PJ.** Migraine, aura and cortical spreading depression: why are we still talking about it? *Annals of Neurology* 49: 4-6, 2001.
308. **Goadsby PJ.** Parallel concept of migraine pathogenesis. *Annals of Neurology* 51: 140, 2002.

309. **Goadsby PJ.** Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. *Lancet Neurology* 1: 37-43, 2002.
310. **Goadsby PJ.** The pharmacology of headache. *Progress in Neurobiology* 62: 509-525, 2000.
311. **Goadsby PJ.** Sphenopalatine ganglion stimulation increases regional cerebral blood flow independent of glucose utilization in the cat. *Brain Research* 506: 145-148, 1990.
312. **Goadsby PJ.** Trigeminal autonomic cephalalgias. *Continuum Lifelong Learning Neurology* 18: 883-895, 2012.
313. **Goadsby PJ, and Akerman S.** The trigeminovascular system does not require a peripheral sensory input to be activated--migraine is a central disorder. Focus on 'Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system'. *Cephalalgia* 32: 3-5, 2012.
314. **Goadsby PJ, Akerman S, and Storer RJ.** Evidence for postjunctional serotonin (5-HT₁) receptors in the trigeminocervical complex. *Annals of Neurology* 50: 804-807, 2001.
315. **Goadsby PJ, Cittadini E, and Cohen AS.** Trigeminal autonomic cephalalgias: paroxysmal hemicrania, SUNCT/SUNA and hemicrania continua. *Seminars in Neurology* 30: 186-191, 2010.
316. **Goadsby PJ, and Classey JD.** Evidence for 5-HT_{1B}, 5-HT_{1D} and 5-HT_{1F} receptor inhibitory effects on trigeminal neurons with craniovascular input. *Neuroscience* 122: 491-498, 2003.
317. **Goadsby PJ, and Classey JD.** Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. *Brain Research* 875: 119-124, 2000.
318. **Goadsby PJ, Dodick DW, Almas M, Diener HC, Tfelt-Hansen P, Lipton RB, and Parsons B.** Treatment-emergent CNS symptoms following triptan therapy are part of the attack. *Cephalalgia* 27: 254-262, 2007.
319. **Goadsby PJ, and Duckworth JW.** Low frequency stimulation of the locus coeruleus reduces regional cerebral blood flow in the spinalized cat. *Brain Research* 476: 71-77, 1989.
320. **Goadsby PJ, and Edvinsson L.** Human *in vivo* evidence for trigeminovascular activation in cluster headache. *Brain* 117: 427-434, 1994.
321. **Goadsby PJ, and Edvinsson L.** Neuropeptide changes in a case of chronic paroxysmal hemicrania- evidence for trigemino-parasympathetic activation. *Cephalalgia* 16: 448-450, 1996.
322. **Goadsby PJ, and Edvinsson L.** Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. *Headache* 34: 394-399, 1994.
323. **Goadsby PJ, and Edvinsson L.** The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. *Annals of Neurology* 33: 48-56, 1993.
324. **Goadsby PJ, Edvinsson L, and Ekman R.** Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. *Annals of Neurology* 23: 193-196, 1988.
325. **Goadsby PJ, Edvinsson L, and Ekman R.** Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. *Annals of Neurology* 28: 183-187, 1990.
326. **Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, and Mills JG.** Randomized double blind, placebo-controlled proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. *Cephalalgia* 29: 742-750, 2009.
327. **Goadsby PJ, Grosberg BM, Mauskop A, and Cady R.** Effect of non-invasive vagus nerve stimulation on acute migraine: an open label pilot study. *Cephalalgia* 34: 986-993, 2014.

328. **Goadsby PJ, and Gundlach AL.** Localization of [³H]-dihydroergotamine binding sites in the cat central nervous system: relevance to migraine. *Annals of Neurology* 29: 91-94, 1991.
329. **Goadsby PJ, and Hoskin KL.** Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. *Pain* 82: 15-22, 1999.
330. **Goadsby PJ, and Hoskin KL.** The distribution of trigeminovascular afferents in the nonhuman primate brain *Macaca nemestrina*: a c-fos immunocytochemical study. *Journal of Anatomy* 190: 367-375, 1997.
331. **Goadsby PJ, and Hoskin KL.** Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)_{1B/D} receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? *Pain* 67: 355-359, 1996.
332. **Goadsby PJ, and Hoskin KL.** Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5-HT_{1B/1D} receptor: a central action in migraine? *Annals of Neurology* 43: 711-718, 1998.
333. **Goadsby PJ, and Knight YE.** Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. *Cephalalgia* 17: 153-158, 1997.
334. **Goadsby PJ, and Knight YE.** Inhibition of trigeminal neurons after intravenous administration of naratriptan through an action at the serotonin (5HT_{1B/1D}) receptors. *British Journal of Pharmacology* 122: 918-922, 1997.
335. **Goadsby PJ, Lambert GA, and Lance JW.** Differential effects on the internal and external carotid circulation of the monkey evoked by locus coeruleus stimulation. *Brain Research* 249: 247-254, 1982.
336. **Goadsby PJ, Lambert GA, and Lance JW.** Effects of locus coeruleus stimulation on carotid vascular resistance in the cat. *Brain Research* 278: 175-183, 1983.
337. **Goadsby PJ, Lambert GA, and Lance JW.** The mechanism of cerebrovascular vasoconstriction in response to locus coeruleus stimulation. *Brain Research* 326: 213-217, 1985.
338. **Goadsby PJ, Lambert GA, and Lance JW.** The peripheral pathway for extracranial vasodilatation in the cat. *Journal of the Autonomic Nervous System* 10: 145-155, 1984.
339. **Goadsby PJ, and Lipton RB.** A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic features, including new cases. *Brain* 120: 193-209, 1997.
340. **Goadsby PJ, Lipton RB, and Ferrari MD.** Migraine- current understanding and treatment. *New England Journal of Medicine* 346: 257-270, 2002.
341. **Goadsby PJ, and Macdonald GJ.** Extracranial vasodilatation mediated by VIP (Vasoactive Intestinal Polypeptide). *Brain Research* 329: 285-288, 1985.
342. **Goadsby PJ, Piper RD, Lambert GA, and Lance JW.** The effect of activation of the nucleus raphe dorsalis (DRN) on carotid blood flow. I The Monkey. *American Journal of Physiology* 248: R257-R262, 1985.
343. **Goadsby PJ, Piper RD, Lambert GA, and Lance JW.** The effect of activation of the nucleus raphe dorsalis (DRN) on carotid blood flow. II The Cat. *American Journal of Physiology* 248: R263-R269, 1985.
344. **Goadsby PJ, and Shelley S.** High frequency stimulation of the facial nerve results in local cortical release of vasoactive intestinal polypeptide in the anesthetised cat. *Neuroscience Letters* 112: 282-289, 1990.
345. **Goadsby PJ, and Sprenger T.** Current practice and future directions in the management of migraine: acute and preventive. *The Lancet Neurology* 9: 285-298, 2010.

346. **Goadsby PJ, and Zagami AS.** Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. *Brain* 114: 1001-1011, 1991.
347. **Goadsby PJ, and Zagami AS.** Thalamic processing of craniovascular pain in the cat: a 2-deoxyglucose study. *Proceedings of the Society for Neuroscience* 16: 1144, 1990.
348. **Goder R, Fritzer G, Kapsokalyvas A, Kropp P, Niederberger U, Streng H, Gerber WD, and Aldenhoff JB.** Polysomnographic findings in nights preceding a migraine attack. *Cephalalgia* 21: 31-37, 2001.
349. **Goldstein DJ, Offen WW, Klein EG, Phebus LA, Hipskind P, Johnson KW, and Ryan RE.** Lanepitant, an NK-1 antagonist, in migraine prevention. *Cephalalgia* 21: 102-106, 2001.
350. **Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, and Ferrari MD.** Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. *The Lancet* 358: 1230-1234, 2001.
351. **Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, and Mathew NT.** Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. *Cephalalgia* 17: 785-790, 1997.
352. **Goldstein J, Dahlof CGH, Diener H-C, Olesen J, Schellens R, Senard JM, Simard D, and Steiner TJ.** Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. *Cephalalgia* 16: 497-502, 1996.
353. **Gomez-Mancilla B, Brand R, Jurgens TP, Gobel H, Sommer C, Straube A, Evers S, Sommer M, Campos V, Kalkman HO, Hariry S, Pezous N, Johns D, Diener HC, and for the BGGSG.** Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. *Cephalalgia* 34: 103-113, 2014.
354. **Gooley JJ, Schomer A, and Saper CB.** The dorsomedial hypothalamic nucleus is critical for the expression of food-entrainable circadian rhythms. *Nat Neurosci* 9: 398-407, 2006.
355. **Gordon ML, Lipton RB, Brown SL, Nakraseive C, Russell M, Pollack SZ, Korn ML, Merriam A, Solomon S, and van Praag HM.** Headache and cortisol responses to m-chlorophenylpiperazine are highly correlated. *Cephalalgia* 13: 400-405, 1993.
356. **Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, and Renger JJ.** Orexin receptors as therapeutic drug targets. *Prog Brain Res* 198: 163-188, 2012.
357. **Gowers WR.** *A Manual of Diseases of the Nervous System*. Philadelphia: P. Blakiston, Son & Co, 1899, p. 1357.
358. **Graham JR, and Wolff HG.** Mechanism of migraine headache and action of ergotamine tartrate. *Archives of Neurology and Psychiatry* 39: 737-763, 1938.
359. **Granziera C, Daducci A, Romascano D, Roche A, Helms G, Krueger G, and Hadjikhani N.** Structural abnormalities in the thalamus of migraineurs with aura: A multiparametric study at 3 T. *Hum Brain Mapp* 2013.
360. **Gray H.** *Anatomy of the Human Body* (www.bartleby.com/107/). Philadelphia: Lea & Febiger, 1918.
361. **Greco R, Gasperi V, Maccarrone M, and Tassorelli C.** The endocannabinoid system and migraine. *Exp Neurol* 224: 85-91, 2010.
362. **Grill HJ, Ginsberg AB, Seeley RJ, and Kaplan JM.** Brainstem application of melanocortin receptor ligands produces long-lasting effects on feeding and body weight. *J Neurosci* 18: 10128-10135, 1998.

363. **Grill HJ, Schwartz MW, Kaplan JM, Foxhall JS, Breininger J, and Baskin DG.** Evidence that the caudal brainstem is a target for the inhibitory effect of leptin on food intake. *Endocrinology* 143: 239-246, 2002.
364. **Guldiken B, Guldiken S, Demir M, Turgut N, and Tugrul A.** Low leptin levels in migraine: a case control study. *Headache* 48: 1103-1107, 2008.
365. **Guo Z, and Cao YQ.** Over-Expression of TRESK K(+) Channels Reduces the Excitability of Trigeminal Ganglion Nociceptors. *PLoS One* 9: e87029, 2014.
366. **Hadjikhani N, Sanchez del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Wong KK, Cutrer FM, Rosen BR, Tootell RBH, Sorensen AG, and Moskowitz MA.** Mechanisms of migraine aura revealed by functional MRI in human visual cortex. *Proceedings of the National Academy of Sciences (USA)* 98: 4687-4692, 2001.
367. **Hamblin MW, Ariani K, Adriaenssens PI, and Ciaranello RD.** [³H]Dihydroergotamine as a high-affinity, slowly dissociating radioligand for 5HT_{1b} binding sites in rat brain membranes: evidence for guanine nucleotide regulation of agonist affinity states. *Journal of Pharmacology and Experimental Therapeutics* 243: 989-1001, 1987.
368. **Hans M, Luvisetto S, Williams ME, Spagnolo M, Urrutia A, Tottene A, Brust PF, Johnson EC, Harpold MM, Stauderman KA, and Pietrobon D.** Functional consequences of mutations in the human alpha(1A) calcium channel subunit linked to familial hemiplegic migraine. *Journal of Neuroscience* 19: 1610-1619, 1999.
369. **Hansen JM, Baca SM, VanValkenburgh P, and Charles A.** Distinctive anatomical and physiological features of migraine aura revealed by 18 years of recording. *Brain* 136: 3589-3595, 2013.
370. **Hansen JM, Bolla M, Magis D, de Pasqua V, Ashina M, Thomsen LL, Olesen J, and Schoenen J.** Habituation of evoked responses is greater in patients with familial hemiplegic migraine than in controls: a contrast with the common forms of migraine. *Eur J Neurol* 18: 478-485, 2011.
371. **Hansen JM, Hauge AW, Ashina M, and Olesen J.** Trigger factors for familial hemiplegic migraine. *Cephalalgia* 31: 1274-1281, 2011.
372. **Hansen JM, Hauge AW, Olesen J, and Ashina M.** Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. *Cephalalgia* 30: 1179-1186, 2010.
373. **Hansen JM, Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Goadsby PJ, and Charles A.** Migraine headache is present in the aura phase: a prospective study. *Neurology* 79: 2044-2049, 2012.
374. **Hansen JM, Thomsen LL, Marconi R, Casari G, Olesen J, and Ashina M.** Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. *Cephalalgia* 28: 367-375, 2008.
375. **Hansen JM, Thomsen LL, Olesen J, and Ashina M.** Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine. *Headache* 51: 544-553, 2011.
376. **Hansen JM, Thomsen LL, Olesen J, and Ashina M.** Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. *Cephalalgia* 28: 496-505, 2008.
377. **Hanson ES, Levin N, and Dallman MF.** Elevated corticosterone is not required for the rapid induction of neuropeptide Y gene expression by an overnight fast. *Endocrinology* 138: 1041-1047, 1997.

378. **Harper AM, MacKenzie ET, McCulloch J, and Pickard JD.** Migraine and the blood-brain barrier. *Lancet* 1 (8020): 1034-1036, 1977.
379. **Harrison SD, Balawi SA, Feinmann C, and Harris M.** Atypical facial pain: a double-blind placebo-controlled crossover pilot study of subcutaneous sumatriptan. *Eur Neuropsychopharmacol* 7: 83-88, 1997.
380. **Hasler G, Buysse DJ, Klaghofer R, Gamma A, Ajdacic V, Eich D, Rössler W, and Angst J.** The association between short sleep duration and obesity in young adults: a 13-year prospective study. *Sleep* 27: 661-666, 2004.
381. **Hauge AW, Asghar MS, Schytz HW, Christensen K, and Olesen J.** Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. *Lancet Neurology* 8: 718-723, 2009.
382. **Hay DL, Chen S, Lutz TA, Parkes DG, and Roth JD.** Amylin: Pharmacology, Physiology, and Clinical Potential. *Pharmacol Rev* 67: 564-600, 2015.
383. **Haynes AC, Jackson B, Overend P, Buckingham RE, Wilson S, Tadayyon M, and Arch JR.** Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. *Peptides* 20: 1099-1105, 1999.
384. **Headache Classification Committee of The International Headache Society.** Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. *Cephalalgia* 8: 1-96, 1988.
385. **Headache Classification Committee of The International Headache Society.** The International Classification of Headache Disorders (second edition). *Cephalalgia* 24: 1-160, 2004.
386. **Headache Classification Committee of the International Headache Society.** The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia* 33: 629-808, 2013.
387. **Heilig M.** The NPY system in stress, anxiety and depression. *Neuropeptides* 38: 213-224, 2004.
388. **Heiman ML, Ahima RS, Craft LS, Schoner B, Stephens TW, and Flier JS.** Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. *Endocrinology* 138: 3859-3863, 1997.
389. **Heinrichs SC, Menzaghi F, Pich EM, Hauger RL, and Koob GF.** Corticotropin-releasing factor in the paraventricular nucleus modulates feeding induced by neuropeptide Y. *Brain Res* 611: 18-24, 1993.
390. **Held K, Antonijevic I, Murck H, Kuenzel H, and Steiger A.** Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls. *Psychoneuroendocrinology* 31: 100-107, 2006.
391. **Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge J, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, and Ho TW.** Randomized controlled trial of the CGRP receptor antagonist, MK-3207, in the acute treatment of migraine. *Cephalalgia* 31: 712-722, 2011.
392. **Hisano S, Kagotani Y, Tsuruo Y, Daikoku S, Chihara K, and Whitnall MH.** Localization of glucocorticoid receptor in neuropeptide Y-containing neurons in the arcuate nucleus of the rat hypothalamus. *Neurosci Lett* 95: 13-18, 1988.
393. **Ho T, Mannix L, Fan X, Assaid C, Furtak C, Jones C, Lines CR, Rapoport A, and MK-0974 Protocol 004 Study Group.** Randomized controlled trial of an oral CGRP antagonist, MK-0974, in acute treatment of migraine. *Neurology* 70: 1004-1012, 2008.

394. **Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, and Michelson D.** Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. *Neurology (Minneapolis)* 83: 958-966, 2014.
395. **Ho TW, Edvinsson L, and Goadsby PJ.** CGRP and its receptors provide new insights into migraine pathophysiology. *Nature Reviews Neurology* 6: 573-582, 2010.
396. **Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, and Winner PK.** Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. *Lancet* 372: 2115-2123, 2008.
397. **Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, Fan X, Aurora SK, Brandes JL, Fei K, Beebe L, Lines C, and Krucoff MW.** Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. *Headache* 52: 224-235, 2012.
398. **Ho YC, Lee HJ, Tung LW, Liao YY, Fu SY, Teng SF, Liao HT, Mackie K, and Chiou LC.** Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. *J Neurosci* 31: 14600-14610, 2011.
399. **Hoffmann J, Lo H, Neeb L, Martus P, and Reuter U.** Weather sensitivity in migraineurs. *J Neurol* 258: 596-602, 2010.
400. **Hoffmann J, M. M-O, Suprongsinchai W, Akerman S, Lasalandra M, Zhao Y, Matsson L, Economou-Olsson E, Lee HY, Ptacek LJ, and Goadsby PJ.** The functional consequence of the ckl d t44a mutation on nociceptive activation of the trigeminocervical complex. *Cephalalgia* 35: 8, 2015.
401. **Hoffmann J, and Reuber A.** Migraine and triggers: post hoc ergo propter hoc? *Curr Pain Headache Rep* 17: 370, 2013.
402. **Hoffmann J, Suprongsinchai W, Akerman S, Andreou AP, Winrow CJ, Renger J, Hargreaves R, and Goadsby PJ.** Evidence for orexinergic mechanisms in migraine. *Neurobiology of Disease* 74: 137-143, 2015.
403. **Hoivik HO, Laurijssens BE, Harnisch LO, Twomey CK, Dixon RM, Kirkham AJ, Williams PM, Wentz AL, and Lunn MW.** Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. *Cephalalgia* 30: 1458-1467, 2010.
404. **Hokfelt T, Arvidsson U, Ceccatelli S, Cortes R, Cullheim S, and Dagerlind A.** Calcitonin gene-related peptide in the brain, spinal cord, and some peripheral systems. *Ann N Y Acad Sci* 657: 119-134, 1992.
405. **Holland P, and Goadsby PJ.** The hypothalamic orexinergic system: pain and primary headaches. *Headache* 47: 951-962, 2007.
406. **Holland PR, Akerman S, Andreou AP, Karsan N, Wemmie JA, and Goadsby PJ.** Acid-sensing ion channel-1: a novel therapeutic target for migraine with aura. *Annals of Neurology* 72: 559-563, 2012.
407. **Holland PR, Akerman S, and Goadsby PJ.** Cortical spreading depression associated cerebral blood flow changes induced by mechanical stimulation are modulated by AMPA and GABA receptors. *Cephalalgia* 30: 519-527, 2010.
408. **Holland PR, Akerman S, and Goadsby PJ.** Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. *European Journal of Neuroscience* 24: 2825-2833, 2006.

409. **Holland PR, Akerman S, and Goadsby PJ.** Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. *Journal of Pharmacology and Experimental Therapeutics* 315: 1380-1385, 2005.
410. **Holland PR, Akerman S, Lasalandra MP, and Goadsby PJ.** Antinociceptive effects of Orexin A in the ventrolateral periaqueductal gray are blocked by 5HT 1B/D receptor antagonism. *Headache* 48: S6, 2008.
411. **Holland PR, and Goadsby PJ.** The hypothalamic orexinergic system: pain and primary headaches. *Headache* 47: 951-962, 2007.
412. **Holstege G, Kuypers HGJM, and Martin GF.** The anatomy of brain stem pathways to the spinal cord in cat. A labelled amino acid tracing study. In: *Descending Spinal Pathways to the Spinal Cord Progress in Brain Research*, edited by Kuypers HGJMElsevier Biomedical Press, 1982, p. 145-175.
413. **Holstege JC, Van Dijken H, Buijs RM, Goedknecht H, Gosens T, and Bongers CM.** Distribution of dopamine immunoreactivity in the rat, cat and monkey spinal cord. *J Comp Neurol* 376: 631-652, 1996.
414. **Hommel JD, Trinko R, Sears RM, Georgescu D, Liu ZW, Gao XB, Thurmon JJ, Marinelli M, and DiLeone RJ.** Leptin receptor signaling in midbrain dopamine neurons regulates feeding. *Neuron* 51: 801-810, 2006.
415. **Horvath TL, and Gao XB.** Input organization and plasticity of hypocretin neurons: possible clues to obesity's association with insomnia. *Cell Metab* 1: 279-286, 2005.
416. **Horvath TL, Peyron C, Diano S, Ivanov A, Aston-Jones G, Kilduff TS, and van Den Pol AN.** Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. *J Comp Neurol* 415: 145-159, 1999.
417. **Hoskin KL, Bulmer DCE, and Goadsby PJ.** Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. *Neuroscience Letters* 266: 173-176, 1999.
418. **Hoskin KL, Bulmer DCE, Lasalandra M, Jonkman A, and Goadsby PJ.** Fos expression in the midbrain periaqueductal grey after trigeminovascular stimulation. *Journal of Anatomy* 198: 29-35, 2001.
419. **Hoskin KL, Kaube H, and Goadsby PJ.** Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. *Brain* 119: 1419-1428, 1996.
420. **Hoskin KL, Knight YE, and Goadsby PJ.** Zolmitriptan inhibits c-Fos expression in the dorsal horn of the medulla and upper cervical horn evoked by sagittal sinus stimulation in the cat. *Cephalalgia* 16: 355, 1996.
421. **Hoskin KL, Lambert GA, Donaldson C, and Zagami AS.** The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. *Brain Res* 998: 91-99, 2004.
422. **Hoskin KL, Zagami A, and Goadsby PJ.** Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. *Journal of Anatomy* 194: 579-588, 1999.
423. **Hosoya Y, Matsushita M, and Sugiura Y.** A direct hypothalamic projection to the superior salivatory nucleus neurons in the rat. A study using anterograde autoradiographic and retrograde HRP methods. *Brain Res* 266: 329-333, 1983.
424. **Hosoya Y, Sugiura Y, Ito R, and Kohno K.** Descending projections from the hypothalamic paraventricular nucleus to the A5 area, including the superior salivatory nucleus, in the rat. *Exp Brain Res* 82: 513-518, 1990.

425. **Hostetler ED, Joshi AD, Sanabria-Bohorquez S, Fan H, Zeng Z, Purcell M, Gantert L, Riffel K, Williams M, O'Malley S, Miller P, Selnick HG, Gallicchio SN, Bell IM, Salvatore CA, Kane SA, Li CC, Hargreaves RJ, de Groot T, Bormans G, Van Hecken A, Derdelinckx I, de Hoon J, Reynders T, Declercq R, De Lepeleire I, Kennedy WP, Blanchard R, Marcantonio EE, Sur C, Cook JJ, Van Laere K, and Evelhoch JL.** In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [¹¹C]MK-4232. *J Pharmacol Exp Ther* 347: 478-486, 2013.
426. **Hou M, Kanje M, Longmore J, Tajti J, Uddman R, and Edvinsson L.** 5-HT_{1B} and 5-HT_{1D} receptors in the human trigeminal ganglion: co-localization with calitonin gene-related peptide, substance P and nitric oxide synthase. *Brain Research* 909: 112-120, 2001.
427. **Hougaard A, Amin F, Hauge AW, Ashina M, and Olesen J.** Provocation of migraine with aura using natural trigger factors. *Neurology* 80: 428-431, 2013.
428. **Hougaard A, Hauge AW, Guo S, and Tfelt-Hansen P.** The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: a randomized, double-blind, placebo-controlled cross-over study. *Scandinavian Journal of Pain* 4: 48-52, 2013.
429. **Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, O'Carroll AM, Patel YC, Schonbrunn A, Taylor JE, and Reisine T.** Classification and nomenclature of somatostatin receptors. *Trends in the Pharmacological Sciences* 16: 86-88, 1995.
430. **Hoyer D, Hannon JP, and Martin GR.** Molecular, pharmacological and functional diversity of 5-HT receptors. *Pharmacol Biochem Behav* 71: 533-554, 2002.
431. **Huang D, Li S, Dhaka A, Story GM, and Cao YQ.** Expression of the transient receptor potential channels TRPV1, TRPA1 and TRPM8 in mouse trigeminal primary afferent neurons innervating the dura. *Mol Pain* 8: 66, 2012.
432. **Huhman KL, and Albers HE.** Neuropeptide Y microinjected into the suprachiasmatic region phase shifts circadian rhythms in constant darkness. *Peptides* 15: 1475-1478, 1994.
433. **Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, and Tucker ML.** Preclinical studies on the anti-migraine drug, sumatriptan. *European Neurology* 31: 282-290, 1991.
434. **Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M, and Whalley ET.** Serotonin and migraine. *Annals of the New York Academy of Sciences* 600: 587-598, 1990.
435. **Humphrey PPA, and Goadsby PJ.** Controversies in headache. The mode of action of sumatriptan is vascular? a debate. *Cephalalgia* 14: 401-410, 1994.
436. **Ida T, Nakahara K, Murakami T, Hanada R, Nakazato M, and Murakami N.** Possible involvement of orexin in the stress reaction in rats. *Biochem Biophys Res Commun* 270: 318-323, 2000.
437. **Inoue T, Inui A, Okita M, Sakatani N, Oya M, Morioka H, Mizuno N, Oimomi M, and Baba S.** Effect of neuropeptide Y on the hypothalamic-pituitary-adrenal axis in the dog. *Life Sci* 44: 1043-1051, 1989.
438. **Ivanusic JJ, Kwok MM, Ahn AH, and Jennings EA.** 5-HT_{1D} receptor immunoreactivity in the sphenopalatine ganglion: implications for the efficacy of triptans in the treatment of autonomic signs associated with cluster headache. *Headache* 51: 392-402, 2011.
439. **Iversen H.** Human migraine models. *Cephalalgia* 21: 781-785, 2001.

440. **Iversen HK, and Olesen J.** Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan- a human model for development of migraine drugs. *Cephalalgia* 16: 412-418, 1996.
441. **Iversen HK, Olesen J, and Tfelt-Hansen P.** Intravenous nitroglycerin as an experimental headache model. Basic characteristics. *Pain* 38: 17-24, 1989.
442. **Jacobowitz DM, and O'Donohue TL.** alpha-Melanocyte stimulating hormone: immunohistochemical identification and mapping in neurons of rat brain. *Proc Natl Acad Sci U S A* 75: 6300-6304, 1978.
443. **Jacobs BL, and McGinty DJ.** Effects of food deprivation on sleep and wakefulness in the rat. *Exp Neurol* 30: 212-222, 1971.
444. **Jankord R, and Herman JP.** Limbic regulation of hypothalamo-pituitary-adrenocortical function during acute and chronic stress. *Ann N Y Acad Sci* 1148: 64-73, 2008.
445. **Jasmin L, Burkey AR, Card JP, and Basbaum AI.** Transneuronal labeling of a nociceptive pathway, the spino-(trigemino-)parabrachio-amygdaloid, in the rat. *J Neurosci* 17: 3751-3765, 1997.
446. **Jászberényi M, Bujdosó E, Pataki I, and Telegdy G.** Effects of orexins on the hypothalamic-pituitary-adrenal system. *J Neuroendocrinol* 12: 1174-1178, 2000.
447. **Johnson K, Johnson MP, Ellis B, Maren DL, Morin S, and Wroblewski VJ.** Peripheral and Central Distribution of the CGRP Neutralizing Antibody [125I]-LY2951742 in Male Rats. *Headache* 56: 67, 2016.
448. **Johnson KW, Nisenbaum ES, Johnson MP, Dieckman DK, Clemens-Smith A, Siuda ER, Dell CP, Dehlinger V, Hudziak KJ, Filla SA, Ornstein PL, Ramadan NM, and Bleakman D.** Innovative drug development for headache disorders: glutamate. In: *Innovative Drug Development for Headache Disorders*, edited by Olesen J, and Ramadan N. Oxford: Oxford University Press, 2008, p. 185-194.
449. **Johnson KW, Schaus JM, Durkin MM, Audia JE, Kaldor SW, Flaugh ME, Adham N, Zgombick JM, Cohen ML, Branchek TA, and Phebus LA.** 5-HT_{1F} receptor agonists inhibit neurogenic dural inflammation in guinea pigs. *Neuroreport* 8: 2237-2240, 1997.
450. **Joo KM, Chung YH, Kim MK, Nam RH, Lee BL, Lee KH, and Cha CI.** Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. *J Comp Neurol* 476: 388-413, 2004.
451. **Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cecillion M, Marecha E, Maciazek J, Vayssiere C, Craud C, Cabanis E-A, Ruchoux MM, Wissenbach J, Bach JF, Bousser MG, and Tournier-Lasserre E.** Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. *Nature* 383: 707-710, 1996.
452. **Judit A, Sandor PS, and Schoenen J.** Habituation of visual and intensity dependence of cortical auditory evoked potentials tend to normalise just before and during migraine attacks. *Cephalalgia* 20: 714-719, 2000.
453. **Kaiser EA, Kuburas A, Recober A, and Russo AF.** Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT_{1B/D} agonist. *J Neurosci* 32: 15439-15449, 2012.
454. **Kakui N, and Kitamura K.** Direct evidence that stimulation of neuropeptide Y Y5 receptor activates hypothalamo-pituitary-adrenal axis in conscious rats via both corticotropin-releasing factor- and arginine vasopressin-dependent pathway. *Endocrinology* 148: 2854-2862, 2007.

455. **Kalra SP, Dube MG, Sahu A, Phelps CP, and Kalra PS.** Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. *Proc Natl Acad Sci U S A* 88: 10931-10935, 1991.
456. **Kalsbeek A, Fliers E, Romijn JA, La Fleur SE, Wortel J, Bakker O, Endert E, and Buijs RM.** The suprachiasmatic nucleus generates the diurnal changes in plasma leptin levels. *Endocrinology* 142: 2677-2685, 2001.
457. **Karatas H, Erdener SE, Gursoy-Ozdemir Y, Lule S, Eren-Kocak E, Sen ZD, and Dalkara T.** Spreading depression triggers headache by activating neuronal Panx1 channels. *Science* 339: 1092-1095, 2013.
458. **Karteris E, Machado RJ, Chen J, Zervou S, Hillhouse EW, and Randeva HS.** Food deprivation differentially modulates orexin receptor expression and signaling in rat hypothalamus and adrenal cortex. *Am J Physiol Endocrinol Metab* 288: E1089-1100, 2005.
459. **Katona I, and Freund TF.** Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. *Nat Med* 14: 923-930, 2008.
460. **Kaube H, and Goadsby PJ.** Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. *European Neurology* 34: 30-35, 1994.
461. **Kaube H, Hoskin KL, and Goadsby PJ.** An intact blood-brain barrier prevents central inhibition of trigeminovascular neurons by sumatriptan. *Journal of Cerebral Blood Flow and Metabolism* 13: S119, 1993.
462. **Kaube H, Hoskin KL, and Goadsby PJ.** Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. *Cephalalgia* 13: 41, 1993.
463. **Kaube H, Keay KA, Hoskin KL, Bandler R, and Goadsby PJ.** Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical cord following stimulation of the superior sagittal sinus in the cat. *Brain Research* 629: 95-102, 1993.
464. **Kelman L.** The place of osmophobia and taste abnormalities in migraine classification: a tertiary care study of 1237 patients. *Cephalalgia* 24: 940-946, 2004.
465. **Kelman L.** The postdrome of the acute migraine attack. *Cephalalgia* 26: 214-220, 2006.
466. **Kelman L.** The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. *Headache* 44: 865-872, 2004.
467. **Kim JH, Kim S, Suh SI, Koh SB, Park KW, and Oh K.** Interictal metabolic changes in episodic migraine: a voxel-based FDG-PET study. *Cephalalgia* 30: 53-61, 2010.
468. **Kimball RW, Friedman AP, and Vallejo E.** Effect of serotonin in migraine patients. *Neurology (Minneapolis)* 10: 107-111, 1960.
469. **Kiyashchenko LI, Mileykovskiy BY, Maidment N, Lam HA, Wu MF, John J, Peever J, and Siegel JM.** Release of hypocretin (orexin) during waking and sleep states. *J Neurosci* 22: 5282-5286, 2002.
470. **Klopstock T, May A, Seibel P, Papagiannuli E, Diener H-C, and Reichmann H.** Mitochondrial DNA in migraine with aura. *Neurology* 46: 1735-1738, 1996.
471. **Knight YE, Bartsch T, and Goadsby PJ.** Trigeminal antinociception induced by bicuculline in the periaqueductal grey (PAG) is not affected by PAG P/Q-type calcium channel blockade in rat. *Neuroscience Letters* 336: 113-116, 2003.
472. **Knight YE, Bartsch T, Kaube H, and Goadsby PJ.** P/Q-type calcium channel blockade in the PAG facilitates trigeminal nociception: a functional genetic link for migraine? *Journal of Neuroscience* 22: 1-6, 2002.
473. **Knight YE, Classey JD, Lasalandra MP, Akerman S, Kowacs F, Hoskin KL, and Goadsby PJ.** Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious

- craniovascular stimulation and periaqueductal gray stimulation in the cat. *Brain Research* 1045: 1-11, 2005.
474. **Knight YE, and Goadsby PJ.** The periaqueductal gray matter modulates trigeminovascular input: a role in migraine? *Neuroscience* 106: 793-800, 2001.
475. **Knutson KL, Spiegel K, Penev P, and Van Cauter E.** The metabolic consequences of sleep deprivation. *Sleep Med Rev* 11: 163-178, 2007.
476. **Koban M, Le WW, and Hoffman GE.** Changes in hypothalamic corticotropin-releasing hormone, neuropeptide Y, and proopiomelanocortin gene expression during chronic rapid eye movement sleep deprivation of rats. *Endocrinology* 147: 421-431, 2006.
477. **Kobayashi K, Fukuoka T, Obata K, Yamanaka H, Dai Y, Tokunaga A, and Noguchi K.** Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with adelta/c-fibers and colocalization with trk receptors. *J Comp Neurol* 493: 596-606, 2005.
478. **Kolaczynski JW, Considine RV, Ohannesian J, Marco C, Opentanova I, Nyce MR, Myint M, and Caro JF.** Responses of leptin to short-term fasting and refeeding in humans: a link with ketogenesis but not ketones themselves. *Diabetes* 45: 1511-1515, 1996.
479. **Koob GF.** Drugs of abuse: anatomy, pharmacology and function of reward pathways. *Trends Pharmacol Sci* 13: 177-184, 1992.
480. **Koulchitsky S, Fischer MJ, De Col R, Schlechtweg PM, and Messlinger K.** Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat--possible implications for the pathophysiology of headaches. *J Neurophysiol* 92: 1320-1328, 2004.
481. **Koulchitsky S, Fischer MJ, and Messlinger K.** Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. *Cephalalgia* 29: 408-417, 2009.
482. **Krowicki ZK, and Kapusta DR.** Microinjection of glycine into the hypothalamic paraventricular nucleus produces diuresis, natriuresis, and inhibition of central sympathetic outflow. *Journal of Pharmacology and Experimental Therapeutics* 337: 247-255, 2011.
483. **Kruit MC, van Buchem MA, Hofman PA, Bakkers JT, Terwindt GM, Ferrari MD, and Launer LJ.** Migraine as a risk factor for subclinical brain lesions. *Journal of the American Medical Association* 291: 427-434, 2004.
484. **Kunkler PE, and Kraig RP.** Cortical spreading depression bilaterally activates the caudal trigeminal nucleus in rodents. *Hippocampus* 13: 835-844, 2003.
485. **Kuphal KE, Solway B, Pedrazzini T, and Taylor BK.** Y1 receptor knockout increases nociception and prevents the anti-allodynic actions of NPY. *Nutrition* 24: 885-891, 2008.
486. **Kurosawa M, Messlinger K, Pawlak M, and Schmidt RF.** Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene-related peptide. *Br J Pharmacol* 114: 1397-1402, 1995.
487. **Kurth T, Chabriat H, and Bousser MG.** Migraine and stroke: a complex association with clinical implications. *Lancet Neurol* 11: 92-100, 2012.
488. **Kuru M, Ueta Y, Serino R, Nakazato M, Yamamoto Y, Shibuya I, and Yamashita H.** Centrally administered orexin/hypocretin activates HPA axis in rats. *Neuroreport* 11: 1977-1980, 2000.
489. **Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, and Nakamura M.** Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. *Proc Natl Acad Sci U S A* 95: 15659-15664, 1998.
490. **Kuypers HG.** Corticobular connexions to the pons and lower brain-stem in man: an anatomical study. *Brain* 81: 364-388, 1958.

491. **La Fleur SE, Kalsbeek A, Wortel J, and Buijs RM.** A suprachiasmatic nucleus generated rhythm in basal glucose concentrations. *J Neuroendocrinol* 11: 643-652, 1999.
492. **Laburthe M, and Couvineau A.** Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. *Regul Pept* 108: 165-173, 2002.
493. **Lafreniere RG, Cader MZ, Poulin JF, Andres-Enguix I, Simoneau M, Gupta N, Boisvert K, Lafreniere F, McLaughlan S, Dube MP, Marcinkiewicz MM, Ramagopalan S, Ansorge O, Brais B, Sequeiros J, Pereira-Monteiro JM, Griffiths LR, Tucker SJ, Ebers G, and Rouleau GA.** A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. *Nat Med* 16: 1157-1160, 2010.
494. **Lai T-H, Fuh J-L, and Wang S-J.** Cranial autonomic symptoms in migraine: characteristics and comparison with cluster headache. *Journal of Neurology, Neurosurgery and Psychiatry* 80: 1116-1119, 2009.
495. **Lambert GA, Donaldson C, Boers PM, and Zagami AS.** Activation of trigeminovascular neurons by glycerol trinitrate. *Brain Research* 887: 253-259, 2000.
496. **Lambert GA, Donaldson C, Hoskin KL, Boers PM, and Zagami AS.** Dilatation induced by 5-HT in the middle meningeal artery of the anaesthetised cat. *Naunyn Schmiedebergs Arch Pharmacol* 369: 591-601, 2004.
497. **Lambert GA, Goadsby PJ, Zagami AS, and Duckworth JW.** Comparative effects of stimulation of the trigeminal ganglion and the superior sagittal sinus on cerebral blood flow and evoked potentials in the cat. *Brain Research* 453: 143-149, 1988.
498. **Lambert GA, Hoskin KL, and Zagami AS.** Cortico-NRM influences on trigeminal neuronal sensation. *Cephalalgia* 28: 640-652, 2008.
499. **Lambert GA, Michalick J, Storer RJ, and Zagami AS.** Effect of cortical spreading depression on activity of trigeminovascular sensory neurons. *Cephalalgia* 19: 631-638, 1999.
500. **Lambert GA, Truong L, and Zagami AS.** Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system. *Cephalalgia* 31: 1439-1451, 2011.
501. **Lambert GA, and Zagami AS.** Trigemino-vascular sensory signals CAN be modulated by central mechanisms. A response to a Cephalalgia Viewpoint. *Cephalalgia* 33: 347-350, 2013.
502. **Lance JW.** *Mechanism and Management of Migraine*. Sydney: Butterworths, 1982.
503. **Lance JW, Anthony M, and Hinterberger H.** The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. *Headache* 7: 93-102, 1967.
504. **Lance JW, and Goadsby PJ.** *Mechanism and Management of Headache*. New York: Elsevier, 2005.
505. **Lang E, Kaltenhauser M, Neundorfer B, and Seidler S.** Hyperexcitability of the primary somatosensory cortex in migraine--a magnetoencephalographic study. *Brain* 127: 2459-2469, 2004.
506. **Lashley KS.** Patterns of cerebral integration indicated by the scotomas of migraine. *Archives of Neurology and Psychiatry* 46: 331-339, 1941.
507. **Lassen LH, Ashina M, Christiansen I, Ulrich V, and Olesen J.** Nitric oxide synthesis inhibition in migraine. *The Lancet* 349: 401-402, 1997.
508. **Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, and Olesen J.** CGRP may play a causative role in migraine. *Cephalalgia* 22: 54-61, 2002.
509. **Latham PW.** Clinical Lecture on Nervous or Sick-Headaches. *Br Med J* 1: 336-337, 1872.
510. **Latham PW.** Clinical Lecture on Nervous or Sick-Headaches. *Br Med J* 1: 305-306, 1872.
511. **Latham PW.** *On Nervous of Sick-Headache*. Cambridge: Deighton, Bell and Co, 1873.

512. **Lauritzen M.** Pathophysiology of the migraine aura. The spreading depression theory. *Brain* 117: 199-210, 1994.
513. **Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, and Strong AJ.** Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. *J Cereb Blood Flow Metab* 31: 17-35, 2011.
514. **Laursen JC, Cairns BE, Kumar U, Somvanshi RK, Dong XD, Arendt-Nielsen L, and Gazerani P.** Nitric oxide release from trigeminal satellite glial cells is attenuated by glial modulators and glutamate. *Int J Physiol Pathophysiol Pharmacol* 5: 228-238, 2013.
515. **Laws GL.** The effects of nitroglycerin upon those who manufacture it. *Journal of the American Medical Association* 31: 793-794, 1898.
516. **Le Doare K, Akerman S, Holland PR, Lasalandra MP, Classey JD, Knight YE, and Goadsby PJ.** Occipital afferent activation of second order neurons in the trigeminocervical complex in rat. *Neuroscience Letters* 403: 73-77, 2006.
517. **Leao AAP.** Further observations on the spreading depression of activity in the cerebral cortex. *Journal of Neurophysiology* 10: 409-414, 1947.
518. **Leao AAP.** Pial circulation and spreading activity in the cerebral cortex. *Journal of Neurophysiology* 7: 391-396, 1944.
519. **Leao AAP.** Spreading depression of activity in cerebral cortex. *Journal of Neurophysiology* 7: 359-390, 1944.
520. **Leao AP, and Morison RS.** Propagation of spreading cortical depression. *Journal of Neurophysiology* 8: 33-45, 1945.
521. **Lee MG, Hassani OK, and Jones BE.** Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. *J Neurosci* 25: 6716-6720, 2005.
522. **Leibowitz SF.** Brain neuropeptide Y: an integrator of endocrine, metabolic and behavioral processes. *Brain Res Bull* 27: 333-337, 1991.
523. **Lennerz JK, Ruhle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, and Messlinger K.** Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. *J Comp Neurol* 507: 1277-1299, 2008.
524. **Leo L, Gherardini L, Barone V, De Fusco M, Pietrobon D, Pizzorusso T, and Casari G.** Increased susceptibility to cortical spreading depression in the mouse model of familial hemiplegic migraine type 2. *PLoS Genet* 7: e1002129, 2011.
525. **Leung CG, and Mason P.** Physiological properties of raphe magnus neurons during sleep and waking. *J Neurophysiol* 81: 584-595, 1999.
526. **Levy D, Burstein R, and Strassman AM.** Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. *Ann Neurol* 58: 698-705, 2005.
527. **Levy MJ, Matharu MS, Bhola R, Meeran K, and Goadsby PJ.** Octreotide is not effective in the acute treatment of migraine. *Cephalalgia* 25: 48-55, 2005.
528. **Leysen JE, Gommeren W, Heylen L, Luyten WHML, Weyer IVD, Vanhoenacker P, Haegeman G, Schotte A, Gompel Pv, Wouters R, and Lasage AS.** Alniditan, a new 5-hydroxytryptamine_{1D} agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine_{1Da}, human 5-hydroxytryptamine_{1Db}, and calf 5-hydroxytryptamine_{1D} receptors

investigated with [^3H]-5-hydroxytryptamine and [^3H]alniditan. *Molecular Pharmacology* 50: 1567-1580, 1996.

529. **Li C, Chen P, and Smith MS.** Corticotropin releasing hormone neurons in the paraventricular nucleus are direct targets for neuropeptide Y neurons in the arcuate nucleus: an anterograde tracing study. *Brain Res* 854: 122-129, 2000.

530. **Li JJ, Zhou X, and Yu LC.** Involvement of neuropeptide Y and Y1 receptor in antinociception in the arcuate nucleus of hypothalamus, an immunohistochemical and pharmacological study in intact rats and rats with inflammation. *Pain* 118: 232-242, 2005.

531. **Limmroth V, May A, Auerbach P, Wosnitza G, Eppe T, and Diener HC.** Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine. *Journal of Neurological Sciences* 138: 60-65, 1996.

532. **Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, and Mignot E.** The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. *Cell* 98: 365-376, 1999.

533. **Lindell SG, Schwandt ML, Sun H, Sparenborg JD, Björk K, Kasckow JW, Sommer WH, Goldman D, Higley JD, Suomi SJ, Heilig M, and Barr CS.** Functional NPY variation as a factor in stress resilience and alcohol consumption in rhesus macaques. *Arch Gen Psychiatry* 67: 423-431, 2010.

534. **Liposits Z, Sievers L, and Paull WK.** Neuropeptide-Y and ACTH-immunoreactive innervation of corticotropin releasing factor (CRF)-synthesizing neurons in the hypothalamus of the rat. An immunocytochemical analysis at the light and electron microscopic levels. *Histochemistry* 88: 227-234, 1988.

535. **Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, and Stewart WF.** Cutaneous allodynia in the migraine population. *Ann Neurol* 63: 148-158, 2008.

536. **Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, and AMPA Advisory Group.** Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology* 68: 343-349, 2007.

537. **Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, Fischell RE, Ruppel PL, and Goadsby PJ.** Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. *Lancet Neurol* 9: 373-380, 2010.

538. **Lipton RB, Goadsby PJ, Cady RK, Aurora SK, Grosberg BM, Freitag FG, Silberstein SD, Whiten DM, and Jaax KN.** PRISM study: occipital nerve stimulation for treatment-refractory migraine. *Cephalalgia* 29: 30, 2009.

539. **Lipton RB, Stewart WF, Diamond S, Diamond ML, and Reed M.** Prevalence and burden of migraine in the United States: data from the American Migraine Study II. *Headache* 41: 646-657, 2001.

540. **Liu P, Xiao Z, Ren F, Guo Z, Chen Z, Zhao H, and Cao YQ.** Functional analysis of a migraine-associated TREK K⁺ channel mutation. *J Neurosci* 33: 12810-12824, 2013.

541. **Liu Y, Broman J, and Edvinsson L.** Central projections of sensory innervation of the rat superior sagittal sinus. *Neuroscience* 129: 431-437, 2004.

542. **Liu Y, Broman J, and Edvinsson L.** Central projections of the sensory innervation of the rat middle meningeal artery. *Brain Res* 1208: 103-110, 2008.

543. **Liu Y, Broman J, Zhang M, and Edvinsson L.** Brainstem and thalamic projections from a craniovascular sensory nervous centre in the rostral cervical spinal dorsal horn of rats. *Cephalalgia* 29: 935-948, 2009.

544. **Liveing E.** *On Megrim, Sick-Headache, and Some Allied Disorders. A contribution to the pathology of nerve-storms.* London: Arts & Boeve Nijmegen, 1873.
545. **Lodi R, Montagna P, Soriani S, Iotti S, Arnaldi C, Cortelli P, Pierangeli G, Patuelli A, Zaniol P, and Barbiroli B.** Deficit of brain and skeletal muscle bioenergetics and low brain magnesium in juvenile migraine: an in vivo ³¹P magnetic resonance spectroscopy interictal study. *Pediatr Res* 42: 866-871, 1997.
546. **Lovick TA, and Robinson JP.** Bulbar raphe neurones with projections to the trigeminal nucleus caudalis and the lumbar cord in the rat: a fluorescence double-labelling study. *Exp Brain Res* 50: 299-308, 1983.
547. **Lovick TA, and Wolstencroft JH.** Projections from brain-stem nuclei to the spinal trigeminal nucleus in the cat. *Neuroscience* 9: 411-418, 1983.
548. **Lu J, Bjorkum AA, Xu M, Gaus SE, Shiromani PJ, and Saper CB.** Selective activation of the extended ventrolateral preoptic nucleus during rapid eye movement sleep. *J Neurosci* 22: 4568-4576, 2002.
549. **Lu J, Zhou TC, and Saper CB.** Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. *J Neurosci* 26: 193-202, 2006.
550. **Lu J, Sherman D, Devor M, and Saper CB.** A putative flip-flop switch for control of REM sleep. *Nature* 441: 589-594, 2006.
551. **Lu XY, Bagnol D, Burke S, Akil H, and Watson SJ.** Differential distribution and regulation of OX1 and OX2 orexin/hypocretin receptor messenger RNA in the brain upon fasting. *Horm Behav* 37: 335-344, 2000.
552. **Ma Q-P, Hill R, and Sirinathsinghji D.** Colocalization of CGRP with 5-HT_{1B/1D} receptors and substance P in trigeminal ganglion neurons in rats. *European Journal of Neuroscience* 13: 2099-2104, 2001.
553. **Magon S, May A, Stankewitz A, Goadsby PJ, Tso A, Ashina M, Amin FM, Seifert C, Chakravarty M, Muller J, and Sprenger T.** Morphological abnormalities of thalamic subnuclei in migraine: a multi-center MRI study at 3T. *Journal of Neuroscience* 35: 13800-13806, 2015.
554. **Mainero C, Boshyan J, and Hadjikhani N.** Altered functional magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in migraine. *Ann Neurol* 70: 838-845, 2011.
555. **Maleki N, Becerra L, Nutile L, Pendse G, Brawn J, Bigal M, Burstein R, and Borsook D.** Migraine attacks the Basal Ganglia. *Mol Pain* 7: 71, 2011.
556. **Malick A, and Burstein R.** Cells of origin of the trigeminohypothalamic tract in the rat. *Journal of Comparative Neurology* 400: 125-144, 1998.
557. **Malick A, and Burstein R.** A neurohistochemical blueprint for pain-induced loss of appetite. *Proceedings of the Academy of Sciences (USA)* 98: 9930-9935, 2001.
558. **Malick A, Strassman AM, and Burstein R.** Trigeminothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat. *Journal of Neurophysiology* 84: 2078-2112, 2000.
559. **Maniyar FH, Sprenger T, Monteith T, Schankin C, and Goadsby PJ.** Brain activations in the premonitory phase of nitroglycerin triggered migraine attacks. *Brain* 137: 232-242, 2014.
560. **Maniyar FH, Sprenger T, Schankin C, and Goadsby PJ.** The origin of nausea in migraine – A PET study. *Journal of Headache and Pain* 15: 84, 2014.
561. **Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, and Fischer T.** BMS-927711 for the Acute Treatment of Migraine: A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial. *Cephalalgia* 33: 94, 2013.

562. **Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, and Fischer TZ.** BMS-927711 for the Acute Treatment of Migraine: A Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial. *Cephalalgia* 34: 114-125, 2014.
563. **Marfurt CF.** The central projections of trigeminal primary afferent neurons in the cat as determined by the transganglionic transport of horseradish peroxidase. *J Comp Neurol* 203: 785-798, 1981.
564. **Markovics A, Kormos V, Gaszner B, Lashgarara A, Szoke E, Sandor K, Szabadfi K, Tuka B, Tajti J, Szolcsanyi J, Pinter E, Hashimoto H, Kun J, Reglodi D, and Helyes Z.** Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice. *Neurobiology of Disease* 45: 633-644, 2012.
565. **Markowitz S, Saito K, Buzzi MG, and Moskowitz MA.** The development of neurogenic plasma extravasation in the rat dura mater does not depend upon the degranulation of mast cells. *Brain Res* 477: 157-165, 1989.
566. **Markowitz S, Saito K, and Moskowitz MA.** Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. *Journal of Neuroscience* 7: 4129-4136, 1987.
567. **Markowitz S, Saito K, and Moskowitz MA.** Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. *Cephalalgia* 8: 83-91, 1988.
568. **Martin PR, and Seneviratne HM.** Effects of food deprivation and a stressor on head pain. *Health Psychol* 16: 310-318, 1997.
569. **Martins-Oliveira M, Hoffmann J, Akerman S, and Goadsby PJ.** Modulation of Trigemino-vascular Activity by Leptin: A Novel Antinociceptive Mechanism? *Cephalalgia* 33: 209, 2013.
570. **Martins Oliveira M, Akerman S, Tavares I, and Goadsby PJ.** Neuropeptide Y inhibits the trigeminovascular pathway through NPY Y1 receptor: implications for migraine. *Pain* in press, 2016.
571. **Mason P.** Deconstructing endogenous pain modulations. *J Neurophysiol* 94: 1659-1663, 2005.
572. **Mason P.** Physiological identification of pontomedullary serotonergic neurons in the rat. *J Neurophysiol* 77: 1087-1098, 1997.
573. **Mason P.** Ventromedial medulla: pain modulation and beyond. *J Comp Neurol* 493: 2-8, 2005.
574. **Masuo Y, Ohtaki T, Masuda Y, Tsuda M, and Fujino M.** Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections. *Brain Res* 575: 113-123, 1992.
575. **Matharu MS, Cohen AS, Frackowiak RSJ, and Goadsby PJ.** Posterior hypothalamic activation in paroxysmal hemicrania. *Annals of Neurology* 59: 535-545, 2006.
576. **Matharu MS, Cohen AS, McGonigle DJ, Ward N, Frackowiak RSJ, and Goadsby PJ.** Posterior hypothalamic and brainstem activation in hemicrania continua. *Headache* 44: 747-761, 2004.
577. **Matharu MS, Levy MJ, Meeran K, and Goadsby PJ.** Subcutaneous octreotide in cluster headache- randomized placebo-controlled double-blind cross-over study. *Annals of Neurology* 56: 488-494, 2004.
578. **Mathew R, Chami L, Bergerot A, van den Maagdenberg AMJM, Ferrari MD, and Goadsby PJ.** Immunohistochemical characterization of calcitonin gene-related peptide in the

trigeminal system of the familial hemiplegic migraine 1 knock-in mouse. *Cephalalgia* 31: 1368-1380, 2011.

579. **Matsushita M, Ikeda M, and Okado N.** The cells of origin of the trigeminothalamic, trigeminospinal and trigeminocerebellar projections in the cat. *Neuroscience* 7: 1439-1454, 1982.

580. **May A, Ashburner J, Buchel C, McGonigle DJ, Friston KJ, Frackowiak RSJ, and Goadsby PJ.** Correlation between structural and functional changes in brain in an idiopathic headache syndrome. *Nature Medicine* 5: 836-838, 1999.

581. **May A, Bahra A, Buchel C, Frackowiak RS, and Goadsby PJ.** Hypothalamic activation in cluster headache attacks. *The Lancet* 352: 275-278, 1998.

582. **May A, Bahra A, Buchel C, Turner R, and Goadsby PJ.** Functional MRI in spontaneous attacks of SUNCT: short-lasting neuralgiform headache with conjunctival injection and tearing. *Annals of Neurology* 46: 791-793, 1999.

583. **May A, and Goadsby PJ.** Substance P receptor antagonists in the therapy of migraine. *Expert Opinion in Investigational Drugs* 10: 1-6, 2001.

584. **May A, and Goadsby PJ.** The trigeminovascular system in humans: pathophysiological implications for primary headache syndromes of the neural influences on the cerebral circulation. *Journal of Cerebral Blood Flow and Metabolism* 19: 115-127, 1999.

585. **May A, Kaube H, Buechel C, Eichten C, Rijntjes M, Jueptner M, Weiller C, and Diener HC.** Experimental cranial pain elicited by capsaicin: a PET-study. *Pain* 74: 61-66, 1998.

586. **May A, Ophoff RA, Terwindt GM, Urban C, VanEijk R, Haan J, Diener HC, Lindhout D, Frants RR, Sandkuijl A, and Ferrari MD.** Familial hemiplegic migraine locus on chromosome 19p13 is involved in common forms of migraine with and without aura. *Human Genetics* 96: 604-608, 1995.

587. **May A, Shephard S, Wessing A, Hargreaves RJ, Goadsby PJ, and Diener HC.** Retinal plasma extravasation can be evoked by trigeminal stimulation in rat but does not occur during migraine attacks. *Brain* 121: 1231-1237, 1998.

588. **Mayer DJ.** Analgesia produced by electrical stimulation of the brain. *Prog Neuropsychopharmacol Biol Psychiatry* 8: 557-564, 1984.

589. **Mayevsky A, Doron A, Manor T, Meilin S, Zarchin N, and Ouaknine GE.** Cortical spreading depression recorded from the human brain using a multiparametric monitoring system. *Brain Research* 740: 268-274, 1996.

590. **McCarthy LC, Hosford DA, Riley JH, Bird MI, White NJ, Hewett DR, Peroutka SJ, Griffiths LR, Boyd PR, Lea RA, Bhatti SM, Hosking LK, Hood CM, Jones KW, Handley AR, Rallan R, Lewis KF, Yeo AJ, Williams PM, Priest RC, Khan P, Donnelly C, Lumsden SM, O'Sullivan J, See CG, Smart DH, Shaw-Hawkins S, Patel J, Langrish TC, Feniuk W, Knowles RG, Thomas M, Libri V, Montgomery DS, Manasco PK, Xu CF, Dykes C, Humphrey PP, Roses AD, and Purvis IJ.** Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. *Genomics* 78: 135-149, 2001.

591. **McCrone P, Seed PT, Dowson AJ, Clark LV, Goldstein LH, Morgan M, and Ridsdale L.** Service use and costs for people with headache: a UK primary care study. *J Headache Pain* 12: 617-623, 2011.

592. **McKemy DD, Neuhausser WM, and Julius D.** Identification of a cold receptor reveals a general role for TRP channels in thermosensation. *Nature* 416: 52-58, 2002.

593. **McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, and Foord SM.** RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. *Nature* 393: 333-339, 1998.

594. **McNaughton FL, and Feindel WH.** Innervation of intracranial structures: a reappraisal. In: *Physiological aspects of Clinical Neurology*, edited by Rose FC. Oxford: Blackwell Scientific Publications, 1977, p. 279-293.
595. **Medve RA, and Andrews JS.** Effects of fixed dose combination of nNOS inhibition and 5HT agonism on progression of migraine with and without aura. *Cephalalgia* 29: 126, 2009.
596. **Meguid MM, Yang ZJ, and Laviano A.** Meal size and number: relationship to dopamine levels in the ventromedial hypothalamic nucleus. *Am J Physiol* 272: R1925-1930, 1997.
597. **Meng ID, and Johansen JP.** Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist. *Neuroscience* 124: 685-693, 2004.
598. **Meng W, Ayata C, Waeber C, Huang PL, and Moskowitz MA.** Neuronal NOS-cGMP-dependent ACh-induced relaxation in pial arterioles of endothelial NOS knockout mice. *Am J Physiol* 274: H411-415, 1998.
599. **Mercer JG, Moar KM, and Hoggard N.** Localization of leptin receptor (Ob-R) messenger ribonucleic acid in the rodent hindbrain. *Endocrinology* 139: 29-34, 1998.
600. **Meye FJ, and Adan RA.** Feelings about food: the ventral tegmental area in food reward and emotional eating. *Trends Pharmacol Sci* 35: 31-40, 2014.
601. **Millan MJ.** Descending control of pain. *Progress in Neurobiology* 66: 355-474, 2002.
602. **Miller AD, and Ruggiero DA.** Emetic reflex arc revealed by expression of the immediate-early gene c-fos in the cat. *J Neurosci* 14: 871-888, 1994.
603. **Mirza AF, Mo J, Holt JL, Kairalla JA, Heft MW, Ding M, and Ahn AH.** Is there a relationship between throbbing pain and arterial pulsations? *J Neurosci* 32: 7572-7576, 2012.
604. **Mitsikostas DD, Sanchez del Rio M, Moskowitz MA, and Waeber C.** Both 5-HT_{1B} and 5-HT_{1F} receptors modulate c-fos expression within rat trigeminal nucleus caudalis. *European Journal of Pharmacology* 369: 271-277, 1999.
605. **Mitsikostas DD, Sanchez del Rio M, and Waeber C.** 5-Hydroxytryptamine(1B/1D) and 5-hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse trigeminal nucleus caudalis. *Cephalalgia* 22: 384-394, 2002.
606. **Moncada S, Palmer RMJ, and Higgs EA.** Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacological Reviews* 43: 109-142, 1991.
607. **Montagna P, Cortelli P, Monari L, Pierangeli G, Parchi P, Lodi R, Iotti S, Frassinetti C, Zaniol P, Lugaresi E, and et al.** 31P-magnetic resonance spectroscopy in migraine without aura. *Neurology* 44: 666-669, 1994.
608. **Monteleone P, Bortolotti F, Fabrazzo M, La Rocca A, Fuschino A, and Maj M.** Plasma leptin response to acute fasting and refeeding in untreated women with bulimia nervosa. *J Clin Endocrinol Metab* 85: 2499-2503, 2000.
609. **Moreau JL, and Fields HL.** Evidence for GABA involvement in midbrain control of medullary neurons that modulate nociceptive transmission. *Brain Res* 397: 37-46, 1986.
610. **Moreno MJ, Abounader R, Hebert E, Doods H, and Hamel E.** Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. *Neuropharmacology* 42: 568-576, 2002.
611. **Moriguchi T, Sakurai T, Takahashi S, Goto K, and Yamamoto M.** The human prepro-orexin gene regulatory region that activates gene expression in the lateral region and represses it in the medial regions of the hypothalamus. *J Biol Chem* 277: 16985-16992, 2002.

612. **Moskowitz MA.** The neurobiology of vascular head pain. *Annals of Neurology* 16: 157-168, 1984.
613. **Moulton EA, Becerra L, Maleki N, Pendse G, Tully S, Hargreaves R, Burstein R, and Borsook D.** Painful heat reveals hyperexcitability of the temporal pole in interictal and ictal migraine States. *Cereb Cortex* 21: 435-448, 2011.
614. **Moulton EA, Burstein R, Tully S, Hargreaves R, Becerra L, and Borsook D.** Interictal dysfunction of a brainstem descending modulatory center in migraine patients. *PLoS One* 3: e3799, 2008.
615. **Mouraux A, Diukova A, Lee MC, Wise RG, and Iannetti GD.** A multisensory investigation of the functional significance of the "pain matrix". *Neuroimage* 54: 2237-2249, 2011.
616. **Mraovitch S, Calando Y, Goadsby PJ, and Seylaz J.** Subcortical cerebral blood flow and metabolic changes elicited by cortical spreading depression in rat. *Cephalalgia* 12: 137-141, 1992.
617. **Mulderry PK, Ghatel MA, Spokes RA, Jones PM, Pierson AM, Hamid QA, Kanse S, Amara SG, Burrin JM, Legon S, and et al.** Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. *Neuroscience* 25: 195-205, 1988.
618. **Mullington JM, Chan JL, Van Dongen HP, Szuba MP, Samaras J, Price NJ, Meier-Ewert HK, Dinges DF, and Mantzoros CS.** Sleep loss reduces diurnal rhythm amplitude of leptin in healthy men. *J Neuroendocrinol* 15: 851-854, 2003.
619. **Muroya S, Funahashi H, Yamanaka A, Kohno D, Uramura K, Nambu T, Shibahara M, Kuramochi M, Takigawa M, Yanagisawa M, Sakurai T, Shioda S, and Yada T.** Orexins (hypocretins) directly interact with neuropeptide Y, POMC and glucose-responsive neurons to regulate Ca²⁺ signaling in a reciprocal manner to leptin: orexigenic neuronal pathways in the mediobasal hypothalamus. *Eur J Neurosci* 19: 1524-1534, 2004.
620. **Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basanez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabe E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fevre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gonzalez-Medina D, Gosselin R, Grainger R, Grant B, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H,**

- Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Laden F, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Levinson D, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mock C, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA, 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leon FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahrzad S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiebe N, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, AlMazroa MA, and Memish ZA. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380: 2197-2223, 2012.
621. Myers MG, Münzberg H, Leininger GM, and Leshan RL. The geometry of leptin action in the brain: more complicated than a simple ARC. *Cell Metab* 9: 117-123, 2009.
622. Myren M, Baun M, Ploug KB, Jansen-Olesen I, Olesen J, and Gupta S. Functional and molecular characterization of prostaglandin E2 dilatory receptors in the rat craniovascular system in relevance to migraine. *Cephalalgia* 30: 1110-1122, 2012.
623. Myren M, Olesen J, and Gupta S. Pharmacological and expression profile of the prostaglandin I(2) receptor in the rat craniovascular system. *Vascul Pharmacol* 55: 50-58, 2011.
624. Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, and Xu YC. Preclinical pharmacological profile of the selective 5-HT_{1F} receptor agonist lasmiditan. *Cephalalgia* 30: 1159-1169, 2010.
625. Nesbitt AD, Leschziner GD, and Peatfield RC. Headache, drugs and sleep. *Cephalalgia* 34: 756-766, 2014.
626. Nicolodi M, Moneti G, Pieraccini G, Conti P, Del Bianco PL, and Sicuteri F. Sumatriptan pharmacokinetics in the spinal fluid following oral administration of the drug. *Cephalalgia* 20: 272, 2000.

627. **Niebur E, Hsiao SS, and Johnson KO.** Synchrony: a neural mechanism for attentional selection? *Current Opinion in Neurobiology* 12: 190-194, 2002.
628. **Nishino S, Ripley B, Overeem S, Lammers GJ, and Mignot E.** Hypocretin (orexin) deficiency in human narcolepsy. *Lancet* 355: 39-40, 2000.
629. **Norman B, Panebianco D, and Block GA.** A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. *Cephalalgia* 18: 407, 1998.
630. **Nosedá R, Constandil L, Bourgeois L, Chalus M, and Villanueva L.** Changes of meningeal excitability mediated by corticotrigeminal networks: a link for the endogenous modulation of migraine pain. *J Neurosci* 30: 14420-14429, 2010.
631. **Nosedá R, Jakubowski M, Kainz V, Borsook D, and Burstein R.** Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. *J Neurosci* 31: 14204-14217, 2011.
632. **Nosedá R, Kainz V, Jakubowski M, Gooley JJ, Saper CB, Digre K, and Burstein R.** A neural mechanism for exacerbation of headache by light. *Nat Neurosci* 13: 239-245, 2010.
633. **Nowak KW, Maćkowiak P, Switońska MM, Fabiś M, and Malendowicz LK.** Acute orexin effects on insulin secretion in the rat: in vivo and in vitro studies. *Life Sci* 66: 449-454, 2000.
634. **Offenhauser N, Zinck T, Hoffmann J, Schiemann K, Schuh-Hofer S, Rohde W, Arnold G, Dirnagl U, Jansen-Olesen I, and Reuter U.** CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. *Cephalalgia* 25: 225-236, 2005.
635. **Okamoto K, Tashiro A, Chang Z, and Bereiter DA.** Bright light activates a trigeminal nociceptive pathway. *Pain* 149: 235-242, 2010.
636. **Olesen J.** Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications. *Cerebrovascular and Brain Metabolism Reviews* 3: 1-28, 1991.
637. **Olesen J, Boussier MG, Diener HC, Dodick D, First M, Goadsby P, Gobel H, Lainez M, Lance J, Lipton R, Nappi G, Sakai F, Schoenen J, Silberstein SD, and Steiner TJ.** New appendix criteria open for a broader concept of chronic migraine. *Cephalalgia* 26: 742-746, 2006.
638. **Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, and Lesko LM.** Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. *New England Journal of Medicine* 350: 1104-1110, 2004.
639. **Olesen J, Iversen HK, and Thomsen LL.** Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. *Neuroreport* 4: 1027-1030, 1993.
640. **Olesen J, Larsen B, and Lauritzen M.** Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. *Annals of Neurology* 9: 344-352, 1981.
641. **Olesen J, Thomsen LL, and Iversen HK.** Nitric oxide is a key molecule in migraine and other vascular headaches. *Trends in Pharmacological Sciences* 15: 149-153, 1994.
642. **Olesen J, Thomsen LL, Lassen LH, and Olesen IJ.** The nitric oxide hypothesis of migraine and other vascular headaches. *Cephalalgia* 15: 94-100, 1995.
643. **Oliver KR, A. W, Edvinsson L, Pickard JD, and Hill RG.** Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. *J Cereb Blood Flow Metab* 22: 620-629, 2002.
644. **Ondo WG, He Y, Rajasekaran S, and Le WD.** Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. *Mov Disord* 15: 154-158, 2000.

645. **Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SMG, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen G-JB, Hofker MH, Ferrari MD, and Frants RR.** Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca^{2+} channel gene CACNL1A4. *Cell* 87: 543-552, 1996.
646. **Otsuka R, Yatsuya H, Tamakoshi K, Matsushita K, Wada K, and Toyoshima H.** Perceived psychological stress and serum leptin concentrations in Japanese men. *Obesity (Silver Spring)* 14: 1832-1838, 2006.
647. **Pages N, Orosco M, Rouch C, Yao O, Jacquot C, and Bohuon C.** Refeeding after 72 hour fasting alters neuropeptide Y and monoamines in various cerebral areas in the rat. *Comp Biochem Physiol Comp Physiol* 106: 845-849, 1993.
648. **Palm-Meinders IH, Koppen H, Terwindt GM, Launer LJ, Konishi J, Moonen JME, Bakkers JTN, Hofman PAM, van Lew B, Middelkoop HAM, van Buchem MA, Ferrari MD, and Kruit MC.** Structural brain changes in migraine. *JAMA* 308: 1889-1897, 2012.
649. **Palmer JE, Guillard FL, Laurijssens BE, Wentz AL, Dixon RM, and Williams PM.** A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. *Cephalalgia* 29: 124, 2009.
650. **Panda S, and Hogenesch JB.** It's all in the timing: many clocks, many outputs. *J Biol Rhythms* 19: 374-387, 2004.
651. **Paranjape SA, Vavaiya KK, Kale AY, and Briski KP.** Habituation of insulin-induced hypoglycemic transcription activation of lateral hypothalamic orexin-A-containing neurons to recurring exposure. *Regul Pept* 135: 1-6, 2006.
652. **Pardutz A, Krizbai I, Multon S, Vecsei L, and Schoenen J.** Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. *Neuroreport* 11: 3071-3075, 2000.
653. **Pardutz A, Multon S, Malgrange B, Parducz A, Vecsei L, and Schoenen J.** Effect of systemic nitroglycerin on CGRP and 5-HT afferents to rat caudal spinal trigeminal nucleus and its modulation by estrogen. *Eur J Neurosci* 15: 1803-1809, 2002.
654. **Park JW, Moon HS, Akerman S, Holland PR, Lasalandra M, Andreou AP, van den Maagdenberg AM, and Goadsby PJ.** Differential trigeminovascular nociceptive responses in the thalamus in the familial hemiplegic migraine 1 knock-in mouse: a Fos protein study. *Neurobiology of Disease* 64: 1-7, 2014.
655. **Parker RM, and Herzog H.** Regional distribution of Y-receptor subtype mRNAs in rat brain. *Eur J Neurosci* 11: 1431-1448, 1999.
656. **Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, Earley TJ, Dragoni I, McIntyre P, Bevan S, and Patapoutian A.** A TRP channel that senses cold stimuli and menthol. *Cell* 108: 705-715, 2002.
657. **Pelzer N, Stam AH, Haan J, Ferrari MD, and Terwindt GM.** Familial and sporadic hemiplegic migraine: diagnosis and treatment. *Curr Treat Options Neurol* 15: 13-27, 2013.
658. **Penfield W, and McNaughton FL.** Dural headache and the innervation of the dura mater. *Archives of Neurology and Psychiatry* 44: 43-75, 1940.
659. **Percheron G.** Thalamus. In: *The Human Nervous System*, edited by Paxinos G, and May J. Amsterdam: Elsevier, 2003.
660. **Peroutka SJ.** Neurogenic inflammation and migraine: implications for therapeutics. *Molecular Interventions* 5: 306-313, 2005.

661. **Peters O, Schipke CG, Hashimoto Y, and Kettenmann H.** Different mechanisms promote astrocyte Ca²⁺ waves and spreading depression in the mouse neocortex. *J Neurosci* 23: 9888-9896, 2003.
662. **Petersen KA, Birk S, Doods H, Edvinsson L, and Olesen J.** Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. *Br J Pharmacol* 143: 697-704, 2004.
663. **Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, Nelson DL, Calligaro DO, Kiefer AD, Jr., Branchek TA, and Flaugh ME.** Characterization of LY344864 as a pharmacological tool to study 5-HT_{1F} receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. *Life Sci* 61: 2117-2126, 1997.
664. **Pietrobon D.** Insights into migraine mechanisms and CaV2.1 calcium channel function from mouse models of familial hemiplegic migraine. *J Physiol* 588: 1871-1878, 2010.
665. **Piilgaard H, and Lauritzen M.** Persistent increase in oxygen consumption and impaired neurovascular coupling after spreading depression in rat neocortex. *J Cereb Blood Flow Metab* 29: 1517-1527, 2009.
666. **Porreca F, Ossipov MH, and Gebhart GF.** Chronic pain and medullary descending facilitation. *Trends Neurosci* 25: 319-325, 2002.
667. **Powell KJ, Ma W, Sutak M, Doods H, Quirion R, and Jhamandas K.** Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. *British Journal of Pharmacology* 131: 875-884, 2000.
668. **Pozo-Rosich P, Storer RJ, Charbit AR, and Goadsby PJ.** Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. *Cephalalgia* 35: 1298-1307, 2015.
669. **Pralong FP, Roduit R, Waeber G, Castillo E, Mosimann F, Thorens B, and Gaillard RC.** Leptin inhibits directly glucocorticoid secretion by normal human and rat adrenal gland. *Endocrinology* 139: 4264-4268, 1998.
670. **Price GW, Burton MJ, Collins LJ, Duckworth M, Gaster L, Gothert M, Jones BJ, Roberts C, Watson JM, and Middlesmiss DN.** SB 216641 and BRL-15572- compounds to pharmacologically discriminate h₅-HT_{1B} and h₅-HT_{1D} receptors. *Naunyn-Schmiedeberg's Archives of Pharmacology* 356: 312-320, 1997.
671. **Proletti-Cecchini P, Afra J, and Schoenen J.** Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT_{1B/1D} agonist zolmitriptan (311C90, Zomig). *Cephalalgia* 17: 849-854, 1997.
672. **Qu D, Ludwig DS, Gammeltoft S, Piper M, Pellemounter MA, Cullen MJ, Mathes WF, Przypek R, Kanarek R, and Maratos-Flier E.** A role for melanin-concentrating hormone in the central regulation of feeding behaviour. *Nature* 380: 243-247, 1996.
673. **Rabinowitch IM.** Acute nitroglycerine poisoning. *Can Med Ass J* 50: 199-202, 1944.
674. **Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, and Ashina M.** Vasoactive intestinal peptide causes marked cephalic vasodilatation but does not induce migraine. *Cephalalgia* 28: 226-236, 2008.
675. **Rainero I, Ferrero M, Rubino E, Valfrè W, Pellegrino M, Arvat E, Giordano R, Ghigo E, Limone P, and Pinessi L.** Endocrine function is altered in chronic migraine patients with medication-overuse. *Headache* 46: 597-603, 2006.

676. **Rainero I, Limone P, Ferrero M, Valfrè W, Pelissetto C, Rubino E, Gentile S, Lo Giudice R, and Pinessi L.** Insulin sensitivity is impaired in patients with migraine. *Cephalalgia* 25: 593-597, 2005.
677. **Raskin NH, Hosobuchi Y, and Lamb S.** Headache may arise from perturbation of brain. *Headache* 27: 416-420, 1987.
678. **Rasmussen BK, and Olesen J.** Migraine with aura and migraine without aura: an epidemiological study. *Cephalalgia* 12: 221-228, 1992.
679. **Ray BS, and Wolff HG.** Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. *Archives of Surgery* 41: 813-856, 1940.
680. **Recober A, and Goadsby PJ.** Calcitonin gene-related peptide (CGRP): a molecular link between obesity and migraine? *Drug News and Perspectives* 23: 112-117, 2010.
681. **Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, and Russo AF.** Role of calcitonin gene-related peptide in light-averse behavior: implications for migraine. *J Neurosci* 29: 8798-8804, 2009.
682. **Reuter U, Bolay H, Jansen-Olesen I, Chiarugi A, Sanchez del Rio M, Letourneau R, Theoharides TC, Waeber C, and Moskowitz MA.** Delayed inflammation in rat meninges: implications for migraine pathophysiology. *Brain* 124: 2490-2502, 2001.
683. **Reyngoudt H, Paemeleire K, Descamps B, De Deene Y, and Achten E.** 31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients. *Cephalalgia* 31: 1243-1253, 2011.
684. **Reynolds AC, Dorrian J, Liu PY, Van Dongen HP, Wittert GA, Harmer LJ, and Banks S.** Impact of five nights of sleep restriction on glucose metabolism, leptin and testosterone in young adult men. *PLoS One* 7: e41218, 2012.
685. **Reynolds DV.** Surgery in the rat during electrical analgesia induced by focal brain stimulation. *Science* 164: 444-445, 1969.
686. **Rhode AM, Hosking VG, Happe S, Biehl K, Young P, and Evers S.** Comorbidity of migraine and restless legs syndrome- a case-control study. *Cephalalgia* 27: 1255-1260, 2007.
687. **Rinaman L.** Visceral sensory inputs to the endocrine hypothalamus. *Front Neuroendocrinol* 28: 50-60, 2007.
688. **Robert C, Bourgeois L, Arreto CD, Condes-Lara M, Nosedá R, Jay T, and Villanueva L.** Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches. *J Neurosci* 33: 8827-8840, 2013.
689. **Rocca MA, Ceccarelli A, Falini A, Colombo B, Tortorella P, Bernasconi L, Comi G, Scotti G, and Filippi M.** Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study. *Stroke* 37: 1765-1770, 2006.
690. **Rolls A, Schaich Borg J, and de Lecea L.** Sleep and metabolism: role of hypothalamic neuronal circuitry. *Best Pract Res Clin Endocrinol Metab* 24: 817-828, 2010.
691. **Roon KI, Olesen J, Diener HC, Ellis P, Hettiarachchi J, Poole PH, Christianssen I, Kleinermans D, Kok JG, and Ferrari MD.** No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized double-blind placebo-controlled clinical trials. *Annals of Neurology* 47: 238-241, 2000.
692. **Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, and Evans RM.** Production of a novel neuropeptide encoded by the calcitonin gene via tissue specific RNA processing. *Nature* 304: 129-135, 1983.

693. **Ruiter M, La Fleur SE, van Heijningen C, van der Vliet J, Kalsbeek A, and Buijs RM.** The daily rhythm in plasma glucagon concentrations in the rat is modulated by the biological clock and by feeding behavior. *Diabetes* 52: 1709-1715, 2003.
694. **Russell FA, King R, Smillie SJ, Kodji X, and Brain SD.** Calcitonin gene-related peptide: physiology and pathophysiology. *Physiol Rev* 94: 1099-1142, 2014.
695. **Russell MB, Iselius L, and Olesen J.** Investigation of the inheritance of migraine by complex segregation analysis. *Human Genetics* 96: 726-730, 1995.
696. **Russo AF, Kuburas A, Kaiser EA, Raddant AC, and Recober A.** A Potential Preclinical Migraine Model: CGRP-Sensitized Mice. *Molecular and cellular pharmacology* 1: 264-270, 2009.
697. **Russo SJ, and Nestler EJ.** The brain reward circuitry in mood disorders. *Nat Rev Neurosci* 14: 609-625, 2013.
698. **Sadeghi S, Reisi Z, Azhdari-Zarmehri H, and Haghparast A.** Involvement of orexin-1 receptors in the ventral tegmental area and the nucleus accumbens in antinociception induced by lateral hypothalamus stimulation in rats. *Pharmacol Biochem Behav* 105: 193-198, 2013.
699. **Sahu A, Kalra PS, and Kalra SP.** Food deprivation and ingestion induce reciprocal changes in neuropeptide Y concentrations in the paraventricular nucleus. *Peptides* 9: 83-86, 1988.
700. **Sakurai T.** The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. *Nat Rev Neurosci* 8: 171-181, 2007.
701. **Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, and Yanagisawa M.** Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92: 696-697, 1998.
702. **Sanchez del Rio M, Bakker D, Wu O, Agosti R, Mitsikostas DD, Ostergaard L, Wells WA, Rosen DR, Sorensen G, Moskowitz MA, and Cutrer FM.** Perfusion weighted imaging during migraine: spontaneous visual aura and headache. *Cephalalgia* 19: 701-707, 1999.
703. **Sandkuhler J, and Gebhart GF.** Relative contributions of the nucleus raphe magnus and adjacent medullary reticular formation to the inhibition by stimulation in the periaqueductal gray of a spinal nociceptive reflex in the pentobarbital-anesthetized rat. *Brain Res* 305: 77-87, 1984.
704. **Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Phebus LA, Bleakman D, Ornstein PL, Arnold B, Tepper SJ, and Vandenhende F.** LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. *Cephalalgia* 24: 596-602, 2004.
705. **Saper J, Dodick DW, Silberstein S, McCarville S, Sun M, and Goadsby PJ.** Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. *Cephalalgia* 41: 271-285, 2011.
706. **Sarchielli P, Rainero I, Coppola F, Rossi C, Mancini M, Pinessi L, and Calabresi P.** Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. *Cephalalgia* 28: 714-722, 2008.
707. **Saudek CD, and Felig P.** The metabolic events of starvation. *Am J Med* 60: 117-126, 1976.
708. **Schankin CJ, Maniyar FH, Seo Y, Kori S, Eller M, Chou DE, Blecha J, Murphy ST, Hawkins RA, Sprenger T, van Brocklin HF, and Goadsby PJ.** Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for [¹¹C]-dihydroergotamine during glyceryl trinitrate-induced migraine. *Brain* in press, 2016.

709. **Schoenen J, Ambrosini A, Sandor PS, and Maertens de Noordhout A.** Evoked potentials and transcranial magnetic stimulation in migraine: published data and viewpoint on their pathophysiologic significance. *Clinical Neurophysiology* 114: 955-972, 2003.
710. **Schoenen J, Jacquy J, and Lenaerts M.** Effectiveness of high-dose riboflavin in migraine prophylaxis - A randomized controlled trial. *Neurology* 50: 466-470, 1998.
711. **Schoenen J, Vandersmissen B, Jeanette S, Herroelen L, Vandenheede M, Gerard P, and Magis D.** Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. *Neurology* 80: 697-704, 2013.
712. **Schoonman GG, Evers DJ, Terwindt GM, van Dijk JG, and Ferrari MD.** The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. *Cephalalgia* 26: 1209-1213, 2006.
713. **Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, and Ferrari MD.** Migraine headache is not associated with cerebral or meningeal vasodilatation - a 3T magnetic resonance angiography study. *Brain* 131: 2192-2200, 2008.
714. **Schulte LH, Jurgens TP, and May A.** Photo-, osmo- and phonophobia in the premonitory phase of migraine: mistaking symptoms for triggers? *J Headache Pain* 16: 14, 2015.
715. **Schulte LH, and May A.** The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. *Brain* 2016.
716. **Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, and Kurth T.** Migraine and cardiovascular disease: systematic review and meta-analysis. *British Medical Journal* 339: b3914, 2009.
717. **Schwartz MW, Seeley RJ, Campfield LA, Burn P, and Baskin DG.** Identification of targets of leptin action in rat hypothalamus. *J Clin Invest* 98: 1101-1106, 1996.
718. **Schwartz MW, Seeley RJ, Woods SC, Weigle DS, Campfield LA, Burn P, and Baskin DG.** Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. *Diabetes* 46: 2119-2123, 1997.
719. **Schwedt TJ, Berisha V, and Chong CD.** Temporal lobe cortical thickness correlations differentiate the migraine brain from the healthy brain. *PLoS One* 10: e0116687, 2015.
720. **Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, and Ashina M.** PACAP38 induces migraine-like attacks in patients with migraine without aura. *Brain* 132: 16-25, 2009.
721. **Scott MM, Lachey JL, Sternson SM, Lee CE, Elias CF, Friedman JM, and Elmquist JK.** Leptin targets in the mouse brain. *J Comp Neurol* 514: 518-532, 2009.
722. **Segal-Lieberman G, Bradley RL, Kokkotou E, Carlson M, Trombly DJ, Wang X, Bates S, Myers MG, Flier JS, and Maratos-Flier E.** Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype. *Proc Natl Acad Sci U S A* 100: 10085-10090, 2003.
723. **Selby G, and Lance JW.** Observations on 500 cases of migraine and allied vascular headache. *Journal of Neurology, Neurosurgery and Psychiatry* 23: 23-32, 1960.
724. **Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, Collin L, Jones BJ, Middlemiss DN, and Price GW.** SB-224289 - a novel selective (human) 5-HT_{1B} receptor antagonist with negative intrinsic activity. *British Journal of Pharmacology* 125: 202-208, 1998.
725. **Serra G, Collu M, and Gessa GL.** Dopamine receptors mediating yawning: are they autoreceptors? *European Journal of Pharmacology* 120: 187-192, 1986.
726. **Serra G, Collu M, and Gessa GL.** Yawning is elicited by D₂ dopamine agonists but is blocked by the D₁ antagonist, SCH23390. *Psychopharmacology* 91: 330-333, 1987.
727. **Settle M.** The hypothalamus. *Neonatal Netw* 19: 9-14, 2000.

728. **Shepherd S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, and Hargreaves R.** Possible antimigraine mechanisms of action of the 5HT_{1F} receptor agonist LY334370. *Cephalalgia* 19: 851-858, 1999.
729. **Shields KG, and Goadsby PJ.** Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? *Brain* 128: 86-97, 2005.
730. **Shields KG, and Goadsby PJ.** Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? *Neurobiology of Disease* 23: 491-501, 2006.
731. **Shigenaga Y, Nakatani Z, Nishimori T, Suemune S, Kuroda R, and Matano S.** The cells of origin of cat trigeminothalamic projections: especially in the caudal medulla. *Brain Res* 277: 201-222, 1983.
732. **Shinohara M, Dollinger B, Brown G, Rapoport S, and Sokoloff L.** Cerebral glucose utilization: local changes during and after recovery from spreading cortical depression. *Science* 203: 188-190., 1979.
733. **Shiraishi T, Oomura Y, Sasaki K, and Wayner MJ.** Effects of leptin and orexin-A on food intake and feeding related hypothalamic neurons. *Physiol Behav* 71: 251-261, 2000.
734. **Sicuteri F, Testi A, and Anselmi B.** Biochemical investigations in headache: increase in hydroxyindoleacetic acid excretion during migraine attacks. *International Archives of Allergy* 19: 55-58, 1961.
735. **Silberstein S, Dodick D, Saper J, Huh B, Slavin K, Sharan A, Reed K, Narouze S, Mogilner A, Goldstein J, Trentman T, Vaisma J, Ordia J, Weber P, Deer T, Levy R, Diaz RL, Washburn SN, and Mekhail N.** The safety and efficacy of occipital nerve stimulation for the management of chronic migraine. *Cephalalgia* 32: 1165-1179, 2012.
736. **Silberstein SD, Da Silva AN, Calhoun AH, Grosberg BM, Lipton RB, Cady RK, Goadsby PJ, Simmons K, Mullin C, Saper JR, and Liebler EJ.** Non-invasive Vagus Nerve Stimulation for Chronic Migraine Prevention in a Prospective, Randomized, Sham-Controlled Pilot Study (the EVENT Study): Report from the Double-blind Phase. *Headache* 54: 1426, 2014.
737. **Sim LJ, and Joseph SA.** Arcuate nucleus projections to brainstem regions which modulate nociception. *J Chem Neuroanat* 4: 97-109, 1991.
738. **Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephens TW, Magosin S, Marco C, and Caro JF.** Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. *J Clin Invest* 97: 1344-1347, 1996.
739. **Sinton CM, Fitch TE, and Gershenfeld HK.** The effects of leptin on REM sleep and slow wave delta in rats are reversed by food deprivation. *Journal of sleep research* 8: 197-203, 1999.
740. **Skagerberg G, Bjorklund A, Lindvall O, and Schmidt RH.** Origin and termination of the diencephalo-spinal dopamine system in the rat. *Brain Res Bull* 9: 237-244, 1982.
741. **Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA, and Jerman JC.** SB-334867-A: the first selective orexin-1 receptor antagonist. *Br J Pharmacol* 132: 1179-1182, 2001.
742. **Sohn JW, Elmquist JK, and Williams KW.** Neuronal circuits that regulate feeding behavior and metabolism. *Trends Neurosci* 36: 504-512, 2013.
743. **Somjen GG.** Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. *Physiol Rev* 81: 1065-1096, 2001.
744. **Sommer WH, Lidström J, Sun H, Passer D, Eskay R, Parker SC, Witt SH, Zimmermann US, Nieratschker V, Rietschel M, Margulies EH, Palkovits M, Laucht M, and**

Heilig M. Human NPY promoter variation rs16147:T>C as a moderator of prefrontal NPY gene expression and negative affect. *Hum Mutat* 31: E1594-1608, 2010.

745. **Spencer SE, Sawyer WB, Wada H, Platt KB, and Loewy AD.** CNS projections to the pterygopalatine parasympathetic preganglionic neurons in the rat: a retrograde transneuronal viral cell body labeling study. *Brain Research* 534: 149-169, 1990.

746. **Spiegel K, Leproult R, L'hermite-Balériaux M, Copinschi G, Penev PD, and Van Cauter E.** Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. *J Clin Endocrinol Metab* 89: 5762-5771, 2004.

747. **Spiegel K, Leproult R, and Van Cauter E.** Impact of sleep debt on metabolic and endocrine function. *Lancet* 354: 1435-1439, 1999.

748. **Sprenger T, and Goadsby PJ.** What has functional neuroimaging done for primary headache...and for the clinical neurologist? *Journal of Clinical Neuroscience* 17: 547-553, 2010.

749. **Stankewitz A, Aderjan D, Eippert F, and May A.** Trigeminal nociceptive transmission in migraineurs predicts migraine attacks. *J Neurosci* 31: 1937-1943, 2011.

750. **Stankewitz A, and May A.** The phenomenon of changes in cortical excitability in migraine is not migraine-specific--a unifying thesis. *Pain* 145: 14-17, 2009.

751. **Stanley BG, and Leibowitz SF.** Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior. *Proc Natl Acad Sci U S A* 82: 3940-3943, 1985.

752. **Stanley BG, and Leibowitz SF.** Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. *Life Sci* 35: 2635-2642, 1984.

753. **Stanley BG, Magdalin W, Seirafi A, Thomas WJ, and Leibowitz SF.** The perifornical area: the major focus of (a) patchily distributed hypothalamic neuropeptide Y-sensitive feeding system(s). *Brain Res* 604: 304-317, 1993.

754. **Stengel A, Karasawa H, and Tache Y.** The role of brain somatostatin receptor 2 in the regulation of feeding and drinking behavior. *Horm Behav* 73: 15-22, 2015.

755. **Stephan KE, and Friston KJ.** Analyzing effective connectivity with fMRI. *Wiley Interdiscip Rev Cogn Sci* 1: 446-459, 2010.

756. **Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsiung HM, and Kriauciunas A.** The role of neuropeptide Y in the antiobesity action of the obese gene product. *Nature* 377: 530-532, 1995.

757. **Stewart WF, Ricci JA, Chee E, Morganstein D, and Lipton R.** Lost productive time and cost due to common pain conditions in the US workforce. *Jama* 290: 2443-2454, 2003.

758. **Stewart WF, Staffa J, Lipton RB, and Ottman R.** Familial risk of migraine: a population-based study. *Annals of Neurology* 41: 166-172, 1997.

759. **Stewart WF, Wood C, Reed ML, Roy J, and Lipton RB.** Cumulative lifetime migraine incidence in women and men. *Cephalalgia* 28: 1170-1178, 2008.

760. **Storer RJ, Akerman S, and Goadsby PJ.** Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. *British Journal of Pharmacology* 142: 1171-1181, 2004.

761. **Storer RJ, Akerman S, and Goadsby PJ.** Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex. *British Journal of Pharmacology* 138: 317-324, 2003.

762. **Storer RJ, and Goadsby PJ.** 5-HT_{1F} agonists inhibit nociceptive transmission at the trigeminocervical complex. *Cephalalgia* 31: 9, 2011.

763. **Storer RJ, and Goadsby PJ.** Microiontophoretic application of serotonin (5HT)_{1B/1D} agonists inhibits trigeminal cell firing in the cat. *Brain* 120: 2171-2177, 1997.
764. **Storer RJ, and Goadsby PJ.** Trigemino-vascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. *Neuroscience* 90: 1371-1376, 1999.
765. **Stovner LJ, Linde M, Gravidahl GB, Tronvik E, Aamodt AH, Sand T, and Hagen K.** A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. *Cephalalgia* 34: 523-532, 2014.
766. **Strassman AM, Raymond SA, and Burstein R.** Sensitization of meningeal sensory neurons and the origin of headaches. *Nature* 384: 560-563, 1996.
767. **Strecker T, Dux M, and Messlinger K.** Increase in meningeal blood flow by nitric oxide-interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. *Cephalalgia* 22: 233-241, 2002.
768. **Strong AJ, Fabricius M, Boutelle MG, Hibbins SJ, Hopwood SE, Jones R, Parkin MC, and Lauritzen M.** Spreading and synchronous depressions of cortical activity in acutely injured human brain. *Stroke* 33: 2738-2743, 2002.
769. **Summ O, Charbit AR, Andreou AP, and Goadsby PJ.** Modulation of nociceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. *Brain* 133: 2540-2548, 2010.
770. **Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, and Lenz R.** A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 for the Prevention of Episodic Migraine. *Lancet Neurology* 15: 382-390, 2016.
771. **Supronsinchai W, Hoffmann J, Akerman S, and Goadsby PJ.** KCl-induced repetitive cortical spreading depression inhibits trigeminal neuronal firing mediated by 5-HT_{1B/1D} and opioid receptor. *Journal of Headache and Pain* 14: P69, 2013.
772. **Supronsinchai W, Hoffmann J, Akerman S, and Goadsby PJ.** The Role of the Orexin-2 Receptor in the Nucleus Raphe Magnus on Trigemino-vascular Nociceptive Transmission. *Cephalalgia* 33: 223, 2013.
773. **Supronsinchai W, Storer RJ, Hoffmann J, Andreou AP, Akerman S, and Goadsby PJ.** GABA_A receptors in the nucleus raphe magnus modulate trigeminal cell firing responsive to activation of craniovascular dural afferents. *Headache* 52: 903-904, 2012.
774. **Sutcliffe JG, and de Lecea L.** The hypocretins: setting the arousal threshold. *Nat Rev Neurosci* 3: 339-349, 2002.
775. **Swanson LW, and Sawchenko PE.** Paraventricular nucleus: a site for the integration of neuroendocrine and autonomic mechanisms. *Neuroendocrinology* 31: 410-417, 1980.
776. **Szentirmai E, and Krueger JM.** Central administration of neuropeptide Y induces wakefulness in rats. *Am J Physiol Regul Integr Comp Physiol* 291: R473-480, 2006.
777. **Taheri S, Lin L, Austin D, Young T, and Mignot E.** Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. *PLoS Med* 1: e62, 2004.
778. **Taheri S, Zeitzer JM, and Mignot E.** The role of hypocretins (orexins) in sleep regulation and narcolepsy. *Annu Rev Neurosci* 25: 283-313, 2002.
779. **Tajti J, Uddman R, and Edvinsson L.** Neuropeptide localization in the 'migraine generator' region of the human brainstem. *Cephalalgia* 21: 96-101, 2001.
780. **Tajti J, Uddman R, Moller S, Sundler F, and Edvinsson L.** Messenger molecules and receptor mRNA in the human trigeminal ganglion. *J Auton Nerv Syst* 76: 176-183, 1999.

781. **Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Wool EA, Monroe CA, and Tepper RI.** Identification and expression cloning of a leptin receptor, OB-R. *Cell* 83: 1263-1271, 1995.
782. **Tassorelli C, Costa A, Blandini F, Joseph SA, and Nappi G.** Effect of nitric oxide donors on the central nervous system - Nitroglycerin studies in the rat. *Functional Neurology* 15: 19-27, 2000.
783. **Tassorelli C, and Joseph SA.** Systemic nitroglycerin induces Fos immunoreactivity in brain-stem and forebrain structures of the rat. *Brain Research* 682: 167-181, 1995.
784. **Tavraz NN, Friedrich T, Durr KL, Koenderink JB, Bamberg E, Freilinger T, and Dichgans M.** Diverse functional consequences of mutations in the Na⁺/K⁺-ATPase alpha2-subunit causing familial hemiplegic migraine type 2. *J Biol Chem* 283: 31097-31106, 2008.
785. **Tedeschi G, Russo A, Conte F, Corbo D, Caiazzo G, Giordano A, Conforti R, Esposito F, and Tessitore A.** Increased interictal visual network connectivity in patients with migraine with aura. *Cephalalgia* 36: 139-147, 2016.
786. **Terwindt G, Kors E, Haan J, Vermeulen F, Van den Maagdenberg A, Frants R, and Ferrari M.** Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine. *Arch Neurol* 59: 1016-1018, 2002.
787. **Terwindt GM, Ophoff RA, van Eijk R, Vergouwe MN, Haan J, Frants RR, Sandkuijl LA, and Ferrari MD.** Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura. *Neurology* 56: 1028-1032, 2001.
788. **Tessitore A, Russo A, Giordano A, Conte F, Corbo D, De Stefano M, Cirillo S, Cirillo M, Esposito F, and Tedeschi G.** Disrupted default mode network connectivity in migraine without aura. *J Headache Pain* 14: 89, 2013.
789. **Thompson RH, Canteras NS, and Swanson LW.** Organization of projections from the dorsomedial nucleus of the hypothalamus: a PHA-L study in the rat. *J Comp Neurol* 376: 143-173, 1996.
790. **Thompson RH, and Swanson LW.** Organization of inputs to the dorsomedial nucleus of the hypothalamus: a reexamination with Fluorogold and PHAL in the rat. *Brain Res Brain Res Rev* 27: 89-118, 1998.
791. **Thomsen LL, Ostergaard E, Romer SF, Andersen I, Eriksen MK, Olesen J, and Russell MB.** Sporadic hemiplegic migraine is an aetiologically heterogeneous disorder. *Cephalalgia* 23: 921-928, 2003.
792. **Thorsell A.** Central neuropeptide Y in anxiety- and stress-related behavior and in ethanol intake. *Ann N Y Acad Sci* 1148: 136-140, 2008.
793. **Tkacs NC, Pan Y, Sawhney G, Mann GL, and Morrison AR.** Hypoglycemia activates arousal-related neurons and increases wake time in adult rats. *Physiol Behav* 91: 240-249, 2007.
794. **Toh KL, Jones CR, He Y, Eide EJ, Hinz WA, Virshup DM, Ptacek LJ, and Fu YH.** An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. *Science* 291: 1040-1043, 2001.
795. **Tolner EA, Houben T, Terwindt GM, de Vries B, Ferrari MD, and van den Maagdenberg AM.** From migraine genes to mechanisms. *Pain* 156 Suppl 1: S64-74, 2015.
796. **Tóth A, Hajnik T, Záborszky L, and Détári L.** Effect of basal forebrain neuropeptide Y administration on sleep and spontaneous behavior in freely moving rats. *Brain Res Bull* 72: 293-301, 2007.

797. **Tottene A, Pivotto F, Fellin T, Cesetti T, van den Maagdenberg AM, and Pietrobon D.** Specific kinetic alterations of human CaV2.1 calcium channels produced by mutation S218L causing familial hemiplegic migraine and delayed cerebral edema and coma after minor head trauma. *J Biol Chem* 280: 17678-17686, 2005.
798. **Tottene A, Tottene A, Fellin T, Pagnutti S, Luvisetto S, Striessnig J, Fletcher C, and Pietrobon D.** Familial hemiplegic migraine mutations increase Ca²⁺ influx through single human CaV2.1 channels and decrease maximal Cav2.1 current density in neurons. *Proceedings of the National Academy of Science (USA)* 99: 13284-13289, 2002.
799. **Tracey I.** Imaging pain. *Br J Anaesth* 101: 32-39, 2008.
800. **Tronvik E, Stovner LJ, Helde G, Sand T, and Bovim G.** Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. *Journal of the American Medical Association* 289: 65-69, 2003.
801. **Tso AR, Trujillo A, Guo C, C., Goadsby PJ, and Seeley WW.** The anterior insula shows heightened interictal intrinsic connectivity in migraine without aura. *Neurology (Minneapolis)* 84: 1043-1050, 2015.
802. **Tsuneki H, Wada T, and Sasaoka T.** Role of orexin in the central regulation of glucose and energy homeostasis. *Endocr J* 59: 365-374, 2012.
803. **Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsanyi J, Szabo N, Toth E, Kincses ZT, Vecsei L, and Tajti J.** Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. *Cephalalgia* 33: 1085-1095, 2013.
804. **Uddman R, and Edvinsson L.** Neuropeptides in the cerebral circulation. *Cerebrovascular Brain Metabolism Review* 1: 230-252, 1989.
805. **Uddman R, Edvinsson L, Ekman R, Kingman T, and McCulloch J.** Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. *Neuroscience Letters* 62: 131-136, 1985.
806. **Uddman R, Goadsby PJ, Jansen I, and Edvinsson L.** PACAP, a VIP-like peptide, immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. *Journal of Cerebral Blood Flow and Metabolism* 13: 291-297, 1993.
807. **Uddman R, Moller S, Nilsson T, Nystrom S, Ekstrand J, and Edvinsson L.** Neuropeptide Y Y1 and neuropeptide Y Y2 receptors in human cardiovascular tissues. *Peptides* 23: 927-934, 2002.
808. **Uddman R, Tajti J, Hou M, Sundler F, and Edvinsson L.** Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. *Cephalalgia* 22: 112-116, 2002.
809. **Ullmer C, Schmuck K, Kalkman HO, and Lubbert H.** Expression of serotonin receptor mRNAs in blood vessels. *FEBS Lett* 370: 215-221, 1995.
810. **Ulrich V, Gervil M, Kyvik KO, Olesen J, and Russell MB.** Evidence of a genetic factor in migraine with aura: a population based Danish twin study. *Annals of Neurology* 45: 242-246, 1999.
811. **Ulrich V, Gervil M, Kyvik KO, Olesen J, and Russell MB.** The inheritance of migraine with aura estimated by means of structural equation modelling. *Journal of Medical Genetics* 36: 225-227, 1999.
812. **Valfre W, Rainero I, Bergui M, and Pinessi L.** Voxel-based morphometry reveals gray matter abnormalities in migraine. *Headache* 48: 109-117, 2008.
813. **van den Maagdenberg AMJM, Pietrobon D, Pizzorusso T, Kaja S, Broos LAM, Cesetti T, van de Ven RCG, Tottene A, van der Kaa J, Plomp JJ, Frants RR, and Ferrari M,**

D. A Cacna1a knock-in migraine mouse model with increased susceptibility to cortical spreading depression. *Neuron* 41: 701-710, 2004.

814. **van den Pol AN.** Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. *J Neurosci* 19: 3171-3182, 1999.

815. **Van Dijk G, Thiele TE, Donahey JC, Campfield LA, Smith FJ, Burn P, Bernstein IL, Woods SC, and Seeley RJ.** Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain. *Am J Physiol* 271: R1096-1100, 1996.

816. **Van Rossum D, Hanisch UK, and Quirion R.** Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. *Neuroscience and Biobehavioural Reviews* 21: 649-678, 1997.

817. **Vanagaite J, Pareja JA, Storen O, White LR, Sand T, and Stovner LJ.** Light-induced discomfort and pain in migraine. *Cephalalgia* 17: 733-741, 1997.

818. **Vance ML, and Thorner MO.** Fasting alters pulsatile and rhythmic cortisol release in normal man. *J Clin Endocrinol Metab* 68: 1013-1018, 1989.

819. **Vandenheede M, Coppola G, Di Clemente L, De Pasqua V, and Schoenen J.** High frequency oscillations (600Hz) of somatosensory evoked potentials in migraine between attacks: a measure of thalamocortical activation. *Cephalalgia* 23: 574, 2003.

820. **Veinante P, Jacquin MF, and Deschenes M.** Thalamic projections from the whisker-sensitive regions of the spinal trigeminal complex in the rat. *J Comp Neurol* 420: 233-243, 2000.

821. **Velati D, Viana M, Cresta S, Mantegazza P, Testa L, Bettucci D, Rinaldi M, Sances G, Tassorelli C, Nappi G, Canonico PL, Martignoni E, and Genazzani AA.** 5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms. *Eur J Pharmacol* 580: 43-47, 2007.

822. **Veloso F, Kumar K, and Toth C.** Headache secondary to deep brain implantation. *Headache* 38: 507-515, 1998.

823. **Vera-Portocarrero LP, Ossipov MH, King T, and Porreca F.** Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan. *Gastroenterology* 135: 1369-1378, 2008.

824. **Verret L, Goutagny R, Fort P, Cagnon L, Salvert D, Léger L, Boissard R, Salin P, Peyron C, and Luppi PH.** A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep. *BMC Neurosci* 4: 19, 2003.

825. **Viana M, Linde M, Sances G, Ghiotto N, Guaschino E, Allena M, Terrazzino S, Nappi G, Goadsby PJ, and Tassorelli C.** Migraine aura symptoms: duration, succession and temporal relationship to headache. *Cephalalgia* 36: 413-421, 2016.

826. **Vorona RD, Winn MP, Babineau TW, Eng BP, Feldman HR, and Ware JC.** Overweight and obese patients in a primary care population report less sleep than patients with a normal body mass index. *Arch Intern Med* 165: 25-30, 2005.

827. **Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basanez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabe E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L,**

Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fevre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Ma J, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA, 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leon FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, Murray CJ, AlMazroa MA, and Memish ZA. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 380: 2163-2196, 2012. 828. Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, and Michelson D. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. *Cephalalgia* 2016.

829. **Waelkens J.** Domperidone in the prevention of complete classical migraine. *British Medical Journal* 284: 944, 1982.
830. **Waelkens J.** Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. *Cephalalgia* 4: 85-90, 1984.
831. **Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L, Waldvogel HJ, Jamaluddin MA, Russo AF, and Hay DL.** A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. *Annals of Clinical and Translational Neurology* 2: 595-608, 2015.
832. **Wang JH, Wang F, Yang MJ, Yu DF, Wu WN, Liu J, Ma LQ, Cai F, and Chen JG.** Leptin regulated calcium channels of neuropeptide Y and proopiomelanocortin neurons by activation of different signal pathways. *Neuroscience* 156: 89-98, 2008.
833. **Wang W, and Schoenen J.** Interictal potentiation of passive "oddball" auditory event-related potentials in migraine. *Cephalalgia* 18: 261-265, 1998.
834. **Wang W, Timsit-Berthier M, and Schoenen J.** Intensity dependence of the auditory cortical evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic transmission? *Neurology* 46: 1404-1409, 1996.
835. **Waschek JA.** VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair. *Br J Pharmacol* 169: 512-523, 2013.
836. **Waters AJ, and Lumb BM.** Descending control of spinal nociception from the periaqueductal grey distinguishes between neurons with and without C-fibre inputs. *Pain* 134: 32-40, 2008.
837. **Waters AJ, and Lumb BM.** Inhibitory effects evoked from both the lateral and ventrolateral periaqueductal grey are selective for the nociceptive responses of rat dorsal horn neurones. *Brain Research* 752: 239-249, 1997.
838. **Watts AG, Swanson LW, and Sanchez-Watts G.** Efferent projections of the suprachiasmatic nucleus: I. Studies using anterograde transport of Phaseolus vulgaris leucoagglutinin in the rat. *J Comp Neurol* 258: 204-229, 1987.
839. **Waung MW, Akerman S, Wakefield M, Keywood C, and Goadsby PJ.** Metabotropic glutamate receptor 5: A target for migraine therapy. *Annals of Clinical and Translational Neurology* in press, 2016.
840. **Weatherall MW.** The migraine theories of Liveing and Latham: a reappraisal. *Brain* 135: 2560-2568, 2012.
841. **Weigle DS, Duell PB, Connor WE, Steiner RA, Soules MR, and Kuijper JL.** Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. *J Clin Endocrinol Metab* 82: 561-565, 1997.
842. **Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, and Diener HC.** Brain stem activation in spontaneous human migraine attacks. *Nature Medicine* 1: 658-660, 1995.
843. **Welch KM, Levine SR, D'Andrea G, Schultz LR, and Helpert JA.** Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. *Neurology* 39: 538-541, 1989.
844. **Welch KM, Nagesh V, Aurora S, and Gelman N.** Periaqueductal grey matter dysfunction in migraine: cause or the burden of illness? *Headache* 41: 629-637, 2001.
845. **Westenbroek RE, Sakurai T, Elliott EM, Hell JW, Starr TVB, Snutch TP, and Catterall WA.** Immunochemical identification and subcellular distribution of the alpha(1a) subunits of brain calcium channels. *Journal of Neuroscience* 15: 6403-6418, 1995.

846. **White JD, and Kershaw M.** Increased hypothalamic neuropeptide Y expression following food deprivation. *Mol Cell Neurosci* 1: 41-48, 1990.
847. **Wiater MF, Mukherjee S, Li AJ, Dinh TT, Rooney EM, Simasko SM, and Ritter S.** Circadian integration of sleep-wake and feeding requires NPY receptor-expressing neurons in the mediobasal hypothalamus. *Am J Physiol Regul Integr Comp Physiol* 301: R1569-1583, 2011.
848. **Wienecke T, Olesen J, and Ashina M.** Discrepancy between strong cephalic arterial dilatation and mild headache caused by prostaglandin D(2) (PGD(2)). *Cephalalgia* 31: 65-76, 2011.
849. **Wienecke T, Olesen J, and Ashina M.** Prostaglandin I₂ (epoprostenol) triggers migraine-like attacks in migraineurs. *Cephalalgia* 30: 179-190, 2010.
850. **Williams DL, Kaplan JM, and Grill HJ.** The role of the dorsal vagal complex and the vagus nerve in feeding effects of melanocortin-3/4 receptor stimulation. *Endocrinology* 141: 1332-1337, 2000.
851. **Williams MN, Zahm DS, and Jacquin MF.** Differential foci and synaptic organization of the principal and spinal trigeminal projections to the thalamus in the rat. *Eur J Neurosci* 6: 429-453, 1994.
852. **Williamson DJ, Hargreaves RJ, Hill RG, and Shepherd SL.** Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural blood vessel diameter in the anaesthetized rat. *Cephalalgia* 17: 518-524, 1997.
853. **Williamson DJ, Hargreaves RJ, Hill RG, and Shepherd SL.** Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat- intravital microscope studies. *Cephalalgia* 17: 525-531, 1997.
854. **Williamson DJ, Shepherd SL, Hill RG, and Hargreaves RJ.** The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. *European Journal of Pharmacology* 328: 61-64, 1997.
855. **Willis T, and Pordage S.** *Two discourses concerning the soul of brutes, which is that of the vital and sensitive of man: The first is physiological, shewing the nature, parts, powers, and affections of the same; and the other is pathological, which unfolds the diseases which affect it and its primary seat, to wit, the brain and nervous stock, and treats of their cures: With copper cuts.* London, England: Thomas Dring, Ch Harper and John Leigh, 1683.
856. **Winsky-Sommerer R, Boutrel B, and de Lecea L.** Stress and arousal: the corticotrophin-releasing factor/hypocretin circuitry. *Mol Neurobiol* 32: 285-294, 2005.
857. **Winsky-Sommerer R, Yamanaka A, Diano S, Borok E, Roberts AJ, Sakurai T, Kilduff TS, Horvath TL, and de Lecea L.** Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. *J Neurosci* 24: 11439-11448, 2004.
858. **Winter AC, Berger K, Buring JE, and Kurth T.** Body mass index, migraine, migraine frequency and migraine features in women. *Cephalalgia* 29: 269-278, 2009.
859. **Wober C, Brannath W, Schmidt K, Kapitan M, Rudel E, Wessely P, Wober-Bingol C, and Group PS.** Prospective analysis of factors related to migraine attacks: the PAMINA study. *Cephalalgia* 27: 304-314, 2007.
860. **Wober C, Holzhammer J, Zeithofer J, Wessely P, and Wober-Bingol C.** Trigger factors of migraine and tension-type headache: experience and knowledge of the patients. *J Headache Pain* 7: 188-195, 2006.
861. **Wolff HG.** *Headache and Other Head Pain.* New York: Oxford University Press, 1963.

862. **Xu B, Kalra PS, Moldawer LL, and Kalra SP.** Increased appetite augments hypothalamic NPY Y1 receptor gene expression: effects of anorexigenic ciliary neurotropic factor. *Regul Pept* 75-76: 391-395, 1998.
863. **Xu Y, Padiath QS, Shapiro RE, Jones CR, Wu SC, Saigoh N, Saigoh K, Ptacek LJ, and Fu YH.** Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. *Nature* 434: 640-644, 2005.
864. **Xu Y, Toh KL, Jones CR, Shin JY, Fu YH, and Ptacek LJ.** Modeling of a human circadian mutation yields insights into clock regulation by PER2. *Cell* 128: 59-70, 2007.
865. **Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, Tominaga M, Yagami K, Sugiyama F, Goto K, Yanagisawa M, and Sakurai T.** Hypothalamic orexin neurons regulate arousal according to energy balance in mice. *Neuron* 38: 701-713, 2003.
866. **Yamanaka A, Kunii K, Nambu T, Tsujino N, Sakai A, Matsuzaki I, Miwa Y, Goto K, and Sakurai T.** Orexin-induced food intake involves neuropeptide Y pathway. *Brain Res* 859: 404-409, 2000.
867. **Yamazaki S, Numano R, Abe M, Hida A, Takahashi R, Ueda M, Block GD, Sakaki Y, Menaker M, and Tei H.** Resetting central and peripheral circadian oscillators in transgenic rats. *Science* 288: 682-685, 2000.
868. **Yasui Y, Saper CB, and Cechetto DF.** Calcitonin gene-related peptide (CGRP) immunoreactive projections from the thalamus to the striatum and amygdala in the rat. *J Comp Neurol* 308: 293-310, 1991.
869. **Yeo GS, and Heisler LK.** Unraveling the brain regulation of appetite: lessons from genetics. *Nat Neurosci* 15: 1343-1349, 2012.
870. **Yettefti K, Orsini JC, and Perrin J.** Characteristics of glycemia-sensitive neurons in the nucleus tractus solitarii: possible involvement in nutritional regulation. *Physiol Behav* 61: 93-100, 1997.
871. **Yi CX, Serlie MJ, Ackermans MT, Foppen E, Buijs RM, Sauerwein HP, Fliers E, and Kalsbeek A.** A major role for perifornical orexin neurons in the control of glucose metabolism in rats. *Diabetes* 58: 1998-2005, 2009.
872. **Young RF, and Brechner T.** Electrical stimulation of the brain for relief of intractable pain due to cancer. *Cancer* 57: 1266-1272, 1986.
873. **Yuan PQ, and Yang H.** Neuronal activation of brain vagal-regulatory pathways and upper gut enteric plexuses by insulin hypoglycemia. *Am J Physiol Endocrinol Metab* 283: E436-448, 2002.
874. **Zagami AS, Edvinsson L, and Goadsby PJ.** Pituitary adenylate cyclase activating polypeptide and Migraine. *Annals of Clinical and Translational Neurology* 1: 1036-1040, 2014.
875. **Zagami AS, Edvinsson L, Hoskin KL, and Goadsby PJ.** Stimulation of the superior sagittal sinus causes extracranial release of PACAP. *Cephalalgia* 15: 109, 1995.
876. **Zagami AS, and Lambert GA.** Craniovascular application of capsaicin activates nociceptive thalamic neurons in the cat. *Neuroscience Letters* 121: 187-190, 1991.
877. **Zagami AS, and Lambert GA.** Stimulation of cranial vessels excites nociceptive neurones in several thalamic nuclei of the cat. *Experimental Brain Research* 81: 552-566, 1990.
878. **Zanchin G, Dainese F, Trucco M, Mainardi F, Mampreso E, and Maggioni F.** Osmophobia in migraine and tension-type headache and its clinical features in patients with migraine. *Cephalalgia* 27: 1061-1068, 2007.

879. **Zhang X, Levy D, Kainz V, Nosedá R, Jakubowski M, and Burstein R.** Activation of central trigeminovascular neurons by cortical spreading depression. *Ann Neurol* 69: 855-865, 2011.
880. **Zhang X, Levy D, Nosedá R, Kainz V, Jakubowski M, and Burstein R.** Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. *J Neurosci* 30: 8807-8814, 2010.
881. **Zhang XC, Strassman AM, Burstein R, and Levy D.** Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. *J Pharmacol Exp Ther* 322: 806-812, 2007.
882. **Ziegler DK, Hassanein RS, Kodanaz A, and Meek JC.** Circadian rhythms of plasma cortisol in migraine. *J Neurol Neurosurg Psychiatry* 42: 741-748, 1979.
883. **Zurak N.** Role of the suprachiasmatic nucleus in the pathogenesis of migraine attacks. *Cephalalgia* 17: 723-728, 1997.